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1CHAPTER I
INTRODUCTION
Cranial sutures
Anatomy and origins of the cranial vault
The mammalian calvaria, or skull vault, houses and protects the brain and sensory
organs.  It is composed of five main flat bones, including pairs of the frontal, parietal, and
squamosal bones, and the anterior portion of the occipital bone.  Flexible joints composed
of fibrous connective tissue separate the cranial bones.  These are termed the cranial
sutures.  Although sutures are found throughout the skull, there are five major sutures in
the cranial vault.  These include the sagittal suture (between the paired parietal bones),
coronal suture (between the frontal and parietal bones), lambdoid suture (between the
parietal and occipital bones (the occipital is also referred to as the interparietal bone in
the murine skull)); squamosal suture (between the squamosal and parietal bones), and the
metopic/interfrontal suture (between the paired frontal bones) (Fig 1.1).
The cranial sutures are not simply a space between the bones, but a complex
structure made of multiple components.  These include: 1) the differentiated bones; 2) the
bone fronts, which are regions of proliferating and differentiating osteoblasts lining the
edges of the advancing bones, 3) the suture mesenchyme, which remains
undifferentiated; 4) the periosteum; and 5) the dura (Fig 1.2).  Each of these components
provides signals that are necessary for the formation and maintenance of a newly formed
suture.
2Figure 1.1.  Cranial bones and sutures.  The mammalian skull is composed of paired
frontal, parietal, and squamosal bones, plus the anterior portion of the occipital bone (the
occipital is also known as the interparietal bone in mice).  These bones form through
intramembranous ossification, which occurs without a cartilage intermediate.  Separating
the cranial bones are flexible joints known as the cranial sutures.  These include the
interfrontal suture (separating the paired frontal bones), sagittal suture (separating the
paired parietal bones), coronal suture (separating the frontal and parietal bones),
squamosal suture (separating the parietal and squamosal bones), and lambdoid suture
(separating the parietal and interparietal/occipital bones).  The sutures are the main sites
for cranial growth during development.
Adapted from The Anatomy of the Laboratory Mouse, Margaret J. Cook 1965.
3Figure 1.2.  Components and structure of the suture.  The suture is composed of: 1)
the differentiated bones (here the frontal bone, blue; parietal bone, red); 2) the bone fronts
(yellow), which contain the proliferating and differentiating osteoblasts; 3) the
undifferentiated suture mesenchyme (orange); 4) the periosteum (black); and 5) the dura
(green).
4Along with fontanelles (the soft spots in a newborn’s head), the sutures provide
flexible joints for the compression of the calvaria during passage through the birth canal.
However, as the calvaria grows after birth, the fontanelles quickly diminish, but the
sutures remain (Rice, 2008).  The sutures are the main sites for cranial growth during
development.  These dynamic structures also act as shock absorbers, prevent separation
of the cranial bones, and accommodate room for the rapidly growing brain (Cohen,
2005).
The cranial bones are of mixed origin, being derived from both the cranial neural
crest and the paraxial mesoderm.  The neural crest is a distinct ectoderm population in
vertebrates.  A portion of these cells migrate off the crest of the neural tube into multiple
regions of the developing embryo, differentiating into structures including cranial
ganglia, cartilage, bone, and connective tissue (Knecht and Bronner-Fraser, 2002).  The
paraxial mesoderm is a cell population located on either side of the neural tube.  During
development they pinch off into a defined number of somites and go on to form the
vertebrae, ribs, and skeletal muscle (Gilbert, 2003).
Origin of cranial tissues in mice: The exact contribution of the neural crest and
mesoderm to each of the bones and sutures was highly controversial.  Bones were
sometimes assigned different origins depending on the lab or method of study.
Historically, fate-labeling methods used to map neural crest contributions have included
dye labeling and β-galactosidase retroviral infection.  A more definitive genetic
methodology was developed utilizing the Wnt1-Cre and R26R mouse lines (Fig 1.3A).  In
the Wnt1-Cre transgenic mice, Cre recombinase is expressed under the control of the
5Figure 1.3.  Fate mapping of the cranial bones.  A) (Above) Structure of the R26R locus, which stably expresses ß-galactosidase
upon Cre-mediated recombination.  (Below) The Wnt1-Cre transgene, which expresses Cre under the control of the Wnt1 promoter
and enhancer.  When expressed together, they stably label derivates of the neural crest with lacZ.  Adapted from Soriano 1999 and
Danielian et al. 1998.  B) (Above) Wnt1-Cre and R26R labeling of a wild-type coronal suture reveals a distinct boundary between the
frontal bone cells (labeled with lacZ) and the cells of the parietal bone.  (Below) In the Twist1 mutant there is a mixing of the frontal
and parietal bone cells (arrow) at sites of coronal craniosynostosis.  Adapted from Merrill et al. 2006.  C) Origins of each of the cranial
bones and sutures in the mammalian skull as determined by fate mapping studies using the Wnt1-Cre and R26R mouse lines.  The
nasal, frontal, and interparietal bones are derived from the cranial neural crest (blue) along with the interfrontal suture and a portion of
the sagittal suture.  The parietal and occipital bones and the lambdoid and coronal sutures are derived from the paraxial mesoderm.
Adapted from Jiang et al. 2002.  fb, frontal bone; pb, parietal bone.
6Wnt1 promoter and enhancer (Danielian et al., 1998).  Wnt1 is expressed transiently in
the neural plate, dorsal neural tube, and early migrating neural crest cells, and is silenced
after the neural crest migrates away from the neural tube (Jiang et al., 2000).  The
skeletogenic cranial neural crest cells in the branchial arches, which contribute to the
facial and cranial bones, are all derived from Wnt1-expressing cells (Jiang et al., 2002).
The R26R mouse line expresses β-galactosidase from the ROSA26 locus following Cre-
mediated recombination (Soriano, 1999).  ROSA26 is a ubiquitously expressed locus, and
therefore, the combination of R26R and Wnt1-Cre alleles together results in expression of
β-galactosidase in migrating neural crest cells and their derivatives.  Once a R26R-
carrying cell undergoes Cre-mediated recombination it will stably express β-
galactosidase, allowing labeling of neural crest-derivatives throughout development.
These tools demonstrated that the frontal bone and the underlying dura in mice
are derived from the neural crest, with the parietal bone derived entirely from the paraxial
mesoderm (Jiang et al., 2002).  The boundary between rudiments of the frontal and
parietal bones, the future site of the coronal suture (CS), is evident in mouse embryos as
early as embryonic day (E) 9.5, at the end of neural crest migration (Jiang et al., 2002).
The interfrontal suture mesenchyme and a portion of the sagittal suture extending from
the frontal bones are also neural crest-derived, whereas the remaining sutures are
mesoderm-derived (Fig 1.3C).  Therefore, the CS and a portion of the sagittal suture form
at interfaces between cell populations of different embryonic origins.  In contrast, the
interfrontal suture is formed at the junction between two neural crest-derived bones with
a neural crest-derived suture, with no involvement of the mesoderm (Fig 1.3C) (Jiang et
al., 2002)
7Origins of cranial tissues in other vertebrates:  Due to their quick reproductive cycle
and large number of progeny, zebrafish are an attractive model organism for
developmental research.  Although not historically used to study cranial development and
the suture, zebrafish do have a highly similar cranial anatomy compared to humans and
mice (Quarto and Longaker, 2005), including the presence of interfrontal, coronal,
sagittal, and lambdoid sutures.  The origins of the bones are also the same, with frontal
bones derived from cranial neural crest and parietal bones derived from paraxial
mesoderm.
The arrangement of the cranial bones and sutures in zebrafish is not conserved
across all vertebrate species.  Although the mammalian frontal bones are now believed to
be derived from the cranial neural crest, the frontal bones in avians have a dual neural
crest/mesoderm origin, and therefore the boundary between the two does not form at a
cranial suture (Evans and Noden, 2006).  However, it theorized that early in avian
evolution, the frontal and parietal fused into a single bone, which extend as far back as
the cerebellum (Morriss-Kay, 2001).  Frogs do in fact have a single frontal-parietal bone,
but it is composed entirely of neural crest origin (Hanken and Gross, 2005).  Although
the cranial bones may be anatomically similar, this does not mean they are also
evolutionarily homologous.
Mice are an optimal model system for study of the human coronal suture because
of the homology between mice and human in the origins of the cranial bones and the
possibility that tissue origin has a critical impact on the development of the cranial suture.
Also, the genetic tools available in mice for fate mapping this cell population make mice
an ideal model organism for studying human suture development.
8Intramembranous ossification and development of the cranial sutures
The flat bones of the skull vault form through the process of intramembranous
ossification.  In contrast to the endochondral ossification of the long bones (Fig 1.4A),
intramembranous ossification occurs without a cartilage intermediate and instead,
osteoblasts differentiate directly from mesenchymal cells (Fig 1.4B).  An exception is the
occipital bone: the anterior portion forms through intramembranous ossification while the
posterior portion forms through endochondral ossification (Fig 1.4C).  In mice, the
anterior and posterior portions form two separate bones, the interparietal and occipital
bones respectively (Fig 1.1).  However, in the majority of humans, the anterior and
posterior portions form from multiple ossification centers that fuse into a single occipital
bone (Shapiro and Robinson, 1976).
In addition to the flat bones of the skull, portions of the clavicle, mandible,
maxilla, scapula, and pelvis all form through intramembranous ossification.  It was
previously hypothesized that all intramembranous bones were neural crest-derived and
endochondral bones were derived from the mesoderm.  However, this was contradicted
by the mesoderm-derived parietal bone, which forms through intramembranous
ossification (Jiang et al., 2002), and areas of the shoulder girdle and cervical vertebrae
that are neural crest-derived and form endochondral bone (Matsuoka et al., 2005).
Instead, portions of the bones in the neck and shoulder region have the same origins as
the muscles at the site of attachment (Matsuoka et al., 2005).
The ossification of the cranial vault begins with the migration of mesenchymal
cells to positions between the surface ectoderm and the brain (Lenton et al., 2005).
9Figure 1.4.  Comparison of endochondral and intramembranous ossification. (A) Endochondral ossification begins with the
formation of a mesenchymal condensation, expressing type II collagen (blue). Cells differentiate into chondrocytes, which
hypertrophy and express type X collagen (purple). Progression to the mature growth plate accompanies development of the
perichondrium (yellow) and the formation of a center of ossification containing osteoblasts (yellow). (B) In intramembranous
ossification, mesenchymal cells differentiate directly into osteoprogenitor cells expressing Cbfa1 (pink) and then to mature osteoblasts
(yellow) that deposit bone matrix. Osteoblasts either die by apoptosis or are embedded in the matrix, becoming osteocytes. Adapted
from Ornitz and Marie, 2002. (C) List of cranial bones that form through intramembranous ossification, endochondral ossification, or
a combination of the two.
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Interactions between the epithelia and the mesenchyme lead to mesenchymal
condensations, or blastemas, which are the precursors to each of the bones in the cranial
vault (Opperman, 2000).  Bone morphogenetic proteins (BMPs) expressed in the
epidermis are hypothesized to send an osteogenic signal to the cranial mesenchyme
through activation of Cbfa1, a transcription factor (Fig 1.4).  Cbfa1 transforms
mesenchymal cells into osteoblasts by activating bone-specific genes, including
osteocalcin and osteopontin (Ducy et al., 1997).  When these blastemas reach a critical
size, the cells begin to differentiate into osteoblasts, secreting collagens, proteoglycans,
and other bone-related proteins to begin mineralization (Lana-Elola et al., 2007).  For
each bone there is a center of ossification where the process begins and radiates out
peripherally, separating the mesenchyme into the inner dura and the outer ectoperiosteal
layers (Opperman, 2000).
The ossification centers for the paired bones (frontal and parietal) form close to
the skull base, then radiate upward and outward until they meet at the interfrontal and
sagittal sutures.  The sutures are formed as the leading edges of the bone begin to
approximate one another.  The advancing bone fronts that will generate the CS first meet
at the most lateral aspects of the calvaria and progress “zipper-like” upwards toward the
cranial midline (toward the sagittal suture).  Thus, during development, the more lateral
regions of the CS are generally more histologically mature than the medial (Rice, 2008).
Interestingly, interactions with the neural crest-derived meninges is required for the
intramembranous ossification of the parietal bone, but not the frontal bone (Jiang et al.,
2002).
11
As the bone fronts meet, the leading edges of the bones either abut or overlap.
Bones that meet along the midline (at the sagittal and interfrontal sutures) abut each
other, while the bones that meet perpendicular to the midline (at the coronal and
lambdoid sutures) overlap.  A theory as to why these different orientations exist is that
they are suited for the mechanical forces applied to different planes during passage
through the birth canal where the sutures along the midline are more likely to undergo
mechanical forces with equal magnitude on either side, while the coronal and lambdoid
sutures are more likely to experience unequal forces (Cohen, 2005).  At the CS, the bones
are pre-patterned to overlap, as seen at the boundary between the neural crest and
paraxial mesoderm (Fig 1.2, Fig 1.3b).  Even prior to the onset of ossification, the frontal
bone rudiment always underlies the parietal at the CS (Jiang et al., 2002).
Where the sagittal and lambdoid sutures form over easily defined areas of the
brain, the bridge between the cerebral hemispheres and the bridge between the cerebrum
and cerebellum respectively, the CS overlies no visible landmarks (Jiang et al., 2002).
The mechanisms that control where the sutures form are yet unknown.  Some have
hypothesized that it forms as a response a growth factor gradient generated by the
approximation of the advancing ossification centers, while other have proposed that the
region is pre-patterned by surrounding tissues, such as the dura, one of the three
outermost meningeal layers covering the brain (Lenton et al., 2005).  There are several
genes known to be expressed in the dura, including Fgfr1, Fgfr2, Fgfr3, Bmp4, Bmp7,
Msx1, Msx2, Fgf2, and Fgf9 (Opperman, 2000).  Mutations in some of these genes are
also associated with craniosynostosis.
12
Once the suture is formed, the majority of bone growth occurs at its osteogenic
fronts.  A small number of suture mesenchymal cells that immediately flank the
osteogenic fronts can differentiate and be recruited into growing bones, while
mesenchymal cells occupying the center of the suture are not incorporated into the
growing bones and remain undifferentiated (Lana-Elola et al., 2007).  In order for growth
to continue and the suture to remain open, these cells need to remain in an
undifferentiated state.  The ossifying cranial bones are capable of both appositional and
resorptive growth, per the demands of the growing brain and also in response to
pathologies, such as hydrocephalus or craniosynostosis (Rice, 2008).  An active suture is
characterized by a budge of undifferentiated mesenchymal cells, also referred to as a
blastema.  As cranial expansion slows around three weeks after birth in mice, the number
of cells which line the suture declines, and the suture begins to narrow and become more
fibrous (Opperman, 2000).
Craniosynostosis
In mice, all sutures remain open for the lifespan of the animal, with the exception
of the posterior interfrontal suture, which begins to fuse around twenty-five days after
birth in mice (Opperman, 2000).  Interestingly, this suture is homologous to the human
metoptic suture, which fuses in the first few years of life and is also the only suture to be
composed of tissues entirely of neural crest origin (Jiang et al., 2002).  All other sutures
in humans remain open until the third or fourth decade of life, but in some cases can
persist into the seventh (Furuya et al., 1984).
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Craniosynostosis is characterized by the premature fusion of one or more of the
cranial sutures and occurs in approximately 1 in 2,000 live births.  The two largest
contributors to cranial vault growth, the sagittal and CS, are also the most common sites
of synostosis; in 40-60% of craniosynostosis cases the sagittal suture is affected, in 20-
30% of cases the CS is affected, and only 5-10% are due to metopic suture fusion
(Kabbani and Raghuveer, 2004).  Because the interfrontal/metopic suture normally
undergoes fusion postnatally in both humans and mice, it is often used as a model for
craniosynostosis, to study the events that initiate the transition between a patent,
functional suture, to a fused structure.
The size of the human brain increases 2.5-3 times in the first two years of life
(Kabbani and Raghuveer, 2004) and therefore the cranial vault needs to grow
accordingly.  Virchow’s law states that the synostosis of a suture leads to termination of
growth perpendicular to the site of fusion, and compensatory growth increases parallel to
the site of fusion.  This produces a predictable dysmorphic head shape depending on the
identity of the fused suture (Slater et al., 2008) (Fig 1.5).  For example, fusion of the CS
results in a short anterior-posterior diameter with a flat forehead and increased skull
height (Fig 1.5C) while a sagittal fusion produces an elongated skull (Fig 1.5B) (Kabbani
and Raghuveer, 2004).  Unlike changes in head shape caused by trauma or fetal
positioning, abnormal head shapes caused by craniosynostosis get worse with growth and
a palpable ridge is found at the site of the fused suture (Kabbani and Raghuveer, 2004).
Other complications associated with craniosynostosis can include hydrocephalus, airway
defects, and increased intracranial pressure that can result in deafness, blindness,
seizures, or developmental delays (Cohen, 2005; Morriss-Kay and Wilkie, 2005).
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Figure 1.5.  Dysmorphic skull shapes produced by craniosynostosis.
Craniosynostosis of a suture stops growth perpendicular to the site of fusion, and
compensatory growth increases in the other sutures in order to maintain the volume of the
skull vault.  Fusion of the A) metopic, B) sagittal, C) bilateral coronal, D) unilateral
coronal, and E) lambdoid sutures produce a predictable head shape.  These differ from
deformation caused by fetal position (F) in that craniosynostosis gets increasingly worse
over time and palpable ridges can be felt over the sites of suture fusion.
Adapted from Cohen 2005.
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These defects are surgically corrected through a cranioectomy or remodeling of
the cranial vault by excising, trimming, and reshaping the bones.  Most surgeries are
performed at four to eight months of age due to the malleability of the bone, the rapid
healing potential, and because the growth of the brain during this time stimulates bone
remodeling (Kabbani and Raghuveer, 2004).  However, most surgeons will intervene
immediately if there is evidence of increased intracranial pressure (Warren and Longaker,
2001).  Historically, surgeries involved a strip craniectomy to remove the fused suture,
followed by removal and reshaping of the cranial bones in order to correct secondary
deformities caused by the craniosynostosis (Warren and Longaker, 2001).  However,
since the defect that originally led to craniosynostosis is still present, craniectomies often
result in re-fusion of the cranial bones and repeat surgeries.  In addition, these are major
surgeries, with a two percent mortality rate and complications that include seizures, blood
loss, and hypothermia (Slater et al., 2008).  Therefore a more thorough understanding of
the genes and mechanisms that underlie the craniosynostosis phenotype could aid in the
generation of more targeted and effective treatment strategies.
Genetic etiology of craniosynostosis
Cases of craniosynostosis are classified as either isolated non-syndromic cases or
associated with over 150 syndromes, including Pfeiffer’s disease, Apert’s syndrome, and
Crouzon’s disease (Kabbani and Raghuveer, 2004).  However, approximately 70% of
craniosynostosis cases are isolated with no known etiology and no other associated
phenotypes (Passos-Bueno et al., 2008).  Craniosynostosis clearly can have a genetic
component, with overall familial reoccurrence ranging from 6% (in sagittal fusion) to
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14% (in coronal fusion).  Family pedigrees have revealed inheritance patterns of
autosomal dominant, autosomal recessive, and X-linked inheritance (Passos-Bueno et al.,
2008).  Sagittal craniosynostosis presents with a strong male prevalence (3.5:1), while
coronal craniosynostosis cases are about 60-70% female (Boyadjiev, 2007).  There have
been great advances in the last decade in the identification of specific gene mutation
associated with craniosynostosis of the suture, providing great insight into suture biology.
A few notable genes identified in humans include FGFR1, FGFR2, FGFR3, NELL-1,
AXIN-2, TWIST, EFNB1, and MSX2 (Table 1.1).
Mechanisms of suture fusion
There are several known mechanisms leading to premature fusion of a suture.
These may affect not just the formation of the suture structure, but also the maintenance
of a patent suture through development.  These mechanisms include changes in
proliferation, apoptosis, or differentiation of the suture mesenchyme or bone fronts and
failure to form a tissue boundary.
Proliferation and Differentiation: Heterozygous mutations in the Fibroblast Growth
Factors (FGFs) and their receptors (FGFRs) account for the majority of nonsyndromic
craniosynostosis cases where the etiology is known. These mutations are mostly gain-of-
function mutations resulting in increased affinity between the ligand and the receptor,
decreased specificity for receptor-ligand interactions, or increased receptor stabilization
(Table 1.1).  In general, these mutations have been associated with increased cell
proliferation in the osteogenic fronts, leading to craniosynostosis (Lenton et al., 2005).
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Table 1.1.  Known craniosynostosis genes, their associated syndromes, mutation
types, and mechanism that leads to suture fusion.
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Studies in wild-type sutures in mice revealed Fgfr2 expression in proliferating
osteoprogenitor cells in the bone fronts, at a site mutually exclusive of osteopontin
expression, an early marker for osteoblasts differentiation.  FGF2 protein was localized to
the regions low in Fgfr2 expression, and was associated with increases in expression of
the differentiation markers osteopontin and osteonectin, reduced proliferation, and
increased Fgfr1 expression.  As differentiation progressed, Fgfr2 was downregulated and
Fgfr1 was upregulated, suggesting that signaling through Fgfr2 mainly played a role in
proliferation, while Fgfr1 signaling regulated osteogenic differentiation (Iseki et al.,
1999).
Axin-2 is a negative regulator of the canonical WNT pathway and is required for
reduction of β-catenin during osteoblast development (Liu et al., 2007).  Axin-2 is highly
expressed in the cranial neural crest, including the cranial bone fronts and sutures.  The
targeted loss of Axin2 results in craniosynostosis, with the postnatal fusion of both the
Jugum Limitan (the suture that separates the frontal and nasal bones) and the
interfrontal suture (Yu et al., 2005).  For both of these sutures, all components (the suture
mesenchyme and the bones) are derived from the cranial neural crest.  The deficiency in
Axin-2 resulted in increased proliferation of the osteoprogenitor pool and thus increased
intramembranous ossification (Yu et al., 2005).  As an inhibitor of WNT signaling, the
loss of Axin-2 resulted in the accumulation of β-catenin in the membrane, a process
inhibited by Noggin.  Therefore, a BMP signal, initially induced by WNT signaling due
to the loss of Axin2, controlled β-catenin localization to the plasma membrane in mature
osteoblasts.  This increased β-catenin induced cell-cell interactions, promoting osteogenic
differentiation.  Furthermore, haploinsufficiency for β-catenin rescued the suture defects
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in Axin-2 homozygous mutant mice (Liu et al., 2007).  Therefore, Axin-2 deficiency
promotes suture fusion by affecting both the proliferation and differentiation of
osteogenic cells.
Apoptosis: Apoptosis is hypothesized to contribute to premature suture fusion in
multiple ways.  In histological analysis of patients with craniosynostosis have revealed
both increased and decreased apoptosis in sutures actively fusing.  Apoptotic bodies were
observed in the bone fronts flanking normal sutures (Furtwangler et al., 1985).  In this
location, apoptosis is thought to control the population of proliferating and differentiating
cells.  There is evidence that as the posterior interfrontal suture undergoes predictable
fusion in postnatal development, there is a dramatic decline in the number of apoptotic
cells in the bone fronts of the paired frontal bones compared to the anterior interfrontal
suture, which remained patent (Agresti and Gosain, 2005).
In contrast, others have hypothesized that an increased rate of apoptosis
contributes to fusion of a suture by reducing the number of cells occupying the suture
space and bringing the bone fronts in closer proximity.  This appears to be in the case in
mutation Ser252Trp of FGFR2, which is associated with the craniosynostosis syndrome,
Apert Syndrome.  The corresponding mutation, when introduced in mice, resulted in
coronal craniosynostosis and reduced bone formation due to increased apoptosis of the
osteogenic cells.  This resulted in the physical contact of the frontal and parietal bones
(Chen et al., 2003).  Studies in human and mouse calvaria cell lines demonstrated that
increased expression of FGF-2 resulted in increased apoptosis.  The introduction of
human-associated Apert FGFR2 mutations into cell lines both inhibited differentiation
and increased apoptosis (Mansukhani et al., 2000).
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Boundary formation: The formation of boundaries is a common theme throughout
development and is necessary for the proper patterning of structures.  Boundaries form
during the segmentation of the presomitic mesoderm into individual somites, between the
hindgut and the foregut, and the larval wing imaginal discs in Drosophila (Dahmann et
al. 2011).  Sometimes boundaries are not created by differences in origin, but instead a
boundary set by gene expression. For example, expression of wingless and apterous in
the Drosophila larval wing disc establish the dorso-ventral boundary, which activates
vestigial expression at that boundary to stimulate wing patterning and growth (Williams
et al., 1994).
Some human cases of coronal craniosynostosis were found to result from a failure
to form the boundary between the neural crest-derived frontal bone and the paraxial
mesoderm-derived parietal bone.  Saethre-Chotzen syndrome in humans is caused by a
heterozygous loss of function in TWIST1, a highly conserved transcription factor (Merrill
et al., 2006).  Using the neural crest lineage tracing system in Wnt1-Cre and R26R lines,
Merrill and colleagues examined the boundary between these two bones at the CS in
mice.  They found that while the boundary between the neural crest and paraxial
mesoderm remained distinct in wild-type mice, Twist1+/- mice exhibit cell mixing, with
migration of neural crest-derived cells into the paraxial mesoderm (Fig 1.3B) (Merrill et
al., 2006).  This phenotype was first evident at E14.5, corresponding to the timepoint
when ephrin-A2 and ephrin-A4, members of a group of proteins known to be involved in
boundary formation and the inhibition of cell mixing, are transiently expressed in normal
mice.  Ephrin-A2 and ephrin-A4 are localized to a single layer of cells on the ectocranial
side of the early frontal bone, where the frontal bone will eventually overlap with the
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parietal bone.  EphA4 was found in two layers of cells flanking that of ephrin-A4.  In
Twist1 mutant mice, the ephrin-A2 and eprhrin-A4 localization was retracted anteriorly
and away from the suture while the two layers of EphA4 was merged into one (Merrill et
al., 2006).  Likewise, several heterozygous mutations in EFNA4 and EFNB1 have been
identified in patients with non-syndromic craniosynostosis and craniofacial syndromes
(Merrill et al., 2006).  The authors speculated that Twist1 interacts with Msx2, the
underlying gene in Boston-type craniosynostosis, to control the expression of the ephrins
(Merrill et al., 2006).  The expression domain of Msx2 in the calvarial mesenchyme of the
frontal bone was expanded in the Twist1+/- mutant.  Crossing Twist1+/- to Msx2+/- mice
rescued the suture defect, restoring the boundary and expression of the ephrins.
Multiple mechanisms: The underlying mechanisms in the Twist1 mutant cannot be
attributed only to failed boundary formation.  Further evidence suggests that Twist1 may
be involved in separate mechanisms at different points in development.
Haploinsufficency or inhibition of Twist1 expression resulted in decreased cell
proliferation in the suture mesenchyme and increased osteogenic differentiation in the
bone fronts (Yoshida et al., 2005).  This suggests that the gene may play an early role not
only in the proper guidance of the migrating neural crest population to form the boundary
between the neural crest-derived frontal bone and the paraxial mesoderm-derived parietal
bone, but also a later role in the maintenance of the suture structure as development
progresses.
Fusion in the Twist1 mutant occurs postnatally two weeks after birth.
Surprisingly, between postnatal days (P) 9 and 11, chondrocytes were visible within the
CS along with the upregulation of cartilage markers (Behr et al., 2011).  This was
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followed by ossification through the CS, suggesting that craniosynostosis was, at least in
part, due to endochondral ossification of the suture mesenchyme.  Previous studies
demonstrated a similar mechanism contributing to the normal closure of the posterior
interfrontal suture (Sahar et al., 2005).  This is particularly interesting because
endochondral ossification does not normally contribute to ossification of the cranial
bones, and also because the sutures have different origins: the interfrontal suture is neural
crest-derived and the CS is mesoderm derived (Jiang et al., 2002).  In the posterior
interfrontal suture (Sahar et al., 2005) and the sagittal suture (Behr et al., 2010), fusion
was temporally correlated with a decrease in WNT signaling, presumably by inhibiting
Twist1, a target of the WNT pathway, and suggesting similar interactions occur in the CS.
Although Msx2 was associated with boundary formation in the Twist1 mutant,
genetic analyses suggest overlapping phenotypes.  Gain of function mutations in Msx2
produced premature suture fusion in mice and humans, whereas loss of function
mutations caused calvarial ossification defects with persistent frontal foramina.  This
foramina defect was thought to result from defects in the differentiation and proliferation
of the neural crest-derived frontal bone mesenchyme (Ishii et al., 2003).  Twist1+/- mice
also presented with persistent foramina, and the defect was exacerbated in Twist1+/-;
Msx2+/- compound mutants (Ishii et al., 2003).  The authors concluded that in the case of
frontal bone growth, Msx2 (a target of the BMP pathway) and Twist1 (a target of the FGF
pathway) did not function within a linear pathway, but instead through integration of two
separate pathways to control the differentiation and patterning of the frontal bone.
Nell-1 was first identified in a candidate screen to identify genes overexpressed in
the sutures of craniosynostosis patients.  Nell-1, hypothesized to be a signal peptide
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involved in intramembranous ossification (Lenton et al., 2005), is expressed in the bone
fronts and suture mesenchyme (Ting et al., 1999).  Transgenic mice over-expressing Nell-
1 presented with fusion of the interfrontal and sagittal sutures and partial fusion of the
CS.  Histological analysis of these mice revealed both increased differentiation and
reduced proliferation at the suture, while in vitro analysis demonstrated the ability of
Nell-1 to stimulate differentiation and mineralization in calvarial osteoblast cell lines.
Furthermore, Nell-1 expression was associated with increased apoptosis of osteoblasts in
the bone fronts of fusing sutures (Zhang et al., 2002).
Clearly, there is evidence that many craniosynostosis-associated genes can play a
role in multiple mechanisms involved in the formation and maintenance of the suture
structure at different times in development, and that there is no one definitive cause of
premature suture fusion.
Interaction of craniosynostosis pathways
It is becoming increasingly clear that the dynamics of suture development and
signaling cannot be described by a simple mechanism.  The story is further complicated
through interactions between different pathways, as depicted in Figure 1.6.  An example
of this is Twist1, which is negatively regulated by E protein, a basic helix-loop-helix
transcription factor.  Id protein, a helix-loop-helix factor that lacks the basic domain,
binds to E proteins to prevent Twist1/E protein heterodimers (Connerney et al., 2006).
The expression of Id protein in the bone fronts is induced by BMP signaling, and
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Figure 1.6.  Signaling dynamics and interacting pathways in the development and
maintenance of the suture.  Demonstration of the complex interaction of multiple
pathways involved in suture development.  For example, BMP signaling intersects with
the pathway involved in boundary formation at the coronal suture through Msx2 and also
through Id protein, which restricts the formation of Twist1 heterodimers.  Therefore, a
perturbance in an one of these pathways could impact  BMP, FGF, or WNT signaling.
Diagramed by Doug Mortlock.
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therefore BMP signaling indirectly enhances Twist1 function even though Twist1 itself is
regulated by the FGF pathway (Connerney et al., 2006).  Another transcription factor,
Foxc1, is required for BMP-mediated regulation of Alx4 and Msx2, but its expression is
also induced by FGF2 in calvarial mesenchyme, thereby integrating the FGF and BMP
pathways independently of Twist1 (Rice et al., 2005).  There is also evidence that FGFs
can induce BMP expression in the calvaria through a Runx2-dependent mechanism (Choi
et al., 2005).
Axin-2, which is a regulator of WNT signaling, is involved in the proliferation and
differentiation of osteogenic cells at the suture.  Although its effects on proliferation are
independent of BMPs, it promotes osteogenic differentiation in a positive feedback loop
with BMPs (Liu et al., 2007).  All these data suggest that a change within a single
pathway can have large repercussions on overall signaling within the suture and bone
fronts.
Beyond the suture mesenchyme
Multiple signals are required to maintain a suture in an undifferentiated state.
These signals are not only derived from the suture mesenchyme and bone fronts, but also
from the underlying dura mater and periosteal layers.  There is a great deal of evidence
that the dura mater plays a critical role in cranial morphogenesis.  Although it is not
required to establish the suture, it provides a signal(s) required for suture maintenance.  In
one study the position of the dura was altered such that the dura mater underlying the
anterior interfrontal suture (which normally remains patent) was moved to a new position
under the posterior interfrontal suture (which normally fuses).  In this study, the posterior
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interfrontal suture remained patent and the anterior interfrontal suture fused.  This
suggests that once the suture is initiated, the underlying dura mater is altered, possibly by
inducing the dura to prevent the sending of osteogenic signals to the suture mesenchyme.
Osteoblasts cultured with dural cells undergo a greater degree of differentiation,
particularly when dural cells are used that are derived from below the posterior
interfrontal suture (Warren et al., 2003b).  This is likely due to paracrine signaling
emitted from the dura mater which signals to the suture and bone fronts.
Although much less focus has been placed on the periosteum compared to the
dura, there is evidence that it also plays a role in the dynamics at the suture.  Removal of
the periosteum from neonatal rats led to the consistent fusion of the entire interfrontal
suture, and occasionally the coronal and sagittal sutures (Moss, 1960).  During
calvariectomies of neonatal rabbits, the cranial bones and sutures reformed at the correct
anatomical positions, but this process was dependent upon a continuous, undamaged
periosteum at the site (Mabbutt and Kokich, 1979).  Additionally, the overlying ectoderm
induces the underlying neural crest-derived cells to ossify in the frontal bone in chick
(Tyler, 1983); specifically, BMP signals from the head epidermis are thought to induce
the neural crest-derived cells to form bone by causing them to express Runx2, a gene
involved in osteoblast differentiation (Ducy and Karsenty, 2000). 
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Bone morphogenetic proteins
Classification and signaling
The BMPs are a subgroup of the Transforming Growth Factor-Beta (TGFβ)
family of growth factors.  Almost a third of the TGFβ family is comprised of BMPs, with
over twenty different proteins identified (Fig 1.7A) (Ducy and Karsenty, 2000).  The
members of the BMP family are referred to as BMPs, osteogenic proteins, cartilage-
derived morphogenetic proteins, or growth differentiation factors (GDFs) (Ducy and
Karsenty, 2000).  They are divided into subgroups based on amino acid sequence
comparison.  Two of these subgroups, BMP2/4 and BMP5/6/7/8 are found in many
organisms, including worms and flies.  Members within each group share 74-92%
identity in the amino-acid sequence in the C-terminal signaling region, while members
share 40-60% identity across families (Storm et al., 1994).
BMPs were named by Urist et al for their ability to induce bone formation when
planted ectoptically (Urist, 1965).  BMP-2, -4, -5, -6, -7, and –9 are known as the most
osteogenic BMPs, whereas BMP3 appears to antagonize BMP signaling (Xiao et al.,
2007).  Despite their name, BMPs are involved in many developmental processes,
including cell proliferation and differentiation, apoptosis, mesoderm formation and
patterning, neural patterning, morphogenesis, and organogenesis (Ducy and Karsenty,
2000; Hogan, 1996).
BMPs are synthesized as large precursors and cleaved at Arg-X-X-Arg consensus
sites to form carboxy-terminal mature dimers (Ducy and Karsenty, 2000).  The core of
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Figure 1.7.  The Bone Morphogenetic Protein family and signaling mechanism.  A)
The BMP family tree with the GDF subfamily highlighted in the box.  Adapted from
Ducy and Karsenty, 2000.  B) Generalized signaling pathway for BMP family members.
BMP dimers bind to heterodimeric serine-threonine kinase transmembrane receptors,
termed Type I and Type II receptors.   The Type II receptors transphosphorylates the
Type I receptor, activating the Type I kinase, which in turn activates the Smad proteins
1/5/8.  The Smad proteins then translocate to the nucleus where they activate a set of
target genes.  C) Mechanisms of antagonism of BMP signaling.  Where the BMP
antagonist Noggin inhibits signaling by binding to the BMP ligand, and thereby
preventing ligand-receptor interactions, BMP3 inhibits by competing for interaction with
the receptors.  Adapted from Nacamuli et al. 2005.
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each monomer consists of six cysteine residues that reside in the C-terminal domain of all
members of the BMP family (Ducy and Karsenty, 2000) with a seventh cysteine domain
used to dimerize with a second monomer (Xiao et al., 2007).  This distinguishes BMPs
from other members of the TGFβ family, which generally have nine conserved cysteines
in the mature region (Hogan, 1996).  Prior to secretion, BMP monomers consist of an
amino-terminal signal peptide, a prodomain, and mature carboxy terminal peptide.  After
the signal peptide is cleaved, the precursor protein is glycosylated and dimerized (Xiao et
al., 2007).
Upon secretion, the prodomain is cleaved.  Mature BMPs are secreted as
homodimers or heterodimers and then bind to heterodimeric transmembrane receptors
(Fig 1.7B).  These serine-threonine kinase receptors have been termed type I and type II
receptors.  The type II receptors with BMP-binding ability include the type II BMP
receptor (BMPR-II) and activin receptors (ActRIIa and ActR-IIb).  They also bind three
type I receptors, type IA and type IB receptors (BMPR1a and BMPR1b) (Xiao et al.,
2007).  At least in vitro, a given BMP can recognize more than one type II receptor, and
therefore have the ability to interact with multiple type I receptors.  The type II receptors
also have the ability to bind to different ligands with different affinities, providing yet
another regulatory mechanism to the BMP pathway (Hogan, 1996).
Upon binding of the BMP ligand, the constitutively active type II receptor
transphosphorylates the type I receptor, leading to the activation of type I receptor
kinases (Xiao et al., 2007).  This is followed by the activation of the Smad proteins;
Smad 1, 5, and 8 (Ducy and Karsenty, 2000), which are then recruited to a common
mediator and co-Smad, Smad 4 (Xiao et al., 2007).  The Smad proteins then translocate
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to the nucleus where they activate a set of target genes (Ducy and Karsenty, 2000).
Smads can bind to DNA directly or in cooperation with other transcription factors or bind
and displace nuclear factors from their DNA binding sites (Canalis et al., 2003).  Little is
known about this set of downstream genes that are targeted by BMP signaling, although
there is evidence for the activation of the Hox genes by BMPs in Drosophila, mice, and
chick model systems (Hogan, 1996).
BMP signaling can be inhibited by antagonists, including Cerbarus, Dan,
Gremlin, Chordin, and Noggin, all which bind different BMPs with varying specificities
and prevent interaction with their receptors (Fig 1.7C) (Xiao et al., 2007).  For example,
Noggin preferentially binds to BMP2 and BMP4 over BMP7 (McMahon et al., 1998).
Intracellularly, BMP signaling can be blocked by inhibitory Smads that can bind and
activate the receptors, but are unable to activate downstream genes (Canalis et al., 2003).
Growth differentiation factor (Gdf) subfamily
The Growth Differentiation Factors (GDFs) 5, 6, and 7 are a highly conserved
subset of the BMP family of signaling molecules.  Unlike other members of this family,
the GDF group is not known for their bone-inducing ability, but for their critical role in
limb joint formation and chondrogenesis (Storm and Kingsley, 1999).  In mice, the Gdf
genes are some of the earliest markers of limb joint formation and are expressed in stripes
corresponding to sites where joint formation will later occur.  The expression of the Gdfs
in the limbs usually represents a subset of the joints in the structures, with some overlap
between members of the subfamily, and some sites of unique expression.  For example,
Gdf5 expression overlaps with Gdf6 in the elbow and carpal joints at E13.5, but only
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Gdf5 is expressed in shoulder, metacarpophalangeal, and interphalangeal joints (Settle et
al., 2001).  A similar expression pattern is observed in the knee (Fig 1.8F-G).  In limbs,
Gdf7 is only expressed in a stripe across the proximal interphalangeal joint (Fig 1.8H,
arrow).  The GDF5/6/7 subgroup is highly conserved, sharing 80-86% identity (Storm et
al., 1994) but is only found in vertebrate organisms.
The receptors utilized by the Gdf family were identified by their ability to activate
a BMP-responsive promotor construct and phosphorylate Smad1 in MC3T3 cells
(Mazerbourg et al., 2005).  Gdf5, Gdf6, and Gdf7 can all utilize the type I receptors
BMPRIa and BMPRIb and the type II receptors BMPR-II and ActRIIa to activate the
Smad1/5/8 pathway.  This receptor usage is shared with several other members of the
BMP family, including BMP2 and BMP4 (Mazerbourg et al., 2005).  It is difficult to
determine if these are the only receptors utilized by the Gdf family, since mutant embryos
lacking either of the receptors BMPR-II and BMPRIa both suffer early embryonic
lethality due to failed gastrulation and mesoderm formation, respectively.  The BMPRIb
homozygous mutant mouse presents with only defects in cartilage formation of the limbs
(Yi et al., 2000) while the phenotype for ActRIIa homozygous mutant mice are
characterized by only a hypoplastic mandible (Matzuk et al., 1995).  Due to the lack of
other abnormal phenotypes in the BMPRIa and ActRIIa homozygous mutant mice, it is
likely there is some redundancy between the known BMP receptors or with receptors yet
to be characterized.
Despite the high conservation between members of the Gdf family, they present
with surprisingly distinct phenotypes.  Mice lacking the sub-family member Gdf7 have
no known skeletal defects, although Gdf7 does play a role in the development of the
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seminal vesicles and spinal cord interneurons (Lee et al., 1998; Settle et al., 2001).  The
Gdf5 gene is mutated in the brachypodism (bp) mouse, which results in reduced length of
several long bones of the limb, and fusions of the first two bones in most of the digits
(Storm et al., 1994).  Homozygous mutations in Gdf5 disrupt up to 30% of the joints in
the limbs (Storm and Kingsley, 1996).  The proposed functions of Gdf5 include the
regulation of joint formation in the limb and cartilage formation in the sternum (Storm
and Kingsley, 1996).
The Gdf6 homozygous mutant phenotype
Gdf6, also known as BMP-13 and CDMP2, resides on human chromosome
8q22.1 and chromosome 4qA1 in mice and is comprised of two exons.  The Gdf6 mutant
mouse was generated by replacing the second exon, which includes the entire mature
signaling region and a portion of the pro-region, with a neomycin cassette (Settle et al.,
2001).  On a 129/SvJ and C57BL/6J mixed background, Gdf6 homozygous mutants were
able to survive to weaning.  However, the number of surviving mice was less than the
expected 1/4.  The reduction in Gdf6-/- progeny likely occurred at the perinatal period,
since normal Mendelian genotype ratios were found at E18.5 (Settle et al., 2001).
Like Gdf5, Gdf6 is expressed in stripes across skeletal condensations before they
are separated into distinct elements by the joints.  Gdf6 is expressed in the carpal joints
and elbow of the forelimb, and likewise the ankle joints and knee of the hindlimb, from
E13.5-E14.5 (Settle et al., 2001).  Gdf6-/- mice present with fusions of the second, third,
and central carpals in the wrist (Fig 1.8A, A’).  In the ankle, the second and third tarsals
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Figure 1.8.  Skeletal phenotypes of the Gdf6 mutant mouse.    Defects include: A, A’)
fusion of the second, third, and central carpals of the wrist (arrows); B, B’) fusion of the
second and third tarsals (upper arrow) and the central tarsal and the talus (lower arrow),
and shortening of the first distal tarsal (asterix); C,C’) increased gaps and altered
articulations in the malleus, incus, and stapes bones of the middle ear; D, D’) hypoplasia
of the thyroid cartilage and epiglottis and fusion of the arytenoid cartilages; E, E’)
craniosynostosis of the coronal suture (arrow).  Members of the Gdf family are expressed
in joints, including the joints of the ankle (F, G) and the interphalangeal joints of the
digits (F, H).  a, ankle; ac, arytenoid cartilage; d, interphalangeal joints of the digits; ep,
epiglottis; i, incus; m, malleus; s, stapes; tc, thyroid cartilage.
All panels adapted from Settle et al 2003 except for D and D’ (J. Witherspoon and D.P.
Mortlock, unpublished)
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are fused (Fig 1.8B, B’ upper arrow), along with the central tarsal and the talus (Fig 1.8B,
B’ lower arrow), with shortening of the first distal tarsal (Fig 1.8B, B’ asterix) (Settle et
al., 2001).
The bones of the wrist and ankle form from larger precursors that divide into
separate skeletal elements.  As early as E14.5, these early condensations in the Gdf6-/-
mouse fail to separate into individual elements at sites of bone fusion, pointing to a very
early role of Gdf6 in joint development.  However, early markers for joint formation,
including Gdf5 and PTHrP, are observed at the site of future joint fusion, albeit at
reduced or restricted levels, pointing to an initial start of the joint formation process that
fails to progress in the Gdf6-/- mouse (Settle et al., 2003).
In addition to the joints, defects were also observed in the middle ear bones, the
malleus, incus, and stapes (Fig 1.8C, C’).  The gaps between the malleus and the incus
(Fig 1.8C, C’ blue arrows) and the incus and the stapes (Fig 1.8C, C’ green arrows) bones
were increased in the Gdf6-/- mouse.  There were also changes in the shape of each bone;
for example, the stapes lost the processes that articulate with the oval window (Fig 1.8C,
C’ red arrows).  Gdf6 is normally expressed between each of the bones and where the
stapes meets the oval window.  Here, Gdf6 appears to function primarily in cartilage
growth and cell proliferation, as evidenced by the reduced proliferation in regions where
the bones oppose one another, with no changes in proliferation of cells in the interior of
the cartilage elements (Settle et al., 2003).
Another characteristic feature of the Gdf6-/- mouse was hypoplasia of the thyroid
cartilage and epiglottis.  The arytenoid cartilages, which are normally paired, were fused
(Fig 1.8D, D’).  Gdf6 was not expressed in the cartilage element itself, but instead in the
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mesenchyme adjacent to the thyroid cartilage and in the vocal cords at E14.5 (Mortlock
et al., 2003).
The Gdf6-/- mice also lack the CS, the joint that separates the frontal and the
parietal bones of the skull (Fig 1.8E, E’). This suggests that Gdf6 may be a candidate
gene for craniosynostosis and may play a critical role in the development or maintenance
of the CS.
Evidence for BMP involvement in suture development
The contribution of BMPs to skull vault development has been little explored due
to the fact that homozygous mutants for key BMP family members are often embryonic
lethal; Bmp2 homozygous mutant mice generally die by E10.5 with defects in amnion
and heart development (Zhang and Bradley, 1996), Bmp4 homozygous mutant mice die
by E9.5 due to failed mesoderm differentiation (Winnier et al., 1995), and Bmp7
homozygous mutant mice are perinatal lethal due to defects in kidney development
(Dudley et al., 1995).  However, Bmp2, Bmp4, and Bmp7 are all expressed in the cranial
bone rudiments at some point during calvarial development.  Both Bmp4 and Bmp2 are
expressed in the osteogenic fronts, and Bmp4 is further expressed in the suture
mesenchyme and the dura mater underlying the suture mesenchyme (Slater et al., 2008).
There have been several abnormal suture phenotypes associated with the effectors
of BMP signaling.  Alx4, FoxC1, and Msx2 are BMP-responsive transcription factors.
Mutants for each of these genes have a defect in frontal bone formation (Antonopoulou et
al., 2004; Rice et al., 2003).  Furthermore, Msx2 mutant mice have a reduction in the size
of the frontal bone rudiment (Ishii et al., 2003), and Msx1/Msx2 compound mutants had
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complete failure of frontal and parietal bone formation (Han et al., 2007).  Msx2 contains
a BMP-responsive enhancer with a consensus site for Smad binding that controls the
temporal and spatial pattern of BMP-dependent transcription (Brugger et al., 2004).  As
described previously, Msx2 was ectopically expressed in the Twist1 mutant CS, resulting
in the mixing of the boundary between the frontal and parietal bone and coronal
craniosynostosis (Merrill et al., 2006).
The conditional deletion of Bmp4 in the neural crest produced a frontal foramen
phenotype similar to that of Msx2 (Maxson and Ishii, 2008).  Furthermore, Noggin is
expressed postnatally in patent but not fusing rat sutures, and down-regulated in the
posterior interfrontal suture, which normally fuses in rats by P45.  At this same timepoint,
Noggin continued to be expressed in the sagittal and CSs, which remained patent.  Bmp4
was also expressed in the suture mesenchyme and bone fronts of both patent and fusing
posterior interfrontal sutures.  Although Noggin is an antagonist of BMP signaling, BMPs
actually stimulated Noggin expression.  Recombinant human BMP2 protein-coated beads
placed in calvarial explants induced the expression of Noggin (Rice et al., 2005).
Furthermore, primary calvarial osteoblasts expressed Noggin in a dose-dependent manner
when treated with Bmp4 (Warren et al., 2003a).  The suppression of Noggin, despite
Bmp4 stimulation, may be achieved through FGF2, which was only expressed in the
posterior interfrontal suture.  This is indeed the case.  Injection of an FGF2-expressing
adenovirus into the CS suppressed Noggin expression and produced suture fusion.  Gain
of function mutations in FGFR2 associated with Apert’s and Crouzon craniosynostosis
syndromes also inhibited Noggin protein production in the suture and blocked Bmp4-
mediated stimulation of Noggin expression (Warren et al., 2003a).  Together these data
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suggest a role for Noggin in the maintenance of suture patency and may be part of an
underlying mechanism in FGF and FGFR-associated craniosynostosis.
Bmp3 is another antagonist of Bmp4 and Bmp2 signaling that functions by
activating a TGF-β/activin-specific pathway.  If activin and BMP signaling cascades are
activated in the same cell, the strength of each signal will reflect competition for Smad 4,
a common factor in both pathways (Candia et al., 1997).  Therefore, activin is thought to
act as an antagonist to the BMP pathway  (Fig 1.7 C).  Overexpression of Bmp3 resulted
in increased Msx2, and reduced ALP activity and osteocalcin expression (Nacamuli et al.,
2005).  Bmp3 expression differs between the sutures.  In the murine posterior interfrontal
suture, which undergoes postnatal fusion, the expression of Bmp3 decreased over time.
However, in the sagittal suture, which remains patent, Bmp3 expression increased over
time.  These differences between the sutures were most notable during the period in
which the posterior interfrontal suture was undergoing fusion (Nacamuli et al., 2005).
Interestingly, the Bmp3-/- mouse had no abnormal suture phenotype or any abnormal
skeletal phenotype for that matter, other than increased bone density during adulthood
(Daluiski et al., 2001).  However, this might be attributed to redundancy with other BMP
antagonists, including Noggin.
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THESIS OVERVIEW
Although craniosynostosis is a fairly common birth defect, affecting 1 in 2,000
infants, the field of study has been restricted to the study of a small, defined group of
genes, with much of the literature focused on the Fgf receptors, Twist, and Msx2.   The
known genes associated with craniosynostosis can explain only a minority of patient
cases.  Although BMPs are expressed in the suture region, and are historically known for
their roles in skeletogenesis and patterning, Gdf6 is the only member of the BMP family
to be directly associated with abnormal suture fusion, in part due to the common lethality
of BMP homozygous mutant mice.  Gdf6 is itself an understudied member of the BMP
family.  The information known about Gdf6 is restricted to the mutant phenotype, some
sites of expression at specific timepoints in development, the cis-regulation of the gene,
and receptor usage.  Little is known about genes the downstream signaling and how Gdf6
interacts with other members of the BMP family.  The study of Gdf6 in relation to the
suture may provide a large opportunity not only to understand how Gdf6 could explain,
or at least contribute to, a portion of craniosynostosis cases with an unknown etiology,
but also would further advance the understanding the functions of Gdf6, the Gdf
subfamily, and BMPs in general.
This project began with a simple phenotype in the Gdf6 homozygous mutant
mouse: the failure to form the CS.  From there, the goal of the project was to gain a more
thorough developmental understanding of how Gdf6 contributes to the formation of this
structure.  This was to be done through the analysis of when and where Gdf6 is expressed
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during cranial development, the mechanism leading to craniosynostosis of the CS, and
possible interactions between Gdf6 and other members of the BMP family.
Chapter II describes the precise timepoint in development when a suture defect is
first apparent in the Gdf6-/- embryo, in addition to exploring each of the known
mechanisms that could lead to suture fusion (such as changes in the proliferation,
apoptosis, or differentiation of the cells of the osteogenic bone fronts and suture
mesenchyme or failure to form the boundary between the neural crest-derived frontal
bone and paraxial mesoderm-derived parietal bone).  Using bead implantation methods,
we demonstrate the in vivo effects of Gdf6 in the frontal bone primordia.
The goal of Chapter III was to determine if Gdf6 was interacting with fellow BMP
family member, Bmp4, in the development of the CS through genetic crosses of
heterozygous mice.  Chapter IV summaries the additional phenotypes found in the
crosses between Gdf6 and Bmp4, which together demonstrate a unique relationship
between Gdf6 and Bmp4.  Finally, Chapter V explores the relationship between Gdf6 and
its antagonist Noggin, which has known functions in the maintenance of suture patency.
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CHAPTER II
THE BMP LIGAND GDF6 PREVENTS DIFFERENTIATION OF CORONAL
SUTURE MESENCHYME EARLY IN CRANIAL DEVELOPMENT
Introduction
The mammalian skull is composed of five main flat bones separated by joints
known as the cranial sutures.  These sutures are composed of fibrous connective tissue
and act as the main sites for cranial growth during development.  As the cranial vault
expands, bone is deposited at the growing edges of the bone (the bone fronts), while the
suture mesenchyme remains undifferentiated.  Sutures provide flexible joints for passage
through the birth canal, act as shock absorbers, prevent separation of the cranial bones,
and accommodate room for the rapidly growing brain (Cohen, 2005). With the exception
of the metopic suture, human sutures normally do not fuse until the third or fourth decade
of life (Furuya et al., 1984), when the undifferentiated mesenchyme of the suture space
becomes obliterated by bone.
Craniosynostosis is defined as the premature fusion of one or more of the cranial
sutures and occurs in approximately 1 in 2,500 live births (Wilkie, 1997).  When a suture
fuses prematurely, cranial growth ceases perpendicular to the site of fusion, producing a
dysmorphic skull shape.  When the calvarial vault does not expand sufficiently to
accommodate the rapidly growing brain, increased intracranial pressure can occur
(Kabbani and Raghuveer, 2004).  Coronal craniosynostosis can result from a failure to
form the boundary between the neural crest-derived frontal bone and the paraxial
mesoderm-derived parietal bone.  This failed mechanism is evident as a mixing of the
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two tissue populations at sites of suture fusion, as seen in the Twist1 mutant mouse
(Merrill et al., 2006).  It is thought that Twist1 works with Msx2 to control the
localization of ephrin-A2 and ephrin-A4, which are known to play roles in boundary
formation at the frontal/parietal junction (Merrill et al., 2006).  Several additional
mechanisms could lead to fusion of a cranial suture.  These include changes in
proliferation, apoptosis, or the rate of differentiation of the suture mesenchyme or at the
leading edges of the ossifying bone.
For example, gain of function mutations in FGFRs are associated with
craniosynostosis in humans.  Studies in normal mice found Fgfr2 expression in
proliferating osteoprogenitor cells surrounding the ossifying bones while Fgfr1 is
expressed in the frontal and parietal developing bone.  As differentiation progresses,
Fgfr2 is down-regulated and Fgfr1 is upregulated, suggesting that signaling through
FGFR2 mainly plays a role in proliferation, while FGFR1 signaling regulates osteogenic
differentiation (Iseki et al., 1999).
GDFs 5, 6, and 7 are members of the BMP family of secreted signaling
molecules.  The GDF subgroup (GDF5/6/7) is highly conserved in vertebrates and has a
known critical role in limb joint formation and chondrogenesis (Storm and Kingsley,
1999).  Gdf6 homozygous mutant mice display multiple joint defects, including fusions
of tarsal and carpal bones, morphological abnormalities in the malleus, incus, and stapes
bones of the middle ear, and hypoplasia of the thyroid cartilage.  In addition to these
defects, Gdf6-/- mice lack the CS (Settle et al., 2003).  However, the detailed expression
pattern of Gdf6 along with the onset of cranial suture fusion is not reported.
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Gdf5 is the gene associated with brachypodism in mice and is hypothesized to
function mainly in the stimulation of cartilage development, growth, and maturation
(Storm and Kingsley, 1999).  Therefore, Gdf5 can be viewed as promoting aspects of
endochondral bone growth.  Gdf5 and Gdf6 share approximately 80% identity in the
mature signaling region (Storm et al., 1994) and therefore it is likely the Gdf5 and Gdf6
operate by similar mechanisms.  Like Gdf5, Gdf6 can promote chondrogenic
differentiation in vitro (Nochi et al., 2004).  This makes the craniosynostosis phenotype
in the Gdf6-/- mouse particularly interesting because unlike the long bones, the cranial
bones form through intramembranous ossification without a cartilage intermediate.
Therefore, the mechanism of Gdf6 function in the CS may be drastically different than its
function in the other joints.
The aim of this study was to gain a more thorough developmental understanding
of craniosynostosis in the Gdf6-/- mouse and the underlying cause of suture fusion.  We
found that CS fusion occurs in the Gdf6-/- mouse before the first evidence of cranial bone
ossification is observed at E14.5, with changes in early osteogenic markers detected prior
to the onset of ossification.  Our data suggest that Gdf6 may self-regulate its expression in
the developing frontal bone primordium.  Additionally, fusion in the Gdf6-/- mouse is not
due to a failure to form the boundary properly between the frontal and parietal bones, or
changes in cell survival or proliferation, but is likely due to a failure of the suture
mesenchyme to remain in an undifferentiated state.
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Materials and Methods
Mouse crosses
The Gdf6-/- mouse (Settle et al., 2003) was a gift from Dr. David Kingsley and
was backcrossed onto a C57BL/6J background for more than 10 generations.  The Gdf6-
/- allele appears to be perinatal lethal on this background, since no Gdf6-/- adults or
weanlings were found during the described crosses, although normal Mendelian ratios
were present at late embryonic stages (not shown).  Therefore, all timepoints in which the
Gdf6-/- phenotype was analyzed were collected prenatally.  For fate mapping
experiments, Gdf6+/- mice were crossed to R26R+/- (Soriano, 1999) to produce Gdf6+/-;
R26R+/- compound heterozygotes, which were then crossed to Wnt1Cre+/- (Danielian et
al., 1998); Gdf6+/- mice.  The Wnt1-Cre line was maintained on a CD1 background.
Embryonic age was determined through detection of the vaginal plug, with noon of that
day observed as E0.5.  Animal protocols (M/09/293 and M/04/381) were approved by the
Institutional Animal Care and Use Committee at Vanderbilt University.
DNA preparations and Genotyping
DNA preparations were collected using tail snips (from postnatal mice) or yolk
sacs (from embryos), which were placed in a 1.5 ml microcentrifuge tube.   0.7 ml of
lysis buffer [100 mM Tris-HCl pH 8.5, 5 mM EDTA pH 8.0, 0.2% sodium dodecyl
sulfate (SDS), 200 mM NaCl] with 125 ug freshly added Proteinase K (RPI).
Preparations were digested overnight in a 55oC water bath.  0.5 ml of
phenol:chloroform:isoamyl alcohol (Sigma) was added in the hood, vortexed, and spun
44
down at maximum speed (13,000 rpm) for 5 minutes.  400 ul of the aqueous (upper)
phase was transferred to a new 1.5 ml microcentrifuge tube containing 800 ul 100%
ethanol and 40 ul of 3M sodium acetate.  The preparation was mixed by inverting several
times (a clump of DNA was visible) and centrifuged at maximum speed for 10 minutes.
The supernatant was removed by decanting.  500 ul of 70% ethanol was added to the tube
and the preparation was spun again at maximum speed for 5 minutes.  All remaining
ethanol was removed with a pipette tip.  The DNA pellet was resuspended in 200 ul of
Tris-EDTA (TE) pH 7.4.
Genotyping for Gdf6 was carried out using a set of primers to amplify a 176 base
pair fragment of the mature region of the Gdf6 wild-type allele [Type6 F2 5’-
AGCTCTTGGTCATGGATGTTTCTC-3’ and Type6 R2 5’-
CTGATGTAGCCCTTCCACCTTTC-3’] and a second set to amplify a 310 base pair
product from the neomycin resistance cassette [N2F 5’-
TGGAGAGGCTATTCGGCTATGAC-3’ and N2R 5’-
TACTTTCTCGGCAGGAGCAAGG-3’] from the mutant allele.  The PCR program used
for these primers included the following steps: 94oC for 2 minutes, 35x [94oC for 30
seconds, 63oC for 1 minute, 72oC for 40 seconds], and a final extension at 72oC for 5
minutes.
The Wnt1-Cre line was genotyped using the following primers: Primer 1 5’-
ATTCTCCCACCGTCAGTACG-3’ and Primer 2 5’-CGTTTTCTGAGCATACCTGGA-
3’ (Chai et al., 2000) to amplify a 475 base pair produce from the transgene. The
amplification conditions were as follows: 94°C for 2 min, 35x [94°C for 1 minute, 55°C
for 2 minutes, 72°C for 90 seconds], and a final extension at 72°C for 5 minutes.  The
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R26R line was genotyped using the primers: 5’-AAAGTCGCTCTGAGTTGTTAT-3’,
5’-GCGAAGAGTTTGTCCTCAAGG-3’, and 5’-GGAGCGGGAGAAATGGATATG-
3’ that together generate a 500 base pair wild-type allele and a 250 base pair mutant allele
(Soriano, 1999).  The cycling conditions were: 94°C for 2 minutes, followed by 35 cycles
of  [94°C for 30 seconds, 53°C for 45 seconds, 72°C for 90 seconds], and a final
extension at 72°C for 5 minutes.  The homozygous R26R mice are viable, fertile, and
have no obvious deficits, and therefore the line was eventually maintained with a mating
pair of two homozygous R26R mice, with all progeny also being homozygous.
Therefore, no further genotyping was required.
Whole-mount skeletal preparations
E18.5 embryos were collected and skinned, saving the yolk sac for genotyping.
Each embryo was placed in a 50 ml conical tube filled with 95% ethanol for 2 days.
Skeletal preparations were then moved to alcian blue staining solution for 7-10 days.  To
prepare the alcian blue staining, the solution [20% glacial acetic acid (Sigma) and 0.15
mg/ml alcian blue 8GX (Sigma) in 95% ethanol] was incubated in a 37oC water bath then
stirred vigorously on a stir plate for approximately 1 hour in order to help dissolve the
blue stain.  Skeletal preparations were then de-stained for 2 days in 95% ethanol.
Carcasses were rinsed with tap water, soaked in 0.5% potassium hydroxide (KOH) with
400 ul of alizarin red stock solution [5 mg/ml alizarin red, 0.5% KOH in dH2O].  The
solution initially had a dark pink color, which lightened as the skeletal preparations
absorbed the stain.  Preparations were incubated in alizarin red/ 0.5% KOH solution for 2
days.  Samples were rinsed with tap water and transferred to graded glycerol series (25%,
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50%, 70%, 80%, 90%, 100% glycerol (VWR) in phosphate-buffered saline (PBS) pH
7.4).  All incubations were performed on a shaker.  Specimens were imaged under a
dissection microscope in a dish of water (if prior to storage in glycerol) or 100% glycerol
(if after storage in glycerol).  When imaged in glycerol, the skeletal preparations and
glycerol solution were rocked overnight to avoid streaking of the glycerol.
E14.5/E15.5/E16.5. The same protocol was used as described above for E18.5 skeletons
with the following exceptions: 1) 0.25% KOH was used for clearing and alizarin red
staining, and 2) No skinning was necessary as stain was able to penetrate to the ossified
tissues.
Whole-mount and slide in situ hybridization
The Gdf6 RNA probe was generated by cloning a PCR fragment using the
primers 5’- AAGCATGGAAGGAGGATGAAAGGG- 3’ and 5’-
CGACCTCCAGTAACTTTAGTGTTGTCA –3’, targeting the Gdf6 3’ untranslated
region, into the pGEM-Teasy vector (Promega) (probe developed by Dr. Kelly Chandler).
The plasmid template was linearized with NotI for the antisense probe and SpeI for the
sense probe.  RNA probes were labeled with digoxigenin labeled dUTPs (Roche) through
an in vitro transcription reaction using 1 ug of linearized DNA template and Sp6
polymerase (NEB), to generate the antisense probe, and T7 (NEB) for the sense probe.
Reaction was incubated for 2 hours at 37oC (T7) or 40oC (Sp6).  Probe concentration was
determined by running a small aliquot on a gel alongside a DIG-labeled RNA ladder and
comparing band intensity by Quantity One gel imaging software.
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For whole-mount in situ hybridization, embryos were collected at E10.5 and
E11.5, fixed for 24 hours in 4% paraformaldehyde (PFA) at 4oC, followed by dehydration
through a graded methanol series (25%, 50%, 75%, 80%, 90% methanol in H2O, 100%
methanol) and stored at –20oC for no longer than 1 week prior to carrying out in situ
hybridization protocol.  Embryos were re-hydrated in series of methanol/ PBT (PBS pH
7.4 and 0.1% Tween-20) (25%, 50%, 75% methanol in PBT, 100% PBT) then bleached
with 6% hydrogen peroxide in PBT for 1 hour, rocking at room temperature.  Samples
were then protease-treated with 10 ug/ml of Proteinase K (RPI) in PBS for 12 minutes
(for E10.5 embryos) to 15 minutes (for E11.5).  The permeablization step was stopped
with 2 mg/ml glycine, then post-fixed with 4% PFA/ 0.2% glutaraldehyde (ICN)/ 0.1%
Tween-20.  Embryos were then transferred to 2 ml cryovials of (pre)hybridization
solution [50% formamide (Invitrogen), 5X SSC pH 4.5, 10 ug/ml yeast tRNA (Sigma),
10 ug/ml heparin (Sigma), 15% H2O, 1% SDS] and incubated at 65oC for 1 hour in a
rotating hybridization oven.  Fresh hybridization solution was transferred to the cryovials
along with 200 ng/ml of Gdf6 RNA probe.  Samples were incubated overnight at 65oC in
a rotating hybridization oven.
The following day, samples were washed 3x30 minutes with Solution 1 [50%
formamide (Invitrogen), 5X SSC pH 4.5, 1% SDS] followed by 2x30 minute washes with
Solution 2 [50% formamide, 5X SSC pH 4.5] at 65oC rotating in the hybridization oven.
Samples were washed 3x with TBST [TBS and 0.1% Tween-20] then blocked with 10%
normal sheep serum (Jackson Immunological Research Labs) in TBST for 90 minutes at
room temperature, rocking.  This was followed by application of an anti-DIG antibody
(anti-digoxigenin-AP, Fab fragments, Roche) at a 1:1500 dilution in normal sheep serum
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and blocked overnight at 4oC after the antibody was preabsorbed in embryo powder.  The
next 2 days were a series of TBST washes at room temperature.  On the fifth day, the
embryos were washed with NTMT [100 mM NaCl, 100 mM Tris pH 9.5, 50 mM MgCl2,
and 0.1% Tween-20] and the in situ was developed with BM Purple AP Substrate
(Roche).  For the Gdf6 in situ probe, development took to 5 hours depending on the level
of background staining.  For each timepoint, embryos were from the same litter and
stained for an equal length of time.
For slide in situ hybridization, embryos were collected at E12.5 and fixed
overnight in 4% PFA, rocking at 4oC.  After equilibrating embryos in 50% sucrose,
embryos were embedded in Tissue-Tek O.C.T. compound (Sakura Finetek) and frozen
sections were collected at 18 um and placed on 3-aminopropyltriethozysilane-treated
slides.  Sections were treated with 3% hydrogen peroxide for 25 minutes at room
temperature in order to inactivate endogenous enzyme activity, then post-fixed with 4%
PFA for 20 minutes on ice.  This was followed by treatment with 15ug/ml Proteinase K
(RPI) for 1 minute.  Slides were post-fixed in 4% PFA, then treated for acetylation [1.2%
triethanolamine (Sigma) and 0.25% acetic anhydride in H2O].  30 ng of Gdf6 RNA probe
per slide was diluted in hybridization mix [40% formamide, 5X SSC pH 7.0, 1 mg/ml
ssDNA, 1 mg/ml tRNA (Sigma) in H2O], heated to 80oC, then cooled on ice.  The probe
was applied to each slide, covered with a parafilm coverslip cut to the dimensions of the
slide, and placed into a humidification chamber.  The chamber was sealed with electrical
tape and then placed in hybridization oven at 65oC overnight.
The next day the slides were washed with decreasing concentrations of SSC (5X,
0.2X), then incubating in a blocking solution [10 mg/ml Blocking Reagent (Roche) in B1
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[11.6 g/L maleic acid, 8.7 g/L sodium chloride, 7 g/L sodium hydroxide, in H2O, pH 7.5]
for 1 hour.  The slides were then incubated in a 1:5000 dilution of anti-DIG antibody in
B1 for 1 hour.  This was followed by 2x15 minute washes in B1, then a 5 minute wash in
B3 [50 mM Tris pH 9.5, 100 mM NaCl, 5 mM MgCl2 in H20].  Slides were incubated in
developer [100 mM Tris pH 9.5, 100 mM NaCl, 100 g/L polyvinyl alcohol (PVA), in
H2O] that was heated until the PVA went into solution, then supplemented with 3 mM
MgCl2, 0.28 mg/ml nitro-blue tetrazolium chloride (NBT, Bio-rad) and 0.15 mg/ml 5-
bromo-4-chloro-3'-indolyphosphate p-toluidine (BCIP, Bio-rad)] and allowed to develop
overnight at room temperature.  Slides were then rinsed with water before being
coverslipped with Aquamount.
Histology
Embryos were dissected in 1X PBS and fixed for 60 min at 4° in 10% neutral
buffer formalin (Sigma).  Embryos were then decapitated, bisected sagittally, the skin
removed, and fixed for another 15 minutes.  Embryos were then washed 3x30 minutes
with Wash Buffer [2mM MgCl2, 0.01% deoxycholic acid, 0.02% nodidet-P40 (NP-4)
(Roche), 23 mM monobasic sodium phosphate pH 7.3, 77 mM dibasic sodium phosphate
pH 7.3 in H2O], rocking at room temperature.  Enough X-gal stain [0.6 mg/ml X-gal
(Sigma) in dimethylformamide, 0.2 mM K-ferrocyanide, 0.2 mM K-ferricyanide, 1mM
Tris pH 7.5, in Wash Buffer] was applied to cover the embryo and incubated overnight,
rocking at room temperature.  The next day, embryos were washed 3x1 hour with 1X
PBS, then post-fixed with 4% PFA.
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Whole-mount lacZ-stained specimens were further stained in a 0.5% KOH/
alizarin red solution overnight.  Specimens to be sectioned were dehydrated through
ethanol series (25%, 50%, 70%, 80%, 100% ethanol in H2O), followed by 3x30 minute
washes with Citrosolv clearing agent (Fisher).  Samples were then rocked at 55oC in 50%
Citrisolv and 50% paraffin for 1 hour, then 100% paraffin for 1 hour rocking at 55oC
overnight.  Samples were then incubated at 55oC in vacuum oven for 1 hour prior to
embedding.  10 µM sections were collected on Superfrost slides (Fisher) and
counterstained with nuclear fast red (Vector Laboratories).  Slides were dehydrated then
coverslipped using Cytoseal (Fisher).
Alkaline Phosphatase (ALP) Staining
For whole-mount ALP staining, E12.5 embryonic heads were fixed in 4% PFA
pH 7.4 in PBS overnight.  The head was bisected sagittally, the brain removed, and then
fixed for an additional 1 hour.  Samples were washed 3x10 minutes with 1XPBS, 2x5
minutes with TBST, then 2x5 minutes with NTMT on ice.  Embryos were then stained
1/2X ALP staining solution [180 ug/ml NBT and 9 ug/ml BCIP in NTMT] for at least 2
hours on ice, or until background started to develop.  When the staining was complete,
embryos were rinsed with 1X PBS then post-fixed overnight at 4oC.
For transverse sections, embryos were collected at E14.5 and fixed overnight at
4oC in 4% PFA.  After equilibrating embryos in 50% sucrose, embryos were embedded in
Tissue-Tek O.C.T. compound (Sakura Finetek) and frozen sections were collected at 18
um and placed on 3-aminopropyltriethozysilane-treated slides.  Slides were baked on a
slide warmer for 2 hours then stored at –80oC until ready for staining.  Slides were then
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brought to room temperature and washed briefly in 1X PBS, then incubated for 10
minutes in acetone.  Slides were washed 3x3 minutes in TBST, transferred to glass slide
containers, and washed 3x3 minutes in NTMT.  All washes were performed at 4oC.
Slides then staining with 1X ALP staining solution [375 ug/ml NBT, 188 ug/ml BCIP in
NTMT] for 10-15 minutes, depending on the timepoint (E12.5 takes less time then
E14.5).  Slides were washed briefly 3x with H2O, counterstained with nuclear fast red
(Vector Labs H-3403), then coverslipped with Aquamount.
Immunohistochemistry
Immunohistochemistry for phospho-histone-H3 (Ser10) (Cell Signaling) and
cleaved caspase-3 (Asp175) (Cell Signaling) was carried out on cryosections.  Slides
were fixed in neutral buffer formalin for 20 minutes at 4oC, then treated with 0.3% H2O2
in methanol for 30 minutes at room temperature to quench endogenous peroxidase
activity.  Sections were circled with a PAP pen and blocked with 5% normal goat serum
(Vector Labs)/ 0.05% Triton X-100 in PBS for 2 hours in a humidity chamber.  The block
solution was replaced with diluted primary antibody in blocking solution (phospho-
histone-H3 1:200, cleaved caspase-3 1;12,800) and incubated overnight at 4oC in a
humidity chamber.
The next day sections were incubated in a 1:200 dilution of biotinylated rabbit
secondary antibody for 1 hour at 4oC in a humidity chamber.  The secondary antibody
was then replaced with ABC solution (Vector Laboratories, catalogue number SK-4100)
for 30 minutes at room temperature in humidity chamber.  DAB solution (Vector Labs)
was applied to sections and allowed to develop before excess background started to form.
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Sections were then dehydrated (70%, 95%, 100% ethanol), rinsed with Citrisolv,
mounted with Cytoseal, and coverslipped.
In the analysis of proliferation and apoptosis, positive cells were counted in the
suture region (composing the frontal and parietal bones plus the suture) at the same
magnification.  At least 5 sections from 3 separate embryos for each genotype were
analyzed.  Differences in the number of proliferating or apoptotic cells were tested for
significance using a Student’s T-test with a p-value<0.05 deemed as significant.
3-Aminopropyltriethoxysilane Treatment of Slides
Superfrost slides (Fisher) were placed in a slide holder and washed with dish-
washing detergent for 30 minutes followed by a 30 minute wash in running tap water.
Slides were then washed in distilled water in large slide cassettes for 2x5 minutes, then
2x5 minute washes of 95% ethanol.  Slides were air-dried for 10 minutes and then
incubated in a fresh 2% solution of 3-aminopropyltriethanoxysilane in acetone for 5
seconds followed by 2 brief washes with water.  Slides were finally dried overnight on
slide warmer at 42oC and stored at room temperature.
Agarose Bead Preparation
Approximately 20 ul of Affi-gel blue agarose beads (100-200 mesh, Bio-rad)
were transferred into a microcentrifuge tube with 500 ul 1X PBS.  Beads were
resuspended by flicking the tube, then spun down briefly.  The supernatant was removed
and the wash repeated.  Either 0.1% BSA or 100 ng/ul protein was added to the beads,
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then incubated at 37oC for 30 minutes.  Beads were stored on ice until ready for
implantation.  Treated beads can be stored at 4oC for up to 1 month.
Gdf6 bead implantation experiment
 E12.5 embryos were collected and placed (still inside the yolk sac) into a
60x15mm cell culture dish (Falcon) filled with BGJb medium (GIBCO) treated with
100U/ml penicillin and streptomycin and supplemented with 0.1% BSA.  Embryos were
stored temporarily in a 37oC 5% CO2 incubator until bead implantation.  Embryos were
removed one at a time and placed in their own dish filled with media.  Yolk sacs were
collected for genotyping.  Embryos were transferred to culture dishes filled with 2%
agarose as a stable surface to hold the embryo still during the implantation procedure.
Embryos were decapitated at the jaw line to remove the mandible.  This allows for more
efficient absorption of the media into the head throughout the culture period.  Beads
soaked in 0.1% BSA or 100ng/ul recombinant mouse Gdf6 protein were implanted under
the skin into the suture region on the left side of the head (right side served as a control)
using a mouth pipette with drawn glass needles.  The CS has no visible external
landmarks at this stage, so the best way to approximate the implantation site was at an
angle from the embryonic eye. The bead implantation methodology is summarized in the
panels B and C of Figure 2.1.  Embryo heads were placed neck-side down onto a square
of filter paper (Supor 0.45 um filters, Pall Life Sciences).  The filter paper was placed on
a wire mesh grid (stainless steel type 304 mesh #60, smallparts.com) cut into the shape of
a triangle with bent corners in order to sit snugly into the central well of the organ culture
dish (Falcon).   The central well of organ culture dish was filled with media, while the
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outer chamber was filled with 1X PBS.  Media was at the level of the wire mesh grid so
the media was absorbed into the filter paper but the embryo was not submerged.  The
specimens were incubated at 37oC for 48 hours, the media was changed once at 24 hours,
then the specimens were post-fixed in 4% PFA and embedded into O.C.T. for
cryosectioning.
Test of protein function and validation of bead implantation methodology
In order to test the functionality of the recombinant proteins, beads soaked in BSA
(control), Bmp4 (R&D), and Noggin (R&D) were implanted to the E13.5 limb, where all
are known to have effects on limb and joint development.  The same methodology was
applied as for a cranial implantation.  Bead effects were determined by staining the limbs
with alcian blue, which highlighted the cartilage condensations (Fig 2.1A).  While the
bead soaked in BSA appeared to have no effect on the surrounding cartilage in the area
immediately surrounding the bead, the Bmp4 bead appeared to slightly increase cartilage
formation in the region surrounding the bead.  The Noggin- soaked bead appeared to
inhibit cartilage formation in the localized region around the bead.
A second assay was performed to further validate that the recombinant proteins
were indeed active.  Limb bead implantations were repeated.  Limbs were fixed in 4%
PFA for 24 hours, staged in 30% sucrose overnight, then embedded in O.C.T.  Limbs
were sectioned at 18 um, dried for 2 hours, then stored at –80oC.  Limbs sections then
underwent slide in situ hybridization using probes for ColIIa (Appendix B) (Metsaranta
et al., 1991), a marker for cartilage formation (Fig 2.1A).  The antisense probe was
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Figure 2.1. Methodology and validation of bead implantation and organ culture.  A) Beads soaked in BSA, Bmp4, and Noggin
were implanted into the E12.5 limb in order to test bioactivity of the recombinant protein.   Activity was assessed through staining
with alcian blue (AB) (left) and in situ hybridization for ColIIa, and marker for cartilage formation (right).  The asterix indicates the
location of the bead.  B) Beads soaked in BSA (control) and protein (Gdf6, Bmp4, and Noggin) were implanted in the suture region of
E12.5 embryo head using a drawn glass needle and a mouth pipette.  C) Embryos were decapitated at the jaw line to remove the
mandible, placed onto filter paper and a wire mesh grid, then into an organ culture dish.  The central chamber of the organ culture dish
was filled with BGJb media supplemented with 100 U/ml penicillin and streptomycin and 0.1% BSA.  Embryos were cultured for 48
hours.  AB, alcian blue; cs, coronal suture; fbp, frontal bone primordia; pbp, parietal bone primordia.
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generated by linerizing the plasmid with EcoRI restriction enzyme followed by RNA
transcription reaction using T7 RNA polymerase.  The BSA implanted bead appeared to
have no affect on local ColIIa expression where the Bmp4 bead appeared to increase the
expression of ColIIa in the area immediately surrounding the bead.  For Noggin, the same
affect seen in the alcian blue staining was also seen in the limb, with ColIIa expression
inhibited in the area occupied by the bead, and also a more localized reduction of ColIIa
expression was observed in several cell layers surrounding the bead.  These two assays
together provided evidence that the proteins were functional and the bead implantation
method was valid for changing gene expression and morphology even over a short
culture period.
Results
Gdf6-/- coronal suture fuses early in development
The entire CS was absent in the Gdf6-/- mouse (Fig 2.2B), with complete
penetrance (not shown).  This defect was not observed in wild-type (Fig 2.2A) or Gdf6
heterozygote littermates through embryonic development and postnatal life (not shown).
To determine the timepoint during development at which the suture first became fused,
Gdf6-/- embryos were collected at various stages and stained with alizarin red.  At E14.0,
ossification centers were not yet visible in embryos stained with alizarin red.  By E14.5,
frontal and parietal bones were visible as two separate ossification centers.  The nascent
CS was apparent in the wild-type embryo (Fig 2.2E,G) as the gap between the two bones.
Yet in Gdf6-/- embryos, a single continuous ossification center was present (Fig 2.2F,H).
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Figure 2.2.  Analysis of coronal suture development in wild-type and Gdf6-/- embryos with alizarin red.  The coronal suture
separates the frontal and parietal bones in wild-type embryos (A, C), but is lacking in the Gdf6-/- embryo (B, D), while the squamosal
(B), sagittal, and lambdoid (D) sutures are normal.  At E14.5, the early coronal suture separates the frontal and parietal ossification
centers in wild-type embryos (E, G) but is fused in the Gdf6-/- embryo (F,H).  The frontal and parietal bones fuse into one continuous
bone in the Gdf6-/- at E15.5 (J) and continue to fuse along its entire length as ossification progress toward the midline at E16.5 (L). fb,
frontal bone; pb, parietal bone, cs, coronal suture; ls, lambdoid suture; sqs, squamosal suture
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Analysis of multiple Gdf6-/- embryos at E13.5-14.5 failed to identify visibly separate
sites of alizarin staining for frontal and parietal rudiments (not shown).
At E15.5, the frontal and parietal bones were fused into one continuous bone in
the Gdf6-/- embryo (Fig 2.2J), while the bones remained separated by the CS in the wild-
type (Fig 2.2I) embryo.  The CS continued to fuse along its entire length as ossification
progresses outward in the Gdf6-/- embryo through E16.5 (Fig 2.2L) and E18.5 (Fig
2.2B).  The sagittal, lambdoid, and squamosal sutures (Fig 2.2B,D) remained unaffected
in Gdf6-/- mice throughout embryonic development and adult life.
At the macroscopic level, the ossification centers and suture in Gdf6+/- embryos
appear to develop identically to wild-type embryos with regards to the onset of
ossification and size of the bones (not shown).  This data suggests that Gdf6 plays a role
in CS formation at or prior to the onset of ossification.
Gdf6-/- embryo has normal suture boundary formation
Coronal craniosynostosis can result from a failure to form a proper boundary
between cells of the neural crest-derived frontal bone and the paraxial mesoderm-derived
parietal bone.  The formation of this boundary involves the cooperation of Twist1 and
Msx2 to control of the expression domains of ephrin-A2, ephrin-A4, and EphA4 (Merrill
et al., 2006).  Ephrin signaling are hypothesized to inhibit cell mixing and provide
guidance cues for migrating cell populations (Poliakov et al., 2004).  Failed boundary
formation is evident as a mixing of the two tissue populations in the Twist1 mutant
(Merrill et al., 2006).
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To determine whether a similar cell mixing was the cause of the craniosynostosis
in the Gdf6-/- embryos, we visualized the suture boundary the Wnt1-Cre; R26R lines,
which together stably label derivates of the neural crest (Jiang et al., 2002), including the
frontal bone.  At E16.5, CS fusion was evident in whole-mount stained Gdf6-/- embryos
(Fig 2.3A-D). Transverse sections showed the presence of ossified bone across the
boundary between the frontal and parietal bones in the Gdf6-/- embryo (Fig 2.3F, arrow),
while the suture remained open and undifferentiated in wild-type (Fig 2.3E, arrow).  Also
of note was a general thinning of the bone in this region of the Gdf6-/- (Fig 2.3F) along
with the loss of the characteristic suture mesenchyme blastema, seen in wild-type
embryos (Fig 2.3E, arrow).  In the regions of the frontal bone more distal to the suture,
there was no obvious thinning of the Gdf6-/- bone compared to wild-type (not shown).
In the Gdf6-/- embryo, ossified tissue disrupted the boundary between the frontal
and parietal domains (as seen in Fig 2.3F) making it difficult to determine if cells have
crossed the normal boundary.  Therefore embryos were examined at E14.5, when
portions of the Gdf6-/- calvaria were not yet ossified through the suture.  Coronal sections
through the region of the presumptive CS reveal that although the Gdf6-/- embryo lacked
an identifiable suture, the cellular boundary between the frontal and parietal bones
remained distinct just like the wild-type suture (Fig 2.3G,H).  We could find no evidence
of cell mixing between these tissue populations.  There was no obvious difference
between wild-type and Gdf6+/- embryos with regards to the suture boundary (not
shown).  Furthermore, we observed a surprisingly uniform and continuous surface
between the frontal and parietal bones of Gdf6-/- mice, where the suture should reside
(Fig 2.3D, H).
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Figure 2.3. Analysis of boundary formation in Gdf6-/- embryos.  E16.5 Wnt1Cre+/-;
R26R+/-; Gdf6+/+ (A,C) and Wnt1Cre+/-; R26R+/-; Gdf6-/- (B,D) embryos stained for
lacZ, to label the frontal bone, followed by alizarin red to highlight the parietal bone.
Sections through the lacZ/alzarin red stained embryos show the boundary between the
labeled frontal bone and unlabeled parietal bone at the site of the wild-type suture (E,
arrow), with bone continuing through the suture boundary in the Gdf6-/- embryo (F,
arrow).  E14.5 Wnt1Cre+/-; R26R+/-; Gdf6+/+ (G) and Wnt1Cre+/-; R26R+/-; Gdf6-/-
(H) embryos stained with Xgal and counterstained with nuclear fast red.  In both the
wild-type and Gdf6-/- coronal sutures, the boundary is distinct, with no evidence of cell
mixing.  AR, alizarin red; cs, coronal suture; fb, frontal bone; pb, parietal bone.
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Gdf6-/- and Gdf6+/- embryos present with pre-ossification changes in the suture
Whole-mount staining for alkaline phosphatase (ALP) activity, an early
osteoblasts marker, in the wild-type E12.5 embryo highlighted the frontal and parietal
bone primordia with the CS in between (Fig 2.4A, arrow).  In the Gdf6+/- embryo, an
increase in ALP activity within the suture bridges the gap between the frontal and parietal
primordia.  This was the first evidence of abnormal activity in the Gdf6+/- mouse suture
despite that Gdf6+/- mice do develop normal CSs.  This points to a dosage effect, where
the loss of Gdf6 does increase ALP activity in the suture, but this slightly increased
differentiation does not reach the threshold required for fusion of the suture.
The appearance of the parietal bone ossification center appears approximately 12
hours after the appearance of the frontal bone ossification center (Han et al., 2007).  In
many cases, the Gdf6-/- embryos at E12.5 had a further delay in appearance of the
parietal primordia compared to wild-type and Gdf6+/- littermates, according to the
initiation of ALP activity (Fig 2.4C, arrow).  However, at stages when comparable levels
of ALP activity are observed in the frontal and parietal bones, a strong continuous level
of ALP activity bridges the gap between the two bone primordia of Gdf6-/- embryos (Fig
2.4D, arrow).  This suggests a failure to form or maintain the undifferentiated
mesenchyme that occupies a wild-type CS.
Transverse sections through the E12.5 wild-type suture also highlighted the
frontal and parietal bone primordia, with the presumptive CS in between, seen as the gap
in ALP activity (Fig 2.5A).  In Gdf6+/- embryos, ALP activity extended through the
presumptive suture region (Fig 2.5B), revealing a reduction of the undifferentiated suture
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Figure 2.4. Whole-mount alkaline phosphatase staining of E12.5 embryo.  Whole-mounting staining for ALP activity at E12.5
highlights the location of the frontal and parietal bone primordia with the coronal suture occupying the undifferentiated space between
the two (A,E arrows).  In the Gdf6+/- embryo, there is in increase in ALP activity within the suture mesenchyme, bridging the gap
between the two primordia (B, arrow).  Gdf6-/- embryos often had a delay in differentiation of the parietal bone rudiment (C, dotted
line).  When ALP activity in Gdf6-/- embryos were comparable to the rudiments in wild-type embryos, the suture mesenchyme was
completely differentiated, with a continuous level of ALP staining between the frontal and parietal bone primordia (D, arrow). Cs,
coronal suture; fb, frontal bone; pb, parietal bone.
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Figure 2.5.  Alkaline-phosphatase staining in the presumptive suture. Transverse
sections through the E12.5 wild-type suture show a gap in ALP activity between the
frontal and parietal bones (A).  The width of the gap is reduced in the Gdf6+/-, with an
increase in ALP activity within the suture mesenchyme (B).  In the Gdf6-/-, there is a
continuous line of ALP activity through the region, with a reduction in ALP activity in
the parietal portion of the fused bone (C).  Similar changes in ALP staining were
observed in the E13.5 and E14.5 rostral (G-I, M-O) and caudal (J-L, P-R) coronal sutures
and through in situ hybridization for Runx2 (D-F).
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mesenchyme seen in the wild-type suture.  In addition, the suture gap width was reduced
in the Gdf6+/- embryos compared to wild-type (Fig 2.5B).  In the Gdf6-/- embryos, after
the frontal bone primordium there was continuous ALP staining through the region where
the suture should have formed (Fig 2.5C).  In comparison to the wild-type and Gdf6+/-
embryos, the Gdf6-/- embryos lacked the increase in ALP activity found in the parietal
bone (Fig 2.5C, asterix), although it was maintained in the frontal portion of the fused
bone primordia.  This confirms not only a loss of the undifferentiated suture
mesenchyme, but also a delay in parietal bone differentiation was observed in Gdf6-/-
embryos.
Differentiation of the suture mesenchyme was also examined by expression of
Runx2, another marker for early bone differentiation.  Runx2 is required for the
commitment of mesenchymal stem cells into osteoblasts.  It is a master regulator of genes
including collagen type I, bone sialoprotein, osteopontin, TGFβ, and osteocalcin (Marie
et al., 2008).  Like ALP, Runx2 marked the presumptive frontal and parietal bones, with a
gap of undifferentiated mesenchyme in between (Fig 2.5D).  Again, the distance between
the frontal and parietal rudiments was reduced in the Gdf6+/- embryo (Fig 2.5E).  In the
Gdf6-/- embryo, Runx2 was expressed continuously through the suture region (Fig 2.5F).
These observations were confirmed at both caudal (closer to the eye) (Fig 2.4E,
lower dotted line) and rostral (newly formed) (Fig 2.4E, upper dotted line) levels of the
presumptive CS by ALP activity at E13.5 and E14.5 (caudal Fig 2.5J-L, P-R
and rostral Fig 2.5G-I, M-O).  These data all suggest an increase in osteogenic
differentiation of the cells in the developing suture of the Gdf6+/- embryos and Gdf6-/-
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embryos, and also a dosage effect, where the differentiation in the Gdf6+/- embryos is an
intermediate level between wild-type and Gdf6-/- embryos.
A decrease in both the intensity (Fig 2.5C,I) and span (not shown) of ALP activity
in the parietal bone rudiment of Gdf6-/- embryos was observed, suggesting a decrease in
the rate of differentiation in this structure.  This was also observed in the alizarin red
staining of E14.5 embryos, with a reduction of the size of the Gdf6-/- parietal bone
ossification center compared to wild-type and Gdf6+/- embryos (not shown).  This could
be a potential secondary effect of loss of the suture, or a direct effect of the loss of Gdf6.
Suture fusion not due to changes in proliferation or apoptosis in the suture region
In principle, suture fusion could result from changes in the number of cells in the
suture or bone fronts proliferating or undergoing apoptosis, thereby increasing or
decreasing the number of cells in the pre-osteogenic pool.  Between E14.0 and E14.5, the
frontal and parietal rudiments in the Gdf6-/- embryo were first visible by alizarin red
staining as a single fused ossified element (Fig 2.2F,H).  Therefore the sutures of wild-
type, Gdf6+/-, and Gdf6-/- littermates were examined prior to fusion at E13.5 through
immunohistochemistry.  Adjacent sections were stained for ALP activity in order to help
localize the suture (Fig 2.6A-F).  Immunohistochemistry for phospho-histone H3 (Fig
2.6A’-C’) revealed a significant difference (p=0.039) in the proliferation of cells in the
suture region between wild-type and Gdf6+/- embryos, however no difference was
detected between wild-type and Gdf6-/- or Gdf6+/- and Gdf6-/- sutures (Fig 2.6G).
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Figure 2.6.  Analysis of cell proliferation and apoptosis in the E13.5 coronal suture.  Adjacent sections stained for ALP activity,
highlighting the location of the frontal and parietal bones (A-F dotted yellow lines), and immunohistochemistry for phospho-histone
H3 (A’-C’) or cleaved caspase-3 (D’-F’).  Positive cells are marked with arrows.  (G) Quantification of the total number of
proliferating cells counted in the suture region. (H) Quantification of the number of proliferating cells counted in each separate
component of the suture region; the frontal bone, parietal bone, and suture mesenchyme.  The number of proliferating cells in each
separate region of the suture was not counted for Gdf6-/- embryos since there is no suture mesenchyme and the border between the
frontal and parietal bones cannot be distinguished.  N=3 embryos for each genotype and antibody treatment with at least 5 sections per
embryo quantified.  Differences the number of proliferating cells per suture region were analyzed using a t-test with a p value<0.05
deemed as significant.   
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We also compared the number of proliferating cells separately in each tissue of
the suture; the suture mesenchyme, the frontal bone, and parietal bone (Fig 2.6H).  The
number of proliferating cells in the Gdf6-/- embryo was not examined by region because
there is no suture mesenchyme and the boundary between the frontal and parietal portions
of the fused bone cannot be distinguished.  However, we did observe a decrease in the
number of proliferating cells in the Gdf6+/- frontal bone compared to wild-type that was
trending toward significance (p=0.056).  This could be attributed to the increased rate of
differentiation in the suture of Gdf6+/- embryos, reducing the pool of pre-osteogenic
proliferating cells, or a direct affect of Gdf6 on frontal bone proliferation.  No difference
between the frontal bones of wild-type and Gdf6+/- embryos was observed in other
assays.  Although there was reduced proliferation also in the Gdf6+/- parietal bone and
suture mesenchyme compared to wild-type, the difference did not reach the level of
significance (p=0.33, p=0.24).
Cell proliferation was also examined at E12.5, the timepoint when erroneous
differentiation of the suture mesenchyme is first visible by increased ALP activity (Fig
2.5).  Although no suture mesenchyme is present in the Gdf6-/- embryo, at E12.5, the
boundary between the frontal and parietal bone can be distinguished due to the increased
ALP activity in the frontal bone (Fig 2.7A).  Still we found no significant difference in
the number of proliferating cells between the wild-type and Gdf6-/- embryos in the entire
suture region (p=0.18) nor between wild-type and Gdf6+/- or Gdf6+/- and Gdf6-/-
embryos (Fig 2.7B).  The number of proliferating cells counted separately in the frontal
bone, suture mesenchyme, and parietal bone (Fig 2.7C) was also not significant.
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Figure 2.7. Analysis of cell proliferation in the E12.5 coronal suture.  (A) Adjacent sections stained for ALP activity, highlighting
the location of the frontal and parietal bones (dotted yellow lines), and immunohistochemistry for phospho-histone H3.  Example
positive cells are marked with arrows.  (B) Quantification of the total number of proliferating cells counted in the suture region. (C)
Quantification of the number of proliferating cells counted in each separate component of the suture region; the frontal bone, parietal
bone, and suture mesenchyme.  The number of proliferating cells in the suture mesenchyme and parietal bone were not counted for
Gdf6-/- embryos since the boundary between the two cannot be distinguished.  N=3 embryos for each genotype with at least 5 sections
per embryo quantified.  Differences the number of proliferating cells per suture region were analyzed using a t-test with a p
value<0.05 deemed as significant.
69
Unlike E13.5, at E12.5 we detected no difference between the wild-type and
Gdf6+/- suture regions (Fig 2.7B) or specifically in the frontal bone (Fig 2.7C).
Therefore, no differences in proliferation are evident at the time when the suture
mesenchyme begins to differentiate.  This supports the idea that reduced proliferation in
the frontal bone of Gdf6+/- embryos at E13.5 is a secondary affect of increased
differentiation of osteoprogenitor cells and not a contributing factor to fusion of the
suture.
To study cell death at the suture we used cleaved-caspase 3
immunohistochemistry.  Few to no apoptotic cells were detectable in the suture
mesenchyme or bone front at this timepoint in development (Fig 2.6D’-F’), and likewise,
no significant difference between genotypes was found (not shown).  Previous reports
have suggested that apoptotic cell death is first detectable in the CS at E16 (Rice et al.,
1999), and therefore apoptotic activity at the timepoint of the Gdf6-/- phenotype is not
likely a contributing factor in normal suture development or the craniosynostosis
pathology.
Gdf6 is expressed in the frontal bone primordia
By E10.5, the neural crest/paraxial mesoderm boundary and future site of the CS,
has already formed (Jiang et al., 2002).  In order to pinpoint the pattern of Gdf6
expression during cranial development, we performed in situ hybridization on embryos at
E9.5-E14.5.  Gdf6 mRNA was first detected in the developing cranial region in a
triangular-shaped area just anterior to the eye at E10.5 (Fig 2.8A-C, arrow).  This
corresponded closely with the neural crest-derived frontal bone rudiment, as labeled in
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Figure 2.8.  Expression of Gdf6 in early cranial development.  In situ hybridization for Gdf6 at E10.5 (A-C, F,G), E11.5 (H-J), and
E12.5 (K-M).  Gdf6 is expressed in the frontal bone primordia (arrow), which is labeled as neural crest-derived in the Wnt1-Cre; R26R
embryos (D, white arrow).  Gdf6 transcript is expressed more strongly in the Gdf6-/- embryo (C, J) than either the wild-type (A, H) or
Gdf6+/- embryo (B, I), in both the frontal bone rudiment (arrow) and branchial arches (asterix).  In transverse cross section through
the eye and frontal bone primordia at E10.5 (dotted line, E), Gdf6 is expressed in several layers of mesenchyme underlying the surface
ectoderm (F, G).  At E12.5, Gdf6 continues to be expressed in the frontal bone rudiment, in addition to the dorsal retina (K-L) and
orbital bone rudiment (L).  Expression of Gdf6 in the dorsal retina seen in the wild-type and Gdf6+/- embryos (K,L) is absent in the
Gdf6-/- embryo (M).  dr, dorsal retina; e, eye; fr, frontal rudiment; or, orbital bone rudiment.
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Wnt1-Cre; R26R embryos (Fig 2.8D, arrow).  Gdf6 was expressed in the frontal bone
rudiment at E11.5 (Fig 2.8H-J), as the rudiment begins to grow and expand.  Transverse
sections through the E10.5 frontal rudiment (Fig 2.8E, dotted line) reveal this expression
anterior to the eye was localized to several layers of mesenchyme underlying the surface
ectoderm (Fig 2.8F,G).  At E12.5, Gdf6 continued to be exclusively expressed in the
frontal bone rudiment (Fig 2.8K-M, arrow), with no evidence of expression in the suture
mesenchyme or parietal bone rudiment.  By E14.5, when fusion of the ossification
centers was first visible by alizarin red staining, Gdf6 is no longer expressed in the suture
region (Fig 2.9).
The Gdf6 mutant mouse was generated by replacing a large portion of the second
exon, containing the entire mature signaling region (Fig 2.10A, red track), with a
neomycin cassette.  Although no functional Gdf6 protein can be made from the Gdf6-/-
allele, the mutant Gdf6 transcript was detected by our in situ RNA probe, which targets
the 3’ UTR of Gdf6 (Fig 2.10A, green track).  In situ hybridization revealed that Gdf6
transcripts were still present in Gdf6-/- embryos (Fig 2.8C, J, M).  Interestingly, the Gdf6
transcript was more highly expressed in Gdf6-/- embryos than in either wild-type or
Gdf6+/- embryos, with staining in Gdf6+/- embryos at intermediate levels (Fig 2.8A-C,
H-I).  Increased staining was also observed for Gdf6 in the branchial arches (Fig 2.8, A-
C, H-I asterix) and in the orbital bone rudiment (Fig 2.6L) of wild-type, Gdf6+/-, and
Gdf6-/- embryos, each with increased in situ signal in the Gdf6-/- embryos.
These observations suggest that Gdf6 expression may be self-regulated in the
frontal bone, brachial arches, and orbital bone by a negative feedback loop.  Thus, in
wild-type embryos, when functional Gdf6 protein is produced, there might be a negative
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Figure 2.9.  Lack of Gdf6 expression in the E14.5 coronal suture.  Gdf6 transcription
has ceased in the frontal bone by E14.5 in wild-type (B), Gdf6+/- (D), and Gdf6-/-
embryos (F), with adjacent sections stained for ALP activity to highlight the location of
the frontal and parietal bones (A, C, E, dotted lines).  Previously reported expression in
the middle ear bone joints is visible in sections from the same series, acting as a positive
control (G,H arrow).
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Figure 2.10 Autoregulation of Gdf6 in the frontal bone primordia.  A) Image from the
UCSC genome browser denoting the region of the Gdf6 gene replaced in the Gdf6 mutant
mouse by a neomycin cassette (red, mutant track) and the region targeted by the Gdf6 in
situ hybridization probe (green, ISH_Probe track), which do not overlap, allowing us to
detect Gdf6 transcript in our mutant mice. B) Regulation of Gdf6 in the frontal and orbital
bone primordia and the branchial arches.  In wild-type embryos, there might be a
negative feedback loop to repress the continued transcription of Gdf6 (upper).  In the
Gdf6-/- mouse, no functional protein is produced, and with the loss of negative feedback
the in situ signal is increased (lower).  C) Regulation of Gdf6 in the adjacent dorsal retina.
In wild-type embryos there is a positive feedback mechanism (upper), but this is lost in
the Gdf6 mutant, and with no positive feedback and the in situ signal is lost (lower).
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feedback loop to repress continued Gdf6 expression.  However, in the Gdf6-/- embryo, no
functional protein is produced, and with the loss of the negative feedback the in situ
signal is increased (Fig 2.10B).  However, transcript was observed in the dorsal retina
wild-type and Gdf6+/- embryos (Fig 2.8K,L), but was lost in Gdf6-/- embryos (Fig
2.8M), suggesting a tissue-specific effect.  Therefore, in the case of the dorsal retina,
there is normally a positive feedback loop.  However, in the Gdf6-/- mice, with no
functional protein being made, there is no positive feedback to induce Gdf6 expression
(Fig 2.10C), resulting in the elimination of the in situ signal.  Therefore, Gdf6 appears to
have two opposite modes of regulation in two adjacent structures, the dorsal retina and
the frontal bone primordia.
Gdf6 protein has the ability to stimulate differentiation in vivo
In order to test for a direct effect of Gdf6 in vivo, agarose beads soaked in Gdf6
were implanted into the suture region of wild-type E12.5 embryos.  The effect of the
implanted bead on the differentiation process was assessed through staining for ALP
activity.  When a Gdf6-soaked bead was implanted into a region with endogenous ALP
activity, such as the frontal bone (Fig 2.11B) or osteogenic cranial mesenchyme (Fig
2.11C) it was found that Gdf6 was able to stimulate ALP activity in the region
immediately surrounding the bead when compared to beads soaked in BSA (Fig 2.11A).
The BSA and Gdf6-soaked beads had a reduced ability to stimulate ALP activity (Fig
2.11C, red arrow) when implanted in non-osteogenic tissues, such as cranial cartilage
(Fig 2.11C, asterix), brain, or ectoderm (not shown).  Although this apparent ability of
Gdf6 to stimulate differentiation was in contrast to the increased differentiation in the
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Figure 2.11.  In vivo activity of Gdf6 protein in the frontal bone primordia.  Beads soaked in BSA (control) (A) or Gdf6 protein
(B,C) were implanted into the suture region of E12.5 embryos.  The BSA-soaked bead had no effect on ALP activity when implanted
into the frontal bone primordia (A, asterix).  Beads soaked in Gdf6 increased ALP activity in the area immediately surrounding the
bead (arrow) when implanted into the frontal bone primordia (B) or other cranial regions with endogenous ALP activity (C, arrow),
but reduced activity (red arrow) when implanted into a region of cranial cartilage (C, asterix).  ca, cranial cartilage; cm, cranial
mesenchyme; fb, frontal bone primordia; pb, parietal bone primordia.
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Gdf6-/- mice, it is likely that the inhibitory activity of Gdf6 on the suture mesenchyme is
context dependent or moderated by a secondary factor.
Discussion
Here we present data indicating that Gdf6 is genetically required for osteogenic
differentiation in the developing CS during its formation.   Gdf6 is absolutely required for
formation of the suture, as in Gdf6-/- embryos there is an initial failure to establish a
region of delayed differentiation between the frontal and parietal condensations.  Since
Gdf6 mRNA is strongly downregulated in wild-type calvaria by E14.5, Gdf6 may not be
required at later stages to maintain patency of the established suture.  The question of
whether Gdf6 plays a role in suture maintenance will require examination of Gdf6 protein
stability and localization, and/or conditional deletion of Gdf6 at later stages.
Gdf6 represses osteogenic differentiation but not boundary formation in the coronal
suture
We found no evidence for disruption in the frontal/parietal cell boundary in Gdf6-
/- mice.  This is in contrast to the mechanism of suture fusion in the Twist+/- and Epha4-
/- mice where, before E14.5, osteogenic cells from the frontal bone abnormally cross into
the suture mesenchyme (Merrill et al., 2006).  In Twist+/- mice, ALP expression in the
frontal/parietal rudiments is normal up to E14.5.  In contrast, ALP expression
abnormalities are detectable by E12.5 in Gdf6-/- embryos, before ephrin ligands are
expressed in the frontal/parietal region (Merrill et al., 2006).  Therefore Gdf6 is required
for a mechanism that is distinct from that controlled by the Twist/Ephrin pathway.   Twist
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also regulates osteogenic condensation via interaction with Msx2 (Ishii et al., 2003).  Our
data does not exclude Gdf6/Twist interactions during osteogenic differentiation, although
a combined reduction of Twist and Msx2 levels was shown to primarily affect
differentiation of the frontal, but not the parietal bone (Ishii et al., 2003).
Somewhat surprisingly, Gdf6 mRNA was not detected in the suture mesenchyme
itself but in the frontal bone primordia.   This is in contrast to the sites of wrist and ankle
joint fusion in Gdf6-/- embryos, where Gdf6 is clearly expressed in the developing joint
interzones (Settle et al., 2003).  However, several studies suggest that the action of GDFs
in limb joint development is not explained by direct autocrine suppression of
chondrogenesis; for example, both the direct application of GDF5 protein to developing
limb cartilage and transgenic Gdf5 overexpression are pro-chondrogenic (Storm and
Kingsley, 1999; Tsumaki et al., 1999), although in limb joints the pro-chondrogenic
effects of GDFs are probably inhibited by Noggin (Brunet et al., 1998).  A unifying
theme of both limb joints and the frontal bone is that both are important paracrine
signaling centers for adjacent targets (that is, cartilage in the limb and the suture
mesenchyme in the cranium).  Paracrine effects of Gdf6 are also demonstrated in other
structures, including the thyroid cartilage.  Gdf6-/- mice have hypoplastic thyroid
cartilage, however, Gdf6 is not expressed in the cartilage itself, but in the surrounding
mesenchyme (Settle et al., 2003).
Phenotypic restriction to the coronal suture
With Gdf6 expression occurring in the frontal bone primordia, this leads to the
question of why the CS is the only suture affected and not the interfrontal suture, which
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resides between the paired frontal bones?  One possibility could relate the different
origins of the bones and suture.  The interfrontal suture resides at a boundary between
two neural crest-derived bones, while the CS is a boundary between bones of mixed
origin.  We have already demonstrated that Gdf6 has different effects in the frontal bone
primordia and the suture mesenchyme, and therefore it is plausible that Gdf6 could have
different signaling properties in tissues of different origins.
Furthermore, the signaling in the interfrontal suture is distinct from the signaling
within the other sutures.  As discussed in detail in Chapter I, the interfrontal suture is the
only suture in mice to undergo nonpathological postnatal fusion (Opperman, 2000),
involving mechanisms that are distinct from the other sutures.  In addition, the frontal and
parietal bone ossification centers meet almost immediately at E14.5 (Fig 2.2E,G), much
earlier than the bone fronts meet at the remaining sutures later in embryonic and postnatal
development and long after expression of Gdf6 has turned off at E14.5 (Fig 2.9).
Effects of Gdf6 signaling in the developing calvarium
Gdf5/6/7 form a closely related subfamily of BMPs, sharing >80% identity in
their mature C-terminal signaling domains (Storm et al., 1994).  The strong similarity of
Gdf5 and Gdf6 suggest they share similar signaling properties.  Given the Gdf6
expression in developing calvaria, we conclude that Gdf6 signals in a paracrine manner to
regulate suture development.  The simplest model is that Gdf6 expression in the frontal
bone signals to the suture mesenchyme to inhibit osteogenic differentiation and maintain
suture patency (Fig 2.12A).  Therefore, when the Gdf6 signal is lost, the suture
mesenchyme differentiates and the suture space is obliterated by bone.  Although this is
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Figure 2.12.  Alternative models for the function of Gdf6 in suture development. A)
Gdf6 expression in the frontal bone provides a paracrine signal to the suture mesenchyme
to inhibit osteogenic differentiation.  With the loss of Gdf6, the suture mesenchyme
differentiates into bone.  B) Gdf6 is pro-osteogenic, signaling to the parietal bone to
promote differentiation.  The inhibitory effect on differentiation of the suture
mesenchyme is modulated through interactions with secondary factors.  With the loss of
Gdf6, the suture mesenchyme differentiates, but the differentiation of the parietal bone is
delayed.
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consistent with our analysis of increased ALP and Runx2 in the suture mesenchyme of
Gdf6-/- embryos, it seems to contradict our data showing that when beads soaked in
Gdf6 protein are implanted into the frontal bone they stimulate differentiation of the
primordia.  Previous studies demonstrated that beads soaked in Bmp4 protein increased
tissue volume when placed at the bone fronts or within the suture mesenchyme, but had
no effect on suture closure (Kim et al., 1998a).  Therefore, it is not yet clear if this
inhibitory effect occurs via direct signaling or through indirect effects transmitted by
downstream effectors.  Interestingly, the onset of ALP activity is delayed in the parietal,
but not frontal, primordia in Gdf6-/- embryos.  Since Gdf6 is expressed in the frontal but
not parietal primordia, this suggests Gdf6 signaling from the frontal primordium also acts
in a paracrine manner to influence maturation of the parietal.   In this view, Gdf6 actually
stimulates osteogenic maturation of the parietal rudiment, although it is not clear if this
effect is direct or indirect (for example, it could be a secondary effect mediated by Gdf6
regulating a separate factor in the suture mesenchyme) (Fig 2.12B).  Homozygous
mutants for Noggin, an antagonist of BMP signaling, also present with delayed
ossification of the parietal bone, with no parietal bone ossification center evident at E14.5
(Tylzanowski et al., 2006).  The frontal and parietal bone are derived from different
tissues (the cranial neural crest and paraxial mesoderm) and therefore it is possible that
different tissues respond differently to Gdf6 signal.  Msx1-/-; Msx2-/- compound mutant
mice also have defects in the ossification of both the frontal and parietal bones, although
they are only expressed together in the frontal bones.  This affect is possibly due to the
loss of these genes in the dura, which is also derived from the cranial neural crest (Han et
al., 2007).
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Therefore, data regarding Gdf6’s possible roles in skeletal differentiation are
important for interpretation of our results.  Several reports indicate that like Gdf5, Gdf6
can stimulate chondrogenic differentiation in cell culture models (Nochi et al., 2004).
Whether Gdf6 is pro- or anti-osteogenic is less clear.  Some studies indicate that in vitro,
Gdf6 can have pro-osteogenic effects on osteoblastic cells in similar manner to Gdf5,
albeit its ability to induce osteoblast markers is much less than that of the “canonical”
osteogenic BMPs such as BMP2 or BMP7 (Bobacz et al., 2006).  However, Gdf6 can
inhibit ALP activity and mineralization in bone marrow-derived mesenchymal stem cells
(Shen et al., 2009a).  In vitro experiments must be interpreted with caution, due to
potential differences in expression of BMP receptors and/or inhibitors across cell lines.
In general, in vitro studies indicate that Gdf6 seems consistently capable of promoting
differentiation of chondrogenic cells but relatively poor, or inhibitory, at promoting
osteogenesis.
Injection of GDF5 into perinatal mouse calvaria in vivo led to increased bone
formation after 2 weeks (Yoshimoto et al., 2006).  While this suggests that GDFs can
have stimulatory effects on calvarial osteogenic differentiation, the different timing and
context of GDF5 application may not lead to the same effects as Gdf6 in the prenatal
calvaria and Gdf6 may have distinct signaling effects compared to Gdf5, despite similar
receptor usage (Mazerbourg et al., 2005).  Other studies indicate that the effects of Gdf6
on ALP induction are context-dependent (Williams et al., 2008), which coincides with
our own bead implantation studies.
This effect may be mediated by receptor subunit combinations, interactions with
inhibitors such as Noggin, or even heterodimerization with other BMP family members.
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Noggin is expressed in a layer surrounding the developing frontal and parietal bones and
can bind Gdf6 (Chang and Hemmati-Brivanlou, 1999).  Noggin can repress BMP
signaling in the CS (Warren et al., 2003a), so it likely inhibits Gdf6-mediated signaling.
However, Noggin is not required for suture formation, as Noggin -/- embryos do form
CSs (described in detail in Chapter V) despite having other severe cranial defects.
Xenopus GDF6 can heterodimerize with other BMPs, such as BMP2, in vivo (Chang and
Hemmati-Brivanlou, 1999; Lyons et al., 1995) and other BMP heterodimers can have
distinct and potent effects as compared to homodimers (Butler and Dodd, 2003).
One theory in suture development states that the position of the suture is
determined by a growth factor gradient established by the advancing bone fronts (Lenton
et al., 2005).  It is possible that the relative temporal development of the frontal and
parietal rudiments is critical for this process, and that the relative delay of the parietal
ossification sequence leads indirectly to failure of suture establishment.  However, the
onset of Runx2 transcription is not delayed in Gdf6-/- embryos, suggesting Gdf6 is not
required for temporal control of Runx2 mRNA in calvarial rudiments. We postulate that
the suture mesenchyme and the parietal rudiment may be differentially sensitive to Gdf6
signaling.
Gdf6 autoregulation and interaction with other BMPs
We observed that Gdf6 transcription is increased in frontal bone but reduced in
eyes of Gdf6-/- embryos.  This suggests differential, tissue-specific autoregulation of
Gdf6.   Interestingly, Gdf5 represses its own transcription in limb joints (Storm and
Kingsley, 1999).   Bmp4 also shows evidence of temporal autoregulation in osteoblast
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cultures derived from rat calvaria, with Bmp4 causing a temporary increase in Bmp4
transcript followed by a clear inhibition of Bmp4 expression (Pereira et al., 2000).  We
propose that Gdf6 autoregulates itself in the frontal bone and that Gdf6/BMP signaling
levels are fine-tuned during normal CS development to coordinate proper differentiation
and morphogenesis.  Interestingly, Bmp4 and Gdf6 are co-expressed in both the dorsal
retina and the frontal bone primordia (Danesh et al., 2009; Mortlock et al., 2003).
Mutations in Bmp4 and Gdf6 independently disrupt eye development (Asai-Coakwell et
al., 2007; den Hollander et al.; Dunn et al., 1997).  Although Gdf6 is expressed in the
frontal bone rudiment, there is no evidence for a frontal bone defect in Gdf6-/- mice.
This is likely due to compensation by Bmp4.  Bmp4+/-; Gdf6-/- mice at E18.5 do in fact
have a frontal bone defect, with the persistence of large foramina that is not observed in
either single heterozygotes (discussed in Chapter III).  We speculate that these two BMP
ligands cooperate to regulate suture and/or calvarial development.
Conclusions
In summary, we found that Gdf6 is required to control an early stage of repressed
osteogenic differentiation in the CS.   Not only does this suggest potential new
mechanisms for this BMP family member in regulating bone growth, it nominates Gdf6
as a candidate gene harboring mutations in individuals with coronal craniosynostosis.
Gdf6 mutations in humans have been associated with eye and postcranial skeletal
abnormalities although these effects are characterized by incomplete penetrance and
phenotypic heterogeneity (Asai-Coakwell et al., 2007; Tassabehji et al., 2008).
Interestingly, a literature search for genomic lesions in the GDF6 genomic region
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identified Nablus mask-like facial syndrome (Raas-Rothschild et al., 2009; Salpietro et
al., 2003; Shieh et al., 2006) which is a complex multigene deletion syndrome
characterized by loss of a critical region just proximal to Gdf6.  In one of only two known
patients where the genomic deletion included Gdf6, coronal craniosynostosis was
observed (Raas-Rothschild et al., 2009; Salpietro et al., 2003).  We propose that some
individuals having coronal craniosynostosis with unknown etiology may harbor
mutations in GDF6.
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CHAPTER III
BMP4 AND GDF6 COOPERATIVELY CONTROL THE FORMATION OF THE
CORONAL SUTURE
Introduction
The mammalian cranial vault is mainly composed of flat bones separated by the
cranial sutures; joints composed of fibrous connective tissue that act as the main sites for
cranial growth during development (Cohen, 2005).  As the cranial bones expand, new
bone is deposited at the growing ends of the bones, or bone fronts, while the suture
mesenchyme remains undifferentiated (Lana-Elola et al., 2007).  Sutures provide flexible
joints for passage through the birth canal, act as shock absorbers, prevent separation of
the cranial bones, and accommodate room for the rapidly growing brain (Cohen, 2005).
With the exception of the metopic suture, human sutures normally do not fuse until the
third or fourth decade of life (Furuya et al., 1984), when the undifferentiated
mesenchyme of the suture space becomes obliterated by bone.
Craniosynostosis is defined as the premature fusion of one or more of the cranial
sutures and occurs in approximately 1 in 2,500 live births (Wilkie, 1997).  When a suture
fuses prematurely, cranial growth ceases perpendicular to site of suture fusion while
compensatory growth increases in the remaining sutures, producing a dysmorphic skull
shape (Slater et al., 2008).  Craniosynostosis of the CS, the joint that separates the frontal
and parietal bones, accounts for approximately 30% of the documented cases of cranial
suture fusion (Kabbani and Raghuveer, 2004).  The CS also serves as a tissue boundary,
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with the frontal bones being derived from the cranial neural crest and the parietal bones
derived from the paraxial mesoderm (Jiang et al., 2000).
Growth Differentiation Factor -6 (Gdf6) and Bone Morphogenetic Protein-4
(Bmp4) are both members of the Bone Morphogenetic Protein (BMP) family of secreted
signaling molecules.  The GDF subgroup is highly conserved in vertebrates and play a
critical role in limb joint formation and chondrogenesis (Storm and Kingsley, 1999).  The
Gdf6 mutant mouse displays multiple joint-associated defects, including fusion in the
bones of the wrist and ankle, hypoplasia of the thyroid cartilage, defects in the bones of
the middle ear, and craniosynostosis of the CS (Settle et al., 2003).
In Chapter II, we demonstrated that the CS in the Gdf6-/- developing embryo is
fused by E14.5, the earliest timepoint when ossification of the cranial bones can be
detected through alizarin red staining.  At E12.5, several days before ossification begins,
an increase in the expression and activity of early bone markers Runx2 and ALP indicated
the loss of the undifferentiated mesenchyme occupying the suture.  The suture
mesenchyme must remain undifferentiated in order for the suture to remain patent and a
functioning center of growth.  This suggests a paracrine Gdf6 signal from the frontal
bone primordia, the site of Gdf6 expression, in inhibiting differentiation of the suture
mesenchyme.  However, experiments in which beads soaked in Gdf6 protein were
implanted into the frontal bone showed that Gdf6 is actually able to stimulate
differentiation of the frontal bone in the area immediately surrounding the bead.
Therefore, the ability of Gdf6 to prevent ossification of the suture mesenchyme is likely
accomplished through interactions with other unidentified factors.
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It is possible that Gdf6 may interact with other members of the BMP family,
particularly Bmp4.  Gdf6 and Bmp4 utilize the same type I (BMPR1a and BMPR1b) and
type II (BMPR2 and ACVR2A) receptors (Mazerbourg et al., 2005).  While Bmp4 has
not been directly associated with a craniosynostosis phenotype, it is known to be involved
in the signaling dynamics at the suture.  The posterior interfrontal suture in mice is a
common model to study the events which contribute to craniosynostosis, since it is the
only suture in mice which undergoes predictable fusion during postnatal development
(Opperman, 2000).  Bmp4 is expressed in the suture mesenchyme and bone fronts of both
patent and fusing posterior interfrontal sutures, where it is believed to stimulate the
expression of its own antagonist, Noggin.  Noggin in turn is expressed in patent, but not
fusing sutures, suggesting a role for Noggin in the maintenance of suture patency (Warren
et al., 2003a).
The aim of this chapter was to determine if Gdf6 was interacting with Bmp4 in the
development of the CS.  We found that like Gdf6, Bmp4 is expressed in the frontal bone
primordia from E10.5-E12.5.  Furthermore, Bmp4 lacZ/+; Gdf6 +/- compound mutant
mice reproduce the coronal craniosynostosis phenotype found in Gdf6 homozygous
mutants.  Unlike the Gdf6-/- embryos, a portion of the Bmp4 lacZ/+; Gdf6 +/- embryos
do initially form a CS, but the aberrant differentiation of the suture mesenchyme is only
delayed.  Bmp4-lacZ/+; Gdf6-/- embryos have an additional defect in the ossification of
the frontal bone that is not observed in single or compound heterozygotes, or the Gdf6-/-
embryo.  This suggests that Gdf6 and Bmp4 function cooperatively in the development of
the CS and likely also the differentiation of the frontal bones.
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Materials and Methods
Mouse crosses
Methodology for the Gdf6-/- mouse is described in the methods section of
Chapter II.  The Bmp4-lacZ mice (Lawson et al., 1999) were generously provided by Dr.
Brigid Hogan.  The Bmp4-lacZ mice were crossed to the Gdf6+/- mice to generate
Bmp4lacZ/+; Gdf6+/- compound mutants, then again crossed to Gdf6+/- mice to produce
wild-type, Gdf6+/- and Bmp4-lacZ/+ single heterozygotes, Bmp4-lacZ/+; Gdf6+/-
compound mutants, Gdf6-/- homozygous mutants, and Bmp4lacZ/+; Gdf6-/- progeny.
Embryonic age was determined through detection of the vaginal plug, with noon of that
day observed as E0.5.
DNA preparations and Genotyping
DNA preparation methods were described in detail in the methods section of
Chapter II.  Bmp4-lacZ mice were genotyped using the lacZ primers 5’-
TTTCCATGTTGCCACTCGC-3’ and 5’-AACGGCTTGCCGTTCAGCA-3’ to generate
a 375 base-pair product.  The PCR program used for these primers included the following
steps: 94oC 5 minutes, 10x [98oC 5 minutes, 94oC 30 seconds, 60oC 1 minute, 72oC 40
seconds], 24x [94oC 30 seconds, 56oC 1 minute, 72oC 40 seconds], 72oC 5 minutes.
Alternatively, tails snips or portions of the embryos could be stained with X-gal to
genotype for the lacZ allele.
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Whole-mount alizarin red skeletal preparations
P21: Weanling mice were collected 21 days after birth.  Mice were sacrificed in a CO2
chamber for approximately 5 minutes.  The mice carcasses were then skinned, starting
with the head and moving caudally, including careful removal of the skin from the paws.
All organs were removed except for the brain: although the brain will sometimes expand
during the staining procedure, it was left in place in order to maintain the integrity of the
cranial vault.  Nylon string was tied around the spine below the ribs and labeled with the
cage, litter, and mouse number is order to match skeletal preps with their genotype
information.  Multiple carcasses were placed in a 1 liter bottle filled with 95% ethanol for
2 days.  Skeletal preps were then moved to the alcian blue staining solution for 7-10 days.
The alcian blue solution [20% glacial acetic acid (Sigma) and 0.15 mg/ml alcian blue
8GX (Sigma) in 95% ethanol] was incubated in a 37o water bath then stirred vigorously
on a stir plate for approximately 1 hour in order to help dissolve the blue stain.  Skeletal
preps were then de-stained for 2 days in 95% ethanol.  Carcasses were rinse with tap
water and then transferred to a 1 liter bottle of 1% potassium hydroxide (KOH).  A 2%
KOH solution was also used quicker clearing, however, care was taken to prevent the
skeleton from disintegrating into individual bones.  The 1% KOH was replaced with a
fresh solution every day.  This was continued for 7-10 days or until the bones were white
and readily visible through the cleared muscle tissue.  2 ml of alizarin red stock solution
[0.25 g alizarin red, 0.5 g KOH, and 50 ml dH2O] was then added to the 1 liter 1% KOH
solution.  Solution initially had a dark pink color, which lightens as the skeletal preps
absorbed the stain.  The skeletal preps were incubated in alizarin red / 1% KOH solution
for 1 day.  Preparations were rinsed with tap water and transferred to a graded glycerol
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series (25%, 50%, 70%, 80%, 90%, 100% glycerol in 1X PBS pH 7.4).  All incubations
were done on a shaker or a stir plate with constant, but gentle, stirring.  Specimens were
imaged under a dissection microscope in a dish of water, prior to glycerol staging, or
100% glycerol after staging.  If imaged in glycerol, the skeletal prep and glycerol solution
were rocked overnight to avoid streaking of the glycerol.
E18.5. The same protocol was used as described above for P21 skeletons with the
following exceptions: 1) each embryo was processed in its own 50 ml conical tube
instead of multiple preps in a 1 liter bottle, 2) 0.5% KOH was used for clearing, 3)
because of the delicate skeletons of the embryonic preps, alizarin red was added initially
along with the 0.5% KOH and incubated for only 2 days.
E14.5/E15.5/E16.5. The same protocol was used as described above for P21 skeletons
with the following exceptions: 1) each embryo was processed in its own 50 ml conical
tube instead of multiple preps in a 1 liter bottle, 2) 0.25% KOH was used for clearing, 3)
because of the delicate skeletons of embryonic preps, alizarin red was added initially
along with the 0.25% KOH and incubated overnight, 4) no skinning was necessary since
staining solution are able to penetrate the skin.
Additional methods
Detailed methodology for the following techniques was described in Chapter II:
Whole-mount and slide in situ hybridization, 3-Aminopropyltriethoxysilane treatment of
slides, and alkaline phosphatase staining of sections.
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LacZ staining
Embryos were fixed in 4% PFA pH 7.4 for 1 hour at 4 degrees, followed by 3x30
minute washes with Wash Buffer [2mM MgCl2, 0.01% deoxycholic acid, 0.02% nodidet-
P40 (Roche), 23 mM monobasic sodium phosphate pH 7.3, 77 mM dibasic sodium
phosphate pH 7.3 in H2O], rocking at room temperature.  Enough X-gal stain [0.6 mg/ml
X-gal (Sigma) in dimethylformamide, 0.2 mM K-ferrocyanide, 0.2 mM K-ferricyanide,
1mM Tris pH 7.5, in Wash Buffer] was applied to cover the embryo and incubated
overnight, rocking at room temperature.  The next day, embryos were washed 3x 1 hour
with 1X PBS, then post-fixed with 4% PFA.
Results
Gdf6 and Bmp4 are co-expressed in the frontal bone primordia
As shown in the Chapter II, Gdf6 is expressed in the frontal bone primordia from
E10.5-E12.5 (Fig 3.1 D-F, arrow), a triangular region just above the developing eye.
Bmp4 is co-expressed with Gdf6 in multiple sites in the cranial region, as determined by
lacZ transgene expression in the Bmp4-lacZ/+ embryo from E10.5-E12.5.  These include
the branchial arches (Fig 3.1 A-B, D-E asterix) and the dorsal retina (Fig 3.1 C, F), but
also in the frontal bone primordia (Fig 3.1 A-C, arrows).  This is several days before
ossification centers for the frontal and parietal bones are visible by alizarin red staining at
E14.5, but corresponds to the timepoint at E12.5, when the first markers for osteoblasts
differentiation are visible (ALP and Runx2) in the frontal and parietal bone primordia
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Figure 3.1. Bmp4 and Gdf6 are co-expressed in the frontal bone primordia.  LacZ highlights the expression of Bmp4 in the Bmp4-
lacZ embryo at E10.5 (A), E11.5 (B), and E12.5 (C) just above the developing eye.  Gdf6 in the frontal bone primordia is seen in wild-
type embryos through in situ hybridization at E10.5 (D), E11.5 (E), and E12.5 (F).  Co-expression of Bmp4 and Gdf6 is also seen in
the branchial arches at E10.5 and E11.5 (A-B, D-E asterix) dorsal retina at E12.5 (C,F).  E, eye; dr, dorsal retina; fr, frontal bone
primordia.
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(Fig 2.5 A,D).  E12.5 is also the timepoint when the first changes in suture mesenchyme
differentiation are apparent in the Gdf6-/- embryo (Fig 2.4 C,F).  At this stage, the
undifferentiated state of the CS is already specified.  This suggests that the loss of Bmp4,
like Gdf6, could result in premature suture mesenchyme differentiation early in CS
development.
Bmp4/Gdf6 compound mutant mice present with coronal craniosynostosis
To determine if Gdf6 and Bmp4 interact during suture development, Gdf6+/- and
Bmp4-lacZ/+ mice were crossed to produce compound heterozygotes (Bmp4-lacZ/+;
Gdf6+/-).  Mice were collected at P21 and stained with alcian blue, which stains
cartilage, and alizarin red, which stains bone.  The CS is the joint that separates the
frontal and parietal bones in wild-type mice (Fig 3.2A, arrow).  Both the Gdf6+/- and
Bmp4-lacZ/+ mice had normal CSs (Fig 3.2B-C, arrows).  However, the Gdf6+/-; Bmp4-
lacZ/+ compound mutants had complete fusion of the CS (Fig 3.2 E).   This defect was
identical to the Gdf6-/- mouse (Fig 3.2 D), with the CS being the only cranial suture
affected (the P21 Gdf6-/- mouse used as a reference in Figure 3.2 was collected prior to
backcrossing the Gdf6 line to a C57BL/6J background; on a mixed strain background
some Gdf6-/- mice survived postnatally.  No evidence of partial or total fusion was
observed in the sagittal, squamosal, interfrontal, or lambdoid sutures (not shown).  Also
like the Gdf6-/- mouse, the fusion between the frontal and parietal bones appears as a
continuous surface at this point in development (Fig 3.2 D,E).  The craniosynostosis
phenotype was highly penetrant in our cross (93%, 26/28), and no fusion events were
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Figure 3.2.  Coronal craniosynostosis in Bmp4-lacZ/+; Gdf6+/- compound mutant mice.  P21 mice from a Bmp4-lacZ/+ by
Gdf6+/- cross were stained with alcian blue (cartilage) and alizarin red (bone).  While wild-type (A, arrow), Gdf6+/- (B, arrow), and
Bmp4-lacZ/+ (C, arrow) single heterozygotes have normal coronal sutures, the Bmp4-lacZ/+; Gdf6+/- mouse (E) has complete fusion
of only the coronal suture, like the Gdf6-/- mouse (D).
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Table 3.1.  Analysis of suture fusion in the Bmp4-lacZ/+ by Gdf6+/- cross
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observed in the wild-type (n=24), Gdf6+/- (n=41), or Bmp4-lacZ/+ (n=31) mice (Table
3.1).
Determining the timing of fusion in the Bmp4/Gdf6 compound heterozygote embryo
There are two steps to producing a stable, functioning suture; the formation of the
suture structure and the maintenance of an existing suture.  Although the CS is fused by
day P21 in the Bmp4-lacZ/+; Gdf6+/- mice, we wanted to determine if Bmp4 and Gdf6
were operating in the same steps of suture formation by establishing the timing of fusion
in the Bmp4-lacZ/+; Gdf6+/- embryos compared the Gdf6-/- embryos.
As discussed in Chapter II, fusion of the CS in the Gdf6-/- embryo occurs prior to
the onset of ossification of the cranial bones at E14.5 (Fig 2.2 E-H).  Embryos from a
Gdf6+/- by Bmp4-lacZ/+; Gdf6+/- cross were collected at increasingly early timepoints,
stained with alizarin red, and assessed for fusion of the CS.  The analysis of suture fusion
is summarized in Table 3.2.  At E18.5, the frontal and parietal bones overlap, with the
frontal bone underlying the parietal bone, highlighting the location of the suture (Fig
3.3A, arrow).  The Bmp4-lacZ/+ (Fig 3.3B) and Gdf6+/- (Fig 3.3C) embryos have
normal CSs compared to wild-type (Fig 3.3A).
At E18.5, we observed varying phenotypes in the Bmp4-lacZ/+; Gdf6+/-
embryos.  In half of the embryos collected of this genotype (5/10), there was complete
fusion of the frontal and parietal bones (Fig 3.3E), with a seamless surface between the
two bones, as seen previously in the Gdf6-/- embryos.  However in some embryos,
although the suture is fused, the morphological remnants of a CS structure can still be
seen (Fig 3.3D, yellow arrow).  Although evidence of a remnant suture was never
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Figure 3.3.  Analysis of the timing of suture fusion in Bmp4-lacZ/+; Gdf6+/- compound mutants.  Embryos were collected at
E18.5 (A-G), E16.5 (H-N), and early (V-Y) and late (O-U) stage E14.5.  At E18.5, wild-type (A, arrow), Bmp4-lacZ/+ (B, arrow), and
Gdf6 +/- (C, arrow) have normal coronal sutures.  In the Bmp4-lacZ/+; Gdf6+/- embryos, there were mixed phenotypes.  Some
embryos had complete fusion of the coronal suture (E), while others had remnants of a previously existing suture (D).  Remnants of
the suture were also visible in Gdf6-/- embryos, suggesting an effect of the mixed genetic background.  The Bmp4-lacZ/+; Gdf6-/-
embryos also had a fused coronal suture, but also the added phenotype of a large frontal foramen (F, double arrow).  A reduced frontal
bone was also seen at earlier timepoints (M, T, X).  At E16.5, mixed results were again seen in the Bmp4-lacZ/+; Gdf6+/-, with 3/3
embryos having a completely fused suture on one side (L) and the other side had evidence of early fusion (K, yellow arrow). Panels K
and L of Figure 3.3 are taken from each side of the same embryo.  In the Bmp4-lacZ/+; Gdf6+/- embryos at E14.5 the frontal and
parietal ossification centers are distinct, but show evidence of beginning-stage fusion (S) or a ridge between the two bones (R).  This
differs from the Gdf6-/- (U) and Bmp4-lacZ/+; Gdf6-/- (T) embryos which have a smooth surface between the two bones.  The
asymmetrical fusion is also been as the very earliest stages of E14.5, when the bone centers first appear (V,W).
99
Table 3.2. Analysis of suture fusion in the Bmp4-lacZ/+ by Bmp4-lacZ/+; Gdf6-/- cross
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observed in our Gdf6+/- by Gdf6+/- crosses discussed in Chapter II, it was very rarely
observed in the Gdf6-/- embryos (Fig 3.3G, yellow arrow) collected from the Gdf6+/- by
Bmp4-lacZ/+; Gdf6+/- crosses, but only at P21.  This perhaps suggests an affect of the
genetic background, as the original Gdf6+/-; Gdf6+/- crosses were all performed on a
C57BL/6J background, while the Gdf6+/- by Bmp4-lacZ/+; Gdf6+/- crosses were a
mixed C57BL/6J and CD1 background.
Not surprisingly, the Bmp4-lacZ/+; Gdf6-/- embryos had complete fusion of the
CS (Fig 3.3F), with no evidence of a remnant suture.  However, these embryos presented
with persistence of large frontal foramina (Fig 3.3F, double arrow), which was not seen
in the Bmp4-lacZ/+; Gdf6+/- and Gdf6-/- embryos.  The foramen is the widest at the
point where the CS should reside.  A reduced size of the fused frontal-parietal bone was
also noted at E14.5 in the Bmp4-lacZ/+; Gdf6-/- embryos compared to all the other
genotypes (Fig 3.3 T,X).  It is especially noticeable at E16.5, where the anterior frontal
portion of the fused bone is smaller compared to the posterior parietal portion (Fig 3.3M).
The delay in ossification of the frontal and parietal bones (particularly the frontal bone)
producing the large frontal foramina at E18.5 likely starts very early in development.
This would be consistent with the early expression of Gdf6 and Bmp4 in the E10.5-E12.5
frontal bone primordia, prior to the initiation of ossification.  This is the first evidence
that Gdf6 and Bmp4 may also play a role in ossification of the frontal bone along with the
parietal bone and the formation of the suture.
Timepoint E16.5 was very similar to E18.5, with CS clearly observed in wild-type
(Fig 3.3H), Bmp4-lacZ/+ (Fig 3.3I), and Gdf6+/- (Fig 3.3J) embryos.  At this timepoint
complete fusion of the CS was observed in the Bmp4-lacZ/+; Gdf6-/- embryos (Fig
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3.3M), just like the Gdf6-/- embryo (Fig 3.3N).  Again, like the CS at E18.5, mixed
results were observed in the Bmp4-lacZ/+; Gdf6+/- compound heterozygotes.  3/3
embryos of the Bmp4-lacZ/+; Gdf6+/- genotype all had suture fusion delayed on one
side. In this case, the left side had complete fusion of the frontal and parietal bones (Fig
3.3L), while the right side had a clear existing CS, with some evidence of fusion at the
most lateral aspects of the suture (Fig 3.3K, yellow arrow).  In 2/3 Bmp4-lacZ/+; Gdf6+/-
embryos fusion was delayed in the right side, and in 1/3 fusion was delayed on the left
side (not shown).  This delay might explain why remnants of the suture may persist until
E18.5.
The ossification centers for the frontal and parietal bones are first observed on
E14.5.  However, there are often slight variations in the degree of ossification even
between embryos within the same litter.  When we collected multiple litters of embryos
at E14.5, in some cases ossification had progressed to where the CS was readily visible
(Fig 3.3 O-U) and in other embryos the ossification centers for the frontal and parietal
bones had just begun to form (Fig 3.3V-Y).   When comparing the degree of ossification
of the cranial bones to that in other skeletal elements, such as the mandible, it is clear that
these are distinct developmental stages that we could use to further define the timing of
suture fusion.  In the advanced ossification of E14.5 embryos, the Bmp4-lacZ/+; Gdf6+/-
embryos do show evidence of CS fusion.  This fusion appears to begin at the earliest
stages (Fig 3.3S, yellow arrow), where the bones are beginning to fuse at their most
lateral aspects, but the frontal and parietal bones are still distinguishable as individual
elements.  In some cases the CS is completely fused, but a ridge is observed at the site of
fusion that marks the boundary between the two bones (Fig 3.3R, yellow arrow).  The
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existence of a ridge between the bones suggests that a suture initially formed, followed
by fusion of the two bones.  This clearly differs from the fusion in the Gdf6-/- embryo
(Fig 3.3U) and Bmp4-lacZ/+; Gdf6-/- embryo (Fig 3.3T) where there is a continuous
surface between the two bones and no evidence of suture.
By looking embryos collected at E14.5, but were developmentally slightly
delayed based on the cranial ossification sequence, in which the bones centers first
appear, the same observations are seen, with one side forming a normal CS at least
initially (Fig 3.3V) and the other side the ossification centers never appearing as separate
frontal and parietal bone elements (Fig 3.3W).  As discussed in Chapter II, this contrasts
with the phenotype of the Gdf6-/- (Fig 3.3Y) and Bmp4-lacZ/+; Gdf6-/- (Fig 3.3X) E14.5
embryos, where the ossification centers are never seen as distinct structures.  Although
the suture is completely fused by P21, it is difficult to determine the precise timepoint
when the suture in the Bmp4-lacZ/+; Gdf6+/- compound mutant can first be defined as
fused due to variability in timing of suture fusion within this genotype.  However, like the
Gdf6-/- suture, evidence of ossification through the suture space is sometimes evident
even at the earliest stage of cranial ossification (e.g. Fig 3.3W).
Differentiation of the suture mesenchyme is delayed in Bmp4/Gdf6 compound mutant
embryos compared to Gdf6-/- embryo
In the Gdf6-/- embryo, failure of suture formation is evident even prior to the
onset of ossification since we observed from E12.5 to E14.5 increased activity of alkaline
phosphatase (ALP) and Runx2, both early markers for osteoblasts differentiation; namely,
these markers are expressed continuously in the frontal bone, through the region where
the CS should form, and into the parietal bone (Fig 2.5C,F).  The Gdf6+/- embryo is
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characterized by increased ALP activity within the suture and reduced distance between
the frontal and parietal bone primordia (Fig 2.5B).  Although this increase in ALP
activity does not reach a threshold in the Gdf6+/- embryo required for suture fusion, it
does demonstrate a dosage effect, where the Gdf6+/- phenotype is intermediate between
the Gdf6-/- and wild-type suture.
Similar results were found in a Gdf6+/- by Bmp4-lacZ/+; Gdf6+/- cross.  At
E14.5, the wild-type suture is evident as a space between the ALP-stained frontal and
parietal bone rudiments, with a bridge of light ALP staining spanning the suture (Fig
3.4B).  The phenotype in the Bmp4-lacZ/+ suture (Fig 3.4D) was similar to the Gdf6+/-
suture (Fig 3.4C), with increased ALP activity within the suture mesenchyme.  As
previously shown in the Chapter II, in the Gdf6-/- embryo, there is continuous strong
expression of ALP from the frontal to the parietal bone through where the suture
“should” reside (Fig 3.4E).  However, the Bmp4-lacZ/+; Gdf6+/- suture was yet a further
intermediate phenotype between Gdf6+/- and Bmp4-lacZ/+ single heterozygotes and the
Gdf6-/- suture, with a clearly reduced distance between the frontal and parietal bone
fronts and strong ALP activity through the suture (Fig 3.4F).  However, unlike Gdf6-/-
embryos (Fig 3.4E), the individual bony condensations could still be distinguished from
the suture mesenchyme in the Bmp4-lacZ/+; Gdf6+/- compound heterozygotes.  Since
the CS eventually fuses in Bmp4-lacZ/+; Gdf6+/- mice, the threshold for increased
differentiation within the suture mesenchyme that leads to a fused suture must reside at a
level between the single heterozygote and compound heterozygote phenotypes.
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Figure 3.4.  ALP activity in the coronal suture mesenchyme.  In the wild-type E14.5 embryo, the coronal suture is evident as the
space between the ALP labeled frontal and parietal bone primordia (B, arrow).  In the Gdf6+/- (C, arrow) and Bmp4-lacZ/+ (D, arrow)
single heterozygotes have slightly increased ALP activity within the suture mesenchyme.  In the Gdf6-/- (E) there is continual strong
ALP activity from the frontal and parietal bone primordia through the suture mesenchyme, making the two bones indistinguishable.
The Bmp4-lacZ/+; Gdf6+/- suture (F, arrow) is a further intermediate phenotype between the Gdf6-/- (E) and the single heterozygotes
(C,D) with reduced distance between the frontal and parietal bone primordia and strong ALP activity in the suture mesenchyme.
Unlike the Gdf6-/- (E), the frontal and parietal bones are still distinguishable from the suture space.
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Expression of Gdf6 and Bmp4 in the compound mutants
Chapter II described the autoregulation of Gdf6 in the frontal bone primordia,
with increased production of transcript in the Gdf6-/- embryo compared to wild-type
embryos, with intermediate levels in the Gdf6-/- embryo (Fig 2.6).  It has been previously
reported the Bmp4 is also autoregulated and regulated by other members of the BMP
family, including Bmp2 and Bmp6 (Pereira et al., 2000).  Because of their overlapping
expression, it is possible that Gdf6 and Bmp4 could regulate each others’ expression as
well.  To determine if Gdf6 expression in the frontal bone primordia was also altered by
the haploinsufficiency of Bmp4, E10.5 embryos from a Gdf6+/- by Bmp4-lacZ/+ cross
were analyzed through in situ hybridization for Gdf6.  In wild-type embryos, the same
triangle of Gdf6 expression in the frontal bone primordia was observed as in previous in
situs (Fig 2.6, Fig 3.5A, arrow).  Quantitatively, the in situ signal for Gdf6 expression in
Gdf6+/- and Bmp4-lacZ/+ single heterozygote embryos did not seem significantly
increased compared to wild-type, although the domain expression was more defined, with
an extension of the anterior border well past the borders of the eye (Fig 3.4 B,C, arrows).
Compared to the single heterozygotes, expression in the Bmp4-lacZ/+; Gdf6+/-
compound mutant embryos was in a domain that was shorter in length (to the border of
the eye) and broader in height, with less defined borders (Fig 3.4D, arrow).  There also
appears to be increased transcript in the Bmp4-lacZ/+; Gdf6+/- compound mutants
compared to the single heterozygotes (B,C) and wild-type embryo (A).
To determine if Bmp4 expression changes the haploinsufficiency of Gdf6,
expression of Bmp4 was examined using the lacZ reporter transgene in Bmp4-lacZ/+
single heterozygotes and Bmp4-lacZ/+; Gdf6+/- compound mutants.  However, no
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Figure 3.5.  Expression of Gdf6 and Bmp4 in single and compound heterozygotes.
(A-D) Gdf6 in situ hybridization on E10.5 embryos from a Bmp4-lacZ/+ by Gdf6+/-
cross.  Gdf6 is expressed in the frontal bone primordia in wild-type embryos (A, arrow).
This region is expanded ventrally in the Gdf6+/- (B, arrow) and Bmp4-lacZ/+ (C, arrow)
embryos.  In the Bmp4-lacZ/+; Gdf6+/- embryos the expression of Gdf6 in the frontal
bone primordia is shorter and broader with irregular borders (D, arrow) with increased
level of transcript.  (E-F) Expression of Bmp4 by the lacZ transgene in E11.5 Bmp4-
lacZ/+ (E, arrow) and Bmp4-lacZ/+; Gdf6+/- (F, arrow) embryos reveals no obvious
differences in Bmp4 expression in the frontal bone primordia.
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changes in the domain of Bmp4 expression were detected between Bmp4-lacZ/+ (Fig
3.5E) and Bmp4-lacZ/+;Gdf6+/- embryos (Fig 3.5F).  Together, this data does not
provide conclusive evidence that Bmp4 or Gdf6 have the ability to regulate each other’s
expression at the transcriptional level.
Examination of Bmp4 expression in the Gdf6 suture
Although no changes were seen in whole-mount Bmp4-lacZ expression at E11.5
between Bmp4-lacZ/+ single heterozygotes and Bmp4-lacZ/+; Gdf6+- compound
mutants (Fig 3.5E,F), we also examined for subtle changes in Bmp4-lacZ expression at
the suture level at E14.5, the timepoint when fusion of the frontal and parietal bone
ossification centers is first visible through alizarin red staining.  Embryos were collected
from a Gdf6+/- by Bmp4-lacZ/+; Gdf6+/- cross and stained for lacZ to highlight sites of
Bmp4 expression.  Sections were further stained for ALP activity to highlight the location
of the bones and suture.  In the E14.5 wild-type embryo, Bmp4 is expressed in the frontal
bone primordia, the underlying dura mater, and in the periosteum on the ectocranial side
of the frontal bone (Fig 3.6A).  The periosteal expression in the wild-type embryo
appears to end within the suture mesenchyme (Fig 3.6A, arrow).  In the Gdf6+/- suture,
Bmp4 is still expressed in the frontal bone, but the periosteal expression is retracted (Fig
3.6B, arrow) so it does not reach the suture mesenchyme.  In the Gdf6-/- embryo, mixed
results were found.  In some embryos, no lacZ expression was detected in the frontal
bones and the periosteal expression ended where the nasal bones end and frontal bones
begin (not shown).  In other embryos, expression of Bmp4 was similar to expression in
the wild-type and Gdf6+/- embryos and simply ended at the point where the frontal bone
108
Figure 3.6.  Expression of Bmp4 in the Gdf6 mutant suture. Embryos were collected from a Gdf6+/- by Bmp4-lacZ/+; Gdf6+/-
cross and stained for lacZ to highlight sites of Bmp4 expression and ALP to locate the suture. A) In the wild-type embryo, Bmp4 is
expressed in the frontal bone primordia, dura mater (lower blue line), and ectocranial periosteum (upper blue line), and ends in the
suture mesenchyme (arrow).  B) In the Gdf6+/- suture the periosteal expression is retracted (arrow) so it does not reach the suture
mesenchyme.  C) In some Gdf6-/- embryos, Bmp4 expression continues from the frontal bone, through the site of the suture fusion,
into the parietal bone.  Yellow lines outline the bony condensations of the frontal and parietal bones.
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fused to the parietal (not shown).  And furthermore, in some Gdf6-/- sutures the Bmp4
expression continues from the frontal bone, across the site of suture fusion into the
parietal bone, and therefore was expressed in the entirety of the fused bone (Fig 3.6C).
Although it appears that normal Bmp4 expression is altered in the suture region of
Gdf6+/- and Gdf6-/- embryos, it is difficult to draw conclusions about the mechanistic
repercussions of such changes in expression due to the mixed results of Bmp4 expression
in the Gdf6 homozygous mutant embryos.
Discussion
Cooperative function of Bmp4 and Gdf6 in coronal suture development
In this study we found evidence that Gdf6 and Bmp4 function together in the
earliest stages of CS formation.  Both Gdf6 and Bmp4 are co-expressed in the frontal
bone primordia from E10.5-E12.5, several days prior to the onset of ossification.  This
corresponds to the timepoint when the suture mesenchyme loses its undifferentiated state
in the Gdf6-/- embryo.  Furthermore, the haploinsufficiency of both genes leads to
complete craniosynostosis of the CS.
Increased differentiation of the suture mesenchyme is evident at E14.5 in the
Bmp4-lacZ/+; Gdf6+/- compound mutant (Fig 3.4F) as an intermediate phenotype
between the Gdf6-/- embryos (Fig 3.4E) and Gdf6+/- and Bmp4-lacZ/+ single
heterozygotes (Fig 3.4C-D), suggesting a slight delay in suture fusion in the compound
mutants.  This delay was also evident in alizarin red staining of embryos at several points
in development, with partially fused sutures (Fig 3.3K,S), unilateral fusion of one side
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(Fig 3.3K,L), or remnants of a previously existing suture (Fig 3.3D,R).  This leads to the
question: why is fusion delayed in the Bmp4-lacZ/+; Gdf6 compound mutants if Bmp4
and Gdf6 are functioning at the same timepoints in the same processes?
One possibility is that while Gdf6 functions primarily in the very early stages of
suture formation, Bmp4 cooperatively functions with Gdf6 to form the suture by
inhibiting osteogenic differentiation of the suture mesenchyme, but also plays a later role
in development separate from Gdf6 in the maintenance of the suture.  This would explain
why evidence of suture fusion and suture mesenchyme differentiation are evident at the
early stages, and although they are not as severe as the complete fusion seen in the Gdf6-
/- mice; the additional failure to maintain the suture ultimately leads to craniosynostosis.
In addition to the expression we observed of Bmp4 in the frontal bone primordia, Bmp4 is
also expressed in the periosteum, frontal bone, suture mesenchyme, and dura at E14.5,
when Gdf6 expression is undetectable in the suture region (Fig 3.6).   Other publications
have described Bmp4 expression throughout embryonic development to E18.5 in the
osteogenic fronts (Kim et al., 1998b).  The expression of Bmp4 in the dura is of note due
to the importance of the dura in osteogenesis and suture maintenance.  Some studies have
suggested that the suture mesenchyme does not provide autocrine signals that help keep
the suture in an undifferentiated state, but instead remains “primed” to receive signals
from the surrounding tissues, including the dura mater, that serve this function.  For
example, the posterior interfrontal suture, which normally fuses in mice postnatally, only
expressed osteoid markers when cultured together with the adjacent underlying dura
mater.  When suture mesenchymal cells were grown separate from the dura mater, gene
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expression analysis was identical to the sagittal suture mesenchyme, which remains
patent for the lifespan of the animal (Spector et al., 2000).
The delay in suture fusion in the Bmp4/Gdf6 compound mutants might also be
attributed to a more critical role of Gdf6 in suture formation than Bmp4.  Bmp4 and Gdf6
due use the same BMP receptors (Bmpr1a, Bmpr1b, BmprII, and AcvrIIa), however, the
affinity for Bmp4 and Gdf6 for the receptors has not been compared.  One study did
compare affinities closely related family members Bmp2 and Gdf5 and found that Gdf5
had a higher affinity with the Bmpr1b receptor than Gdf5 (Heinecke et al., 2009).
Considering that Gdf5 and Gdf6 likely have similar properties, perhaps if Bmpr1b was
the predominant receptors in the suture region, this could explain why Gdf6 appears to be
more required than Bmp4.  Since Bmp4 expression in the frontal bone primordia was
assayed using the Bmp4-lacZ line, and direct comparison between the expression levels
of Bmp4 and Gdf6 was not performed.  Alternatively, perhaps Bmp4 is expressed at lower
levels than Gdf6 in the frontal bone primordia.
Although suture differentiation in the Bmp4/Gdf6 compound mutants reaches the
threshold to produce suture fusion, enough undifferentiated suture mesenchymal cells
remain to allow the suture to persist past the timing of suture fusion in the more severe
Gdf6-/- case.  This hypothesis is outlined in Figure 3.7.  Both Gdf6 and Bmp4 are
expressed in the frontal bone, providing a paracrine signal to the suture mesenchyme to
inhibit osteogenic differentiation (Fig 3.7A).  In the Bmp4/Gdf6 compound mutant, the
inhibitory signal is reduced, allowing for increased suture mesenchyme differentiation
(Fig 3.7B).  However, in the Bmp4-lacZ/+; Gdf6-/- suture, the inhibitory signal is
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Figure 3.7.  Model of Bmp4 and Gdf6 function in suture development.  A) In wild-
type embryos, Bmp4 (light red) and Gdf6 (dark red) expression in the frontal bone
provides a paracrine signal to the suture mesenchyme to inhibit osteogenic
differentiation.  Because the phenotype of the Gdf6-/- is more severe than the Bmp4/Gdf6
compound heterozygote, it seems that the Gdf6 signal is more required than Bmp4.  Bmp4
and Gdf6 also signal to the parietal bone primordia to promote proliferation and
differentiation.  B) In theBmp4/Gdf6 compound heterozygote, the inhibitory signal is
reduced, increasing the differentiation of the suture mesenchyme to produce suture
fusion, but allows the suture to persist longer than the Gdf6-/- embryo.  C) In the Bmp4-
lacZ/+; Gdf6-/- embryo, the inhibitory signal is reduced to so that the suture
mesenchyme is immediately differentiated.  The stimulatory effect of Bmp4 and Gdf6 in
the frontal bone primordia is also reduced, resulting in the frontal bone foramina.  D)
Possible mechanism involving Bmp4/Gdf6 heterodimers.  Bmp4/Gdf6 heterodimers in
the frontal bone fronts provide a paracrine signal to inhibit differentiation of the suture
mesenchyme.  Bmp4 and Gdf6 homodimers in the frontal bone have a separate function,
to promote proliferation of the frontal bone.  In the case of reduction or elimination and
Bmp4 and/or Gdf6, the heterodimers are reduced or eliminated, leading to differentiation
of the suture mesenchyme.  However, in the frontal bone, Bmp4 and Gdf6 can
compensate for one another, so a bone defect is only seen with extreme reduction of the
combined signal, as in the Bmp4-lacZ/+; Gdf6-/- embryos.
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reduced to such a great extent that suture mesenchyme differentiation occurs rapidly and
completely, hence there is never evidence of an existing suture space.
Due to the co-expression of Gdf6 and Bmp4 in the frontal bone primordia at
E10.5-E12.5 (Fig 3.1) and the similarity in the ectopic suture mesenchyme differentiation
between the Gdf6+/- and Bmp4-lacZ/+ embryos (Fig 3.4 C,D), it is likely that Gdf6 and
Bmp4 are operating at the same timepoints in suture development.  There are several
possible explanations for the differences, albeit inconsistent, seen in Bmp4 expression in
Gdf6-/- mice.  One possibility is that it could be a secondary result of morphological
changes in the suture.  Without the structure of the suture, the boundary between the
frontal and parietal bone is indistinguishable, and therefore signals, which normally
delineate the boundary, are likely also disrupted.  Reduced Bmp4 expression in the
periosteum could result from the elimination of signals which usually emanate from the
suture mesenchyme.
It is also possible that Bmp4 or Gdf6 does not directly play a role in suture
development, but instead one could be involved in the regulation of the other (or another
BMP).  For example, if Bmp4 normally induces the expression of Gdf6, the loss of Bmp4
would reduce levels of Gdf6, which are already reduced due to haploinsufficiency in the
Bmp4/Gdf6 compound mutants.  This would produce a phenotype similar to the Gdf6-/-
mouse without Bmp4 having a direct affect on the suture.  The same could be said if
Gdf6 regulated Bmp4 expression.
However, we found no conclusive evidence that Bmp4 or Gdf6 regulate each
other’s expression.  When we compared Gdf6 expression in the Bmp4/Gdf6 compound
mutant, it is possible the difference in the area occupied by Gdf6 expression (Fig 3.5)
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could contribute to the suture phenotype, where Gdf6 is being ectopically expressed
beyond the frontal bone primordia or the morphology of the frontal bone primordia itself
has been altered.  However, this could also be a secondary effect from an overall
morphological change in the cranial region.  For example, changes in eye development in
the compound heterozygotes (discussed in detail in Chapter IV) could impact craniofacial
morphology and the shape of the frontal bone primordia.  The examination of Bmp4
expression in Gdf6-/- mice failed to produce consistent results.  Again, this could be due
to strain background effects.  The Bmp4/Gdf6 compound mutants were generated on a
mixed C57Bl/6J and CD1 genetic background, and therefore the presence of modifier in
genes within the Bmp4 and Gdf6 pathways may alter the suture phenotype.
Additional experiment could be done to further explore the Bmp4/Gdf6
interaction.  For example, a conditional deletion of Bmp4 using Wnt1-Cre and a floxed
allele of Bmp4 would eliminate Bmp4 expression in the neural crest, including the frontal
bone primordia.  In addition, using the bead implantation methodology discussed in
Chapter II, beads soaked in Bmp4 protein could be implanted into the suture region.  In
both these cases, possible changes in the expression of Gdf6 could be examined through
in situ hybridization.
Role of homodimers and heterodimers in suture development
The mechanism for Gdf6/Bmp4 interaction may be more complicated then a
simple additive model of signaling activity.  The role of molecular heterodimers in the
formation of the CS is a new area of investigation.  Haploinsufficiency of TWIST1 is
associated with Saethre-Chotzen syndrome, characterized by coronal craniosynostosis.
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Twist1 forms both homodimers and heterodimers with E2A E-proteins.  The ratio of
Twist1 homodimers to heterodimers is control by the helix-loop-helix transcription factor
inhibitor Id proteins, which are induced by BMP signaling (Rice et al., 2005).  The Id
proteins, localized to the bone fronts, competes with Twist1 in dimerization with E
proteins, forcing the formation of homodimers.  In the suture mesenchyme where there is
no Id protein, Twist1 can heterodimerize with E proteins.  These dimers activate different
sets of genes; the homodimers activate FGFR2, promoting differentiation, where the
heterodimers induce TSP-1, which is involved in the maintenance of suture patency.  In
Twist1+/- mice, the ratio of homodimers to heterodimers is altered with increased
homodimers in the bone fronts, extending the bone fronts in the suture mesenchyme and
leading to synostosis of the suture (Connerney et al., 2006).
BMPs can form heterodimers, but only when they are expressed in the same cells,
as dimerization proceeds secretion (Chang and Hemmati-Brivanlou, 1999).  Gdf6 was
able to heterodimerize with Bmp2 in frogs (Chang and Hemmati-Brivanlou, 1999), and
given the high homology between Bmp2 and Bmp4, it would not be surprising if Gdf6
also formed heterodimers with Bmp4.  In fact, a dominant-negative form of Gdf6 blocked
mesodermal and epidermal induction by Bmp4 when co-injected into the same embryos
(Chang and Hemmati-Brivanlou, 1999).  In some cases, these BMP heterodimers,
including Bmp2/Bmp7, have been found to have a more potent effect than homodimers
(Xiao, 2007).  Bmp4 can also heterodimerize with Bmp7, with significantly increased
activity compared to the Bmp4 homodimer (Aono et al., 1995; Hazama et al., 1995).
Bmp4 and Bmp7 homodimers alone, and even a mixture of Bmp4 and Bmp7
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homodimers together, act as poor inducers of mesoderm.  Yet Bmp4/Bmp7 heterodimers
act as strong inducers of mesoderm in Xenopus embryos (Suzuki et al., 1997).
In many tissues the expression domains of Bmp2, Bmp4, and Bmp7 overlap,
however, the homozygous mutant phenotypes are very different (Hogan, 1996).  If
heterodimers had a unique function separate from the homodimers, you might expect
there is be some overlap among the mutant phenotypes.  BMP heterodimers have been
generated in vivo, and it’s possible that these could be acting as antagonists by competing
with the homodimers for receptor binding (Hogan, 1996).
In the case of Bmp4 and Gdf6, we have found multiple sites in addition to the CS
where the phenotype of the compound mutant is more severe than that of each single
heterozygote (discussed in Chapter IV).  One could hypothesize that Gdf6 and Bmp4 do
have the ability to form heterodimers, and the function of these heterodimers could be
quite different than the function of homodimers.  This hypothesis is summarized in
Figure 3.7D.  For example, it is possible that while Bmp4 and Gdf6 homodimers function
primarily in the proliferation of the frontal bone, Bmp4/Gdf6 heterodimers function in the
inhibition of the suture mesenchyme or vice versa.  Like the case with Twist1 dimer
formation, a secondary factor could limit the formation of Bmp4/Gdf6 heterodimers, or at
least their diffusion of activity, to the bone fronts, closest in proximity to the suture
mesenchyme.  This would explain why CS fusion is seen in the Bmp4/Gdf6 compound
mutants, but not the frontal bone defect: in the proliferation of the frontal bone, Bmp4
and Gdf6 can compensate for one another, but both are required for the formation of
heterodimers and therefore the inhibition of suture differentiation.
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Total and partial fusion of the coronal suture
In the original design to assess suture formation in the Gdf6/Bmp4 compound
mutants, we planned to score the suture phenotype based on severity: the total percentage
of the suture that has undergone fusion by P21.  This is due to the fact that a coronal
craniosynostosis phenotype as complete as that seen in the Gdf6-/- embryo is rare, where
the frontal and parietal bones are completely fused and there is no evidence of at least
partial suture formation.  In our Gdf6-/- embryos, and liveborn Gdf6-/- mice analyzed on
a mixed strain background (Settle et al., 2001), penetrance of the craniosynostosis
phenotype was 100% (Fig 3.8E).  In our Bmp4-lacZ/+; Gdf6+/- compound mutants the
penetrance was 93% (Figure 3.8E).  This is still remarkably high compared to other
mouse models, demonstrating the importance of Gdf6 in suture development.  In the case
of the Twist1+/- mutant, the mechanism for suture fusion is traced back to the formation
of the boundary between the neural crest-derived frontal bone and the paraxial
mesoderm-derived parietal bone, a boundary that forms around E9.5.  Even so, suture
fusion is often incomplete, unilateral, and/or not present until postnatal stages (Fig 3.8B)
(Merrill et al., 2006).  In the case of EphA4-/- mice, approximately 25% of the suture is
fused and in the Twist1+/-; EphA4+/- mice only 50% of the suture was fused (Ting et al.,
2009).  The fact that in all cases of the Gdf6-/- and Bmp4/Gdf6 compound mutant at P21
the entire length of the suture is fused, speaks to the severity of the defect in these mice.
By P21 in the Bmp4-lacZ/+; Gdf6+/- compound mutants, the suture is completely fused,
with no evidence of a partially fused or remnant suture (Fig 3.2E).  Partial fusion is seen
in the embryonic stages (Fig 3.3D,K,R), however, we believe that this is distinct
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Figure 3.8.  Penetrance and severity of the defects in mouse models for
craniosynostosis.  Twist1+/- (B), EphA4-/- (C), and Twist11+/-; EphA4+/- (D) mice all
present with partial or unilateral fusion of the coronal suture.  The penetrance in these
models ranges from 40-94% (E).  This is compared to the Gdf6-/- and Bmp4-lacZ/+;
Gdf6+/- compound mutants which have a 100% and 93% penetrance respectively (E),
and also complete fusion of the coronal suture.
Panels A-D adapted from Ting et al 2009.
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from the partial fusion observed in other mouse craniosynostosis models.  During the
initial steps of formation of the suture, the ossification centers meet beginning at the most
lateral aspects of the calvaria, and move “zipper-like” up toward the midline, as seen with
the lateral regions of the suture being more histologically mature than the medial regions
(Rice, 2008).  The partial fusions observed in our Bmp4-lacZ/+; Gdf6+/- compound
mutants were always evident at the most lateral aspects of the suture, with the suture
remnants being localized to the medial aspects, next to the sagittal suture (Fig 3.3 D,K,S
yellow arrows).  This is most likely due to the initiation of fusion moving laterally toward
the midline as the suture mesenchyme matures at each site.
However, we did see some remnant suture in the Gdf6-/- E18.5 embryos (Fig
3.3G) in our Gdf6+/- by Bmp4-lacZ/+ crosses that were not seen in our Gdf6+/- by
Gdf6+/- crosses.  We attributed this to the mixed CD1/C57Bl/6J background of the
former cross and the inbred C57Bl/6J background of the later.  More specifically, this
could be due to strain dependent differences in the genes (e.g. Noggin), which encode
proteins that bind and inactivate Bmp4 and/or Gdf6, in the activity of receptors or
downstream effectors of BMP signaling, or in the activity of redundant genes (Dunn et
al., 1997).
Coronal craniosynostosis in the Gdf6-/- embryo and Bmp4/Gdf6 compound
mutant also stands out in the early appearance of the defect.  In the Gdf6-/- embryo, the
defect is apparent by E12.5 with the increased differentiation of the suture mesenchyme.
Even in the Twist1+/- mouse, no changes in the suture can be detected until E14.5,
although ossification through the suture may not be evident until postnatal stages (Merrill
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et al., 2006).  Axin2-/- homozygous mutants have normal sutures at birth and then the
process of fusion initiates (Yu et al., 2005).
Additional role for Bmp4 and Gdf6 in frontal bone growth
Although Gdf6 is expressed exclusively in the frontal bone primordia, no frontal
bone defect is observed in the Gdf6-/- embryo at any timepoint.  When we measured the
size of the frontal and parietal bones in relation to the size of the occipital bone (which is
presumably unaffected by changes in Gdf6), there was no significant difference between
wild-type and Gdf6-/- embryos in relation to the size of the frontal (p=0.77) or parietal
(p=0.25) bones, at least at E15.5 when the bones were measured.  It is not until one
further eliminates a Bmp4 allele (in the Bmp4-lacZ/+; Gdf6-/- embryos) that a frontal
bone defect is observed with the persistence of a frontal foramen (Fig 3.3F).  This
perhaps also demonstrates a cooperative function between Gdf6 and Bmp4 in the
development of this structure.  In Chapter II, we did see a difference between cellular
proliferation between the frontal bones of wild-type and heterozygous embryos at E13.5
that trended toward significance (p=0.056) (proliferation specifically in the frontal bone
of Gdf6-/- embryos could not be examined since the boundary between the frontal and
parietal bones cannot be distinguished).  In addition, beads soaked in Gdf6 protein
promoted osteogenic differentiation when implanted into the frontal bone primordia (Fig
2.11B).  This suggests that Gdf6, and likely Bmp4, play a role in the proliferation and
differentiation of the embryonic frontal bone.  Also of note was a decrease in the size of
the interparietal bone in the Gdf6-/- embryo compared to wild-type (Fig 2.2 C, D),
generating a wider lambdoid suture.  This appears to particularly affect the portion of the
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interparietal bone that is neural crest derived (Fig 1.3C), suggesting a specific function of
Gdf6 on the growth of neural crest-derived cranial bones.  A more detailed analysis of the
occipital bone defect could be carried out by comparing the width and length of the bone
between wild-type and Gdf6-/- embryos.
It is interesting to note that several other craniosynostosis-associated genes are not
only also expressed in the frontal bone primordia, but also promotes frontal bone
osteogenesis.  This is the case with Msx1 and Msx2, both of which are expressed in the
frontal bone primordia at the same timepoints as Gdf6 and Bmp4 (E10.5-E12.5) (Han et
al., 2007).  Various combinations of single and compound mutants (Msx1-/-, Msx1-/-;
Msx2+/-; Msx1+/-; Msx2-/-) all result in frontal foramina, while the Msx1-/-; Msx2-/-
double mutants fail to generate any calvarial bones (Han et al., 2007).  The frontal
foramina phenotype in the Msx2 mutants is also made more severe combined with the
haploinsufficiency of Twist1, another craniosynostosis-associated gene expressed in the
frontal bone primordia (Ishii et al., 2003).
Although not yet supported experimentally, it was originally hypothesized that the
suture forms in response a growth factor gradient generated by the approximation of the
advancing ossification centers.  It is possible that CS fusion is a secondary result of the
frontal bone defect.  A lag in osteogenesis of the frontal bone could alter the position
where it approximates the parietal bone, forming the CS.  There is also evidence that the
position where CS forms is also determined through signals from the dura and coincides
with the cellular boundary between the neural-crest derived frontal bone and the paraxial
mesoderm parietal bone.  Perhaps the meeting of the frontal and parietal bones needs to
occur at the position determined by these other factors, and if not, a suture defect would
123
result.  In this case, the suture would fail to form and the mesenchyme undergo
differentiation as though it was just part of the expanding bones.
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CHAPTER IV
INTERACTIONS BETWEEN GDF6 AND BMP4 IN THE DEVELOPMENT OF
MULTIPLE SKELETAL ELEMENTS
Introduction
In the previous chapter we showed that the CS phenotypes of Bmp4-lacZ/+;
Gdf6+/- compound mutant resembles that of Gdf6-/- mice, with complete fusion of the
CS (Fig 3.2).  Gdf6 and Bmp4 are co-expressed in the frontal bone primordia early in
cranial development (Fig 3.1).   Furthermore, both the Gdf6-/- embryo and the
Bmp4/Gdf6 compound mutants show evidence of ossification through the suture at E14.5
(Fig 3.3) and erroneous differentiation of the suture mesenchyme (Fig 3.4).  This has led
us to conclude that these two BMP family members work cooperatively in the
development of the CS.
There is much evidence in literature for BMP family members with cooperative
functions in development.  Due to the high homology between BMPs, it is likely that in
some developmental processes they are able to compensate for one anther.  In addition to
the CS, other sites where Gdf6 and Bmp4 function cooperatively may be elucidated
through the thorough examination of the compound mutants.  Several phenotypes became
apparent in Gdf5/Gdf6 compound mutants that were not detectable in the Gdf6-/- mutant;
including reductions and fusions of the phalanges, carpal and tarsal bones, and scoliosis
of the spine (Settle et al., 2001).  Gdf5/Bmp5 compound mutants presented with
phenotypes which demonstrated both an additive effect on the length of some skeletal
structures (e.g. certain long bones) in addition to a synergistic effect in formation of
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specific structures (fibula, knee) (Storm and Kingsley, 1996).  While Bmp2/Bmp7 and
Bmp5/Bmp7 compound heterozygotes have no reported abnormal skeletal phenotypes,
Bmp4/Bmp7 compound mutants have defects and abnormalities in the limbs and rib cage.
These include misalignment of the ribs, defective ossification of the sternum, a split
xiphoid process, and preaxial polydactyl of the limb.  All these phenotypes were rarely
observed in the single heterozygotes (Katagiri et al., 1998).
The goal of this study was to determine if Bmp4 and Gdf6 were cooperating in the
formation of structures apart from the CS.  To address this question we generated Bmp4
and Gdf6 compound mutants and analyzed the mice for skeletal phenotypes.  We found
that in the Gdf6/Bmp4 compound mutants there are defects present in the single
heterozygotes that are made more severe in the compound mutants and phenotypes that
are only present in the compound mutants.  Phenotypes in the compound mutants
included sternal anomalies, hypoplasia of the pelvis and thyroid cartilage, preaxial
polydactyly of the hindlimb, and microphthalmia.  These phenotypes demonstrate a
genetic interaction between Bmp4 and Gdf6 that affects multiple skeletal and non-skeletal
structures and various developmental mechanisms.
Materials and Methods
Mouse crosses
Details for the Gdf6 and Bmp4 lines are discussed in detail in the methods section
of Chapters II and III.  The Gdf6 BAC line (also termed Dβgeo or 125L11) was
generated by Doug Mortlock by inserting a cassette containing a internal ribosome entry
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site fused to the βgeo gene into the second exon of Gdf6 in a 129/SvJ mouse BAC
(Mortlock et al., 2003).
Additional methods
The following protocols were outlined in previous chapters: DNA preparations
and genotyping (Chapters II and III), whole-mount alizarin red skeletal preparations
(Chapter III), whole-mount and slide in situ hybridization (Chapter II), 3-
aminopropyltriethoxysilane treatment of slides (Chapter II), and lacZ staining Chapter
III).
Results
Increased presentation of the manubriosternal joint in Bmp4/Gdf6 compound mutants
The mouse sternum begins to form around E12 as a pair of mesenchymal
condensations that elongate and form a cartilage precursor.  The cartilage segments move
towards the midline and fuse to form a cartilaginous rod.  The rod segments as a result of
hypertrophy of the cartilage cells in the intercostal regions and ossifies through the
expansion of six ossification centers (Chen, 1952).
The thoracic bones in mice consist of the manubrium, six sternal segments, and
the xiphoid cartilage.  The manubrium and first sternal segment unite at a site known as
the manubriosternal joint (Fig 4.1A, arrow).  The manubrium and sternum form from a
cartilage precursor, however, like the cranial sutures the manubriosternal joint forms at
the interface between two joining ossification centers, one in the manubrium and one in
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Figure 4.1. Increased presentation of the manubriosternal joint in Bmp4/Gdf6 compound mutants.  The manubrium and first
sternal segment of the sternal body are fused together in wild-type (B) and Gdf6+/- (D) mice.  In 21% of Bmp4+/- mice the
manubriosternal joint is present (C).  This is increased to 60% in Bmp4-lacZ/+; Gdf6+/- mice (D).  No manubriosternal joint was
present in Gdf6-/- mice (F).  Panel F was imaged from a mouse collected at a different timepoint and litter from the remaining
genotypes due to the perinatal lethality of Gdf6-/- mice on the C57BL/6J background, which caused the difference in intensity of
alizarin red staining. M, manubrium; s1, first sternal segment; j, manubriosternal joint.
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the first sternal segment of the body (Gray and Lewis, 1918).  In the Bmp4+/- mice the
manubriosternal joint was present at P21 in 21% of the animals (6/28) (Fig 4.1C),
whereas the manubriosternal joint was never observed in the wild-type (0/21) and
Gdf6+/- mice (0/35) (Fig 4.1B,D), with the manubrium and the sternum fused into a
single bone.  The incidence of the manubriosternal joint was increased to 60% in the
Bmp4+/-;Gdf6+/- compound mutant mice (18/30) (Fig 4.1E).  The difference in the
penetrance of the manubriosternal joint phenotype between the Bmp4-lacZ/+
heterozygotes and Bmp4-lacZ/+; Gdf6+/- compound mutants was statistically significant
(p=0.03, Chi-squared test).  Although the Gdf6-/- allele is perinatal lethal on our
C57BL/6J background, in two adult mice collected and saved when the Gdf6 line was on
a mixed background, no manubriosternal joint was observed (Fig 4.1F) (panel F of figure
4.1 was imaged from a mouse collected at a different time and litter from the remaining
genotypes due to the perinatal lethality of Gdf6-/- mice on the C57BL/6J background,
which caused the difference in intensity of alizarin red staining).
Hypoplasia of the ischium and the pubis
Two bones of the lower os coxae, the ischium and the pubis, join together below
the large obturator foramen (Fig 4.2I).  In wild-type mice at P21, these two bones meet
and fuse together (Fig 4.2A, arrow).  In Gdf6+/- and Bmp4-lacZ/+ mice, there is a small
gap remaining between the two pelvic bones (Fig 4.2B,C arrows).  The width of the gap
between the bones is increased in the Bmp4-lacZ/+; Gdf6+/- compound mutant mice (Fig
4.2D, arrow).  The timing and location of Bmp4 and Gdf6 expression in the pelvic region
is unknown.
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Figure 4.2. Hypoplasia of the pelvic bones and thyroid cartilage.  Two bones of the
lower os coxae, the ischium and the pubis, join together below the large obturator
foramen (I).  In wild-type mice, these two bones meet and fuse together (A, arrow).  In
Gdf6+/- (B) and Bmp4-lacZ/+ (C) mice, there is a small gap remaining between the two
pelvic bones (arrows).  The width of the gap is increased in the Bmp4-lacZ/+; Gdf6+/-
mice (D, arrow).  The thyroid cartilage is the largest cartilage of the larynx, consisting of
two wings fused at the midline of the neck (J).   In wild-type mice, chondrogenesis of the
two wings is almost complete, with only small gaps close to the midline yet to form (E,
arrow).  In the Gdf6+/- mice, there are large holes on either wing lacking cartilage
formation (F, arrow).  The Bmp4-lacZ/+ phenotype more closely resembles wild-type (G,
arrow).  The area lacking cartilage in the Bmp4/Gdf6 compound heterozygotes is larger
than either of the single heterozygotes (H, arrow).  Cr, cricoid cartilage; is, ischium; pb,
pubis.
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Figure 4.3.  Persistence of hypoplasia through adulthood. A) In some Bmp4/Gdf6
compound heterozygotes, a large portion of the cartilage fails to fuse along the midline.
At both at P100 (B) and P180 (C), there is no change in the severity of the cartilage
formation defect, and therefore this is a persisting defect established early in the
development.  The ischium and the pubis do appear to touch during adulthood (E,F
arrows), however, the area of bone in which they unite it much thinner than found in
wild-type mice (not shown).
Figure 4.4.  Wormian bones in the interfrontal suture. Wormian bones are small
calvarial bones that develop from additional ossification centers, separate and at a
distance from the ossification centers of the main cranial bones.  In the Gdf6+/- by Bmp4-
lacZ/+ crosses, these ectopic bones were often observed in the most anterior portion of
the interfrontal suture (B), the suture that separates the paired frontal bones (A). Fb,
frontal bone; ifs, interfrontal suture; wb, wormian bone.
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This leads to the question of whether this represents a permanent defect or simply
a lag in the growth of these structures.  To address this possibility, we also collected adult
Bmp4-lacZ/+; Gdf6+/- compound mutants at P100 (Fig 4.3B) and Pz180 (Fig 4.3C).
Although later in adulthood, the ischium and the pubis do appear to touch (Fig 4.3C,D
arrows), the area of bone in which they unite it much thinner than found in wild-type
mice, even at P21 (Fig.4.2A).  This suggests that although the pelvic bones continue to
grow past P21, the lag in growth fails to catch up with wild-type.
Hypoplasia of the thyroid cartilage
The thyroid cartilage is the largest cartilage of the larynx, consisting of two wings
fused at the midline of the neck (Gray and Lewis, 1918) (Fig 4.2J).  Previously collected
Gdf6-/- adult mice had severe hypoplasia the thyroid cartilage and epiglottis, along with
abnormal fusion of the arytenoids cartilages (not shown). We found that in wild-type P21
mice, chondrogenesis of the two wings of the thyroid cartilage is almost complete, with
only small gaps close to the midline (Fig 4.2E, arrow).  In the Gdf6+/- mice, there are
large holes on either wing lacking cartilage formation (Fig 4.2F, arrow).  While the
Bmp4-lacZ/+ phenotype more closely resembles wild-type then the Gdf6+/- mice (Fig
4.2G), the area of failed cartilage formation in the Bmp4/Gdf6 compound mutant (Fig
4.2H, arrow) is larger than either of the single heterozygotes (Fig 4.2F,G, arrow).  In
some Bmp4/Gdf6 compound mutants, a large portion of the cartilage fails to fuse along
the midline (Fig 4.3D).  Looking at adult Bmp4-lacZ/+; Gdf6+/- compound mutant, both
at P100 (Fig 4.3E) and P180 (Fig 4.3F), there is no change in the severity of the cartilage
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formation defect.  Therefore, by P21 the development of the thyroid cartilage is complete,
resulting in a persisting defect.
Although expression of Bmp4 in this structure is not reported, Gdf6 is expressed
in the mesenchyme adjacent to the thyroid cartilage at E14.5 (not shown).  Therefore, it is
likely the Gdf6 provides a paracrine signal from the adjacent mesenchyme to the thyroid
cartilage to stimulate cartilage growth.  Since the phenotype of Bmp4-lacZ/+ mice was
similar to the wild-type thyroid cartilage, but the severity appeared to increase from the
Gdf6+/- to Bmp4/Gdf6 compound mutants, this suggests a possible interaction of these
two BMP family members in the growth of this structure.
Wormian Bones
Although there was no preference among single and compound heterozygotes, we
often observed the presence of Wormian bones in our Bmp4-lacZ/+; Gdf6+/- intercross.
Wormian bones are small calvarial bones that develop from additional ossification
centers within the sutures or the fontanelles, most often in the lambdoid or squamosal
sutures.  These miniature cranial bones are formed from ossification centers that form de
novo, separate and at a distance from the ossification centers of the main cranial bones
(Rice, 2008).  In the progeny of our Gdf6+/-; Bmp4-lacZ/+ crosses, these ectopic bones
were often observed in the most anterior portion of the interfrontal suture (Fig 4.4B), the
suture that separates the paired frontal bones (Fig 4.4A).
Wormian bones can be associated with pathologies, such as osteogenesis
imperfecta or hydrocephalus, in which the requirement for cranial growth outpaces the
ability of the bones to grow or in which the sutural space is spread apart (Roybal et al.,
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2010).  There has also been some association with craniosynostosis (Sanchez-Lara et al.,
2007).  In Chapter III, a defect in frontal bone growth was observed in Bmp4-lacZ/+;
Gdf6-/- embryos.  It is possible that if Gdf6 and Bmp4 play a role in the proliferation of
the frontal bone, that even slight delays in growth of the bones may contribute to the
formation of these Wormian bones, even if a frontal bone abnormality is not evident in
the single heterozygous mice.
Failed fusion of the vertebrae along the dorsal midline
During our Bmp4-lacZ/+ by Gdf6+/- crosses, we observed an abnormal vertebrae
phenotype in our Bmp4-lacZ/+ and Bmp4-lacZ/+; Gdf6+/- compound mutants that had
not been previously reported in descriptions of the Bmp4 heterozygote mouse.  As the
vertebrae ossify, two broad plates of the neural arch, referred to as the laminae, direct
backward and medial toward the dorsal midline.  They fuse at the dorsal midline to form
the spinous processes, which serve as attachment sites for muscles and ligaments (Gray
and Lewis, 1918) (Fig 4.5A).  In the Bmp4-lacZ/+ single heterozygotes and the Bmp4-
lacZ/+; Gdf6+/- P21 mice, the laminae of the lower thoracic vertebrae and upper lumbar
vertebrae failed to fused along the dorsal midline and lack spinous processes (Fig 4.5
B,D).  The penetrance and severity of the vertebral defects were not increased in the
Bmp4/Gdf6 compound mutants compared to the Bmp4-lacZ/+ single heterozygotes, and
therefore the phenotype is most likely due to Bmp4 alone.  However, this defect appears
to be only a delay in ossification.  At P180 (6 month) mice, the laminae have fused and
the spinous processes are present (Fig 4.5E).
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Figure 4.5.  Failed fusion of the vertebrae along the dorsal midline. P21 mice presented with failed fusion of the lower thoracic
and upper lumbar vertebrae along the dorsal midline in Bmp4-lacZ/+ single heterozygotes (B) and Bmp4-lacZ/+; Gdf6+/- compound
heterozygotes (D) and lack spinous processes.  These defects were not seen in wild-type (A) or Gdf6+/- (C) and the vertebrae
eventually did fuse during adulthood (E) by P180.  There was no increase in the penetrance between Bmp4-lacZ/+ (B) and Bmp4-
lacZ/+; Gdf6+/- (D) mice.
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Preaxial polydactyly of the hindlimb
The murine hindlimb skeleton is composed of ankle (tarsal) bones, metatarsals,
phalanges, and claws (Fig 4.6A).  Likewise, the joints between these segments are
referred to as the tarsal-metatarsal, metatarsal-phalangeal, and phalangeal joints (Fig
4.6A).  Both Bmp4 (Fig 4.6I, arrows) and Gdf6 (Fig 4.6J, arrows) are expressed in the
anterior limb bud (shown at E11.5).  Bmp4-lacZ/+; Gdf6+/- mice presented with preaxial
polydactyly of the hindlimb (Fig 4.6C-H).  This phenotype had been previously reported
in Bmp4 heterozygotes at a 12% penetrance (Dunn et al., 1997; Katagiri et al., 1998).  In
our crosses, no incidence of polydactyly was observed in wild-type (0/21) or Gdf6+/-
mice (0/33) (Table 4.1).  Polydactyly was present in 9% of the Bmp4-lacZ/+ mice (2/23).
This was increased to 77% in Bmp4/Gdf6 compound mutants (24/31) (Table 4.1).  This
increase in the incidence of polydactyly between the Bmp4-lacz/+ and Bmp4/Gdf6
compound mutants was statistically significant (p=0.0017, Fisher’s exact test).  Since
polydactyly was never observed in Gdf6+/- mice but the penetrance was drastically
increased from the Bmp4-lacZ/+ to Bmp4/Gdf6 compound mutants, this suggests that
these two BMP family members have a cooperative function in the patterning of the limb.
No polydactyly was observed in the forelimb of any genotype.  Although Bmp4 and Gdf6
are also expressed in the limb bud of the forelimb (Fig 4.6I, J, arrows), Gdf6 is expressed
at considerably reduced levels in the forelimb compared to the hindlimb (Fig 4.6J,
arrows) and the Gdf6-/- mouse does not present with polydactyly (not shown), and
therefore, Bmp4 is likely more critical in limb patterning.
The analysis of the polydactyly phenotype is summarized in Table 4.1.  The
duplicated digit was always the first digit, however, there was variation in the site where
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Figure 4.6. Pre-axial polydactyly of the hindlimb in Bmp4/Gdf6 compound mutants.  P21 mice stained with alzarin red/alcian
blue.  Bmp4+/-; Gdf6+/- mice present with pre-axial polydactyly of the hindlimb (C,D).  In some cases the polydactyly occurred
along with a duplicated first tarsal segment (C).  There was also variation in the number of phalangeal segments in the duplicated
digits, including three (E, arrow), two (F, arrow), or a single floating segment (G, arrow).  In rare cases polydactyly was evident as a
thickening of the first tarsal segment and the first metatarsal bone (H), but no extra digit.  Co-expression of Gdf6 and Bmp4 in the
anterior limb bud (arrows) was shown through Gdf6 in situ hybridization (I) and lacZ staining of Bmp4-lacZ embryos (J).
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the duplication joined to the paw.  The unction of the duplicated digit sometimes resided
at the tarsal joints (47%, Fig 4.6E), the metatarsal joints (50%, Fig 4.6F), and rarely the
phalangeal joints (3%, Fig 4.6G).  In cases where the duplication initiated at the tarsal
joint, the first tarsal segment was also duplicated (Fig 4.6C, arrow).
An interesting feature of polydactyly phenotype was that a duplicated digit was more
often present in the right hindlimb than in the left.  In the Bmp4-lacZ/+ with polydactyly,
100% (2/2) had polydactyly in only the right hindlimb.  In the Bmp4-lacZ/+; Gdf6+/-
mice, 17% had unilateral polydactyly in the left limb (4/24), 50% had unilateral
polydactyly of the right hindlimb (12/24), and 33% (8/24) had bilateral polydactyly
(Table 4.1).
Lastly, there was also variation in the number of phalangeal segments present in
the extra digit.  In the Bmp4/Gdf6 compound mutants, 31% had a complete extra digit
with three phalangeal segments (10/32, Fig 4.6E), 59% had two phalangeal segments
(19/32, Fig 4.6F), and 6% had a single “floating” phalangeal segment (2/32, Fig 4.6G).
In one case (1/32), polydactyly was clearly evident by a duplicated tarsal segment, and a
thickening of the first metatarsal bone, but there was no extra digit (Fig 4.6H).
Interaction of Gdf6 and Bmp4 in the dorsal retina
Although the phenotypic analysis of Bmp4/Gdf6 compound mutants was focused
on skeletal phenotypes, a defect in eye development was readily visible in our
Bmp4/Gdf6 compound mutants.  In previous studies Bmp4+/- mice exhibited a threefold
greater frequency of microphthalmia (small eyes) and anophthalmia (no eyes) compared
to wild-type (Dunn et al., 1997).  We did not observe any eye abnormalites in our wild-
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type (Fig 4.7A), Bmp4-lacZ/+ (Fig 4.7B), or Gdf6+/- (Fig 4.7C) embryos.  However,
microphthalmia was occasionally observed in Gdf6-/- (Fig 4.6E) and Bmp4-lacZ/+;
Gdf6+/- embryos (not shown).  Furthermore, the majority of the Bmp4-lacZ/+; Gdf6-/-
embryos had unilateral or bilateral anophthalmia (Fig 4.7F, arrow), resulting in an almost
complete failure of formation of rudimentary eye (Fig 4.7L) compared to the structure of
the wild-type embryonic eye (Fig 4.7I).  Expression of Bmp4 is detected in the dorsal
retina at E10.5 (Fig 4.7G, arrow) and E12.5 (Fig 4.7H) in the Bmp4-lacZ mouse.
Expression of Gdf6 in the dorsal retina is also clearly seen in the Gdf6 Dβgeo reporter
BAC line (Mortlock et al., 2003) at E10.5 (Fig 4.7J) and also through in situ
hybridization at E12.5 (Fig 4.7K) (the section in panel K is taken more dorsally than
panel H and therefore does not include the lens).
While the difference in eye size is visibly noticeable at fetal stages, we considered
whether these defects persist into adulthood?  Eyes from weanling mice were isolated and
the diameter measured with microcalipers.  At P21, there is virtually no difference in the
average eye diameter between wild-type (2.53 mm, n=5), Gdf6+/- (2.50 mm, n=14), and
Bmp4-lacZ/+ (2.47 mm, n=4) mice.  However, there is an approximately 10% reduction
in average eye diameter in the Bmp4-lacZ/+; Gdf6+/- compound mutants (2.29 mm,
n=6).  An ANOVA detected no significant difference between the means of each group
(p=0.087).  However, a pair-wise T-test between each genotype group revealed a
difference between the Gdf6+/- and Bmp4-lacZ/+; Gdf6+/- mice in the average eye
diameter, with a p value= 0.0078, even with our small sample size (total n=29).  The
differences between the wild-type and Gdf6+/- ;Bmp4-lacZ (p=0.07) mice and between
the Bmp4-lacZ/+ and Gdf6+/-; Bmp4-lacZ/+ (p=0.08) mice were trending toward
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Figure 4.7.  Anophthalmia in Bmp4-lacZ/+; Gdf6-/- embryos.  While no defects in eye development were seen in wild-type (A),
Bmp4-lacZ/+ (B), or Gdf6+/- (C) E14.5 embryos, microphthalmia was rarely observed in Bmp4-lacZ/+; Gdf6+/- (not shown) and
Gdf6-/- (F) embryos.  Bmp4-lacZ/+; Gdf6-/- embryos often presented with unilateral or bilateral anophthalmia (F).  Bmp4 and Gdf6
are co-expressed in the dorsal retina.  This is seen in Bmp4-lacZ embryos at E10.5 (G, arrow) and E12.5 (H).  Expression of Gdf6 in
the dorsal retina is seen in a Gdf6 lacZ reporter BAC line at E10.5 (J, arrow) and through in situ hybridization at E12.5 (K) (Panel K
section is taken more dorsally than Panel H, and therefore does not include the lens).  Bmp4-lacZ/+; Gdf6-/- embryos have complete
failure to form the rudimentry eye (L) compared to the structure of the wild-type eye (I).  BMPr1b (M) and BMPr2 (N), receptors
shared by Bmp4 and Gdf6, are also expressed in the dorsal retina.
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significance.  Perhaps with a larger sample size the difference between wild-type,
Bmp4+/-, and Gdf6+/-; Bmp4-lacZ/+ mice would also be statistically significant.  All
progeny were gathered from the same mating pair, so differences produced from their
mixed background (C57Bl/6J and CD1) should be equal among groups.  Since Gdf6-/-
mice do not survive postnatally, the anophthalmia phenotype could not be examined in
Gdf6-/-; Bmp4-lacZ/+ mice at adulthood.
Discussion
In this chapter we present data showing an interaction of Gdf6 and Bmp4 in the
sternum, limb, thyroid cartilage, pelvis, and dorsal retina, demonstrating a cooperative
function between these two related members of the BMP family.  These multiple
phenotypes further demonstrate the range of functional activity of these two BMP family
members, including patterning (limb and dorsal retina), cartilage growth (thyroid
cartilage and pelvis), and joint formation (CS and manubriosternal joint).  In some cases,
the interaction of Bmp4 and Gdf6 appears to fit a simply additive model, where a defect
present in both single heterozygotes is increased in severity in the compound
heterozygotes.  This was the case in the pelvis, with a small gap between the ischium and
the pubis in the single heterozygotes was further exaggerated in the Bmp4/Gdf6
compound mutants.  However, most of the abnormalities we observed were found in one
of the single heterozygotes at a low frequency (manubriosternal joint and polydactyly in
the Bmp4+/- mice and the thyroid cartilage and dorsal retina in the Gdf6+/- mice)
increased in not only severity but also the penetrance.  This suggests that although Bmp4
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or Gdf6 alone may play a more important role in the development of that structure, the
two genes likely also have a cooperative function.
Commonality of multiple phenotypes
Although the multiple phenotypes observed in the Gdf6/Bmp4 compound mutants
appear unrelated, groups of these phenotypes occur together in certain individuals with
birth defects.  Many craniosynostosis syndromes also have clinical features of limb
abnormalities, including syndactyly in the hands and/or feet (Apert and Saethre-Chotzen
syndromes), broad thumbs (Pfeiffer syndrome), and broad toes and bony fusion in the
feet (Jackson-Weiss syndrome) (Wilkie, 1997).  Common molecular pathways are likely
involved in the development of both craniofacial and limb structures.  Bmp7 homozygous
mutants have preaxial polydactyly of the hindlimb but also defects in the sternum, with a
missing fourth sternum ossification center and a failure to fully develop the cranial bones
(Dudley et al., 1995).  Bmp4/Bmp7 compound mutants also have defective ossification of
the sternum, a split xiphoid process, and preaxial polydactyl of the limb (Katagiri et al.,
1998).
Klippel-Feil syndrome (KFS) is characterized by multiple skeletal defects
including conductive hearing impairment, malformed thyroid cartilages, carpals and
tarsal fusions, and eye anomalies (Clarke et al., 1995), which correspond closely with the
abnormal phenotypes observed in the Gdf6 homozygous mutant mouse.  In a large family
with KFS, the mutation was determined to be a paracentric inversion with the proximal
breakpoint located 623 kb downstream of GDF6 (Tassabehji et al., 2008); in a region that
likely includes multiple long-distance regulatory elements for Gdf6 (Mortlock et al.,
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2003).  Klippel-Feil patients also have vertebral fusions not seen in Gdf6-/- mice,
however, Gdf5/Gdf6 compound mutant mice do have scoliosis, suggesting these two
BMPs do play a role in vertebral growth (Settle et al., 2001).  Vertebral defects were also
seen in our Bmp4+/- mice (Fig 4.5B), although this was related to a delay in ossification
rather than fusion between vertebrae, as seen in KFS (Clarke et al., 1998).  Some KFS
patients reportedly have cranial defects, including macrocephaly (large head),
microcephaly (small head), and brachycephaly (round head), which could also be
associated with growth of the cranial bones (Tassabehji et al., 2008).
It is also common for several members of the BMP family to be expressed in a
subset of a larger structure and together work in its development.  This appears to be the
case in the sternum.  We showed that Bmp4/Gdf6 compound mutants have an increased
presence of the manubriosternal joint, the joint the separates the manubrium and the first
sternal segment (Fig 4.1), suggesting that the normal function of Bmp4 and Gdf6 is to
promote ossification within this joint.  Gdf5/Bmp5 compound mutants also present with
one or more missing sternal segments (Storm and Kingsley, 1996) where Bmp4/Bmp7
mice have a sinusoidal sternum and a split xiphoid process (Katagiri et al., 1998).  The
Bmp6 homozygous mutant mice possess a single known skeletal abnormality: a delay in
the growth of the cartilage template and ossification of the bones of the sternum.
However, Bmp5-/-; Bmp6-/- compound mutants present with a entirely new phenotype:
the failure of the two sternal bands to fuse along the midline, leaving a gap in the center
of each sternal segment (Solloway et al., 1998).  Therefore, multiple BMPs have a role in
different regions of the sternum to contribute to the overall patterning and growth of the
structure.
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BMPs in patterning of the limb
While the cranial sutures form with the approach of two separate growing
ossification elements, the joints of the limb form through the splitting of larger cartilage
precursor elements.  This process occurs through the formation of “interzones”:
specialized regions that extend across cartilage elements and mark the future site of the
joint.  This is followed by apoptosis in the middle of the interzone region with
differentiation of the articular cartilage at the edges of the interzone, and is finished with
the formation of a fluid-filled space between the two opposing skeletal elements (Storm
and Kingsley, 1996).
At E11.5, digit condensation can first be seen as individual elements and this is
the stage where improper patterning can lead to the deletion or multiplication of the
digits.  Bmp2, Bmp4, and Bmp7 are all expressed in the apical ectodermal ridge (AER)
where they control cell proliferation and signal to the progress zone, an adjacent region of
proliferating undifferentiated cells (Dunn et al., 1997; Katagiri et al., 1998).  The
reduction or absence of BMP expression can cause the abnormal expansion of the
mesenchymal cell condensations.  It is possible that Gdf6 and/or Bmp4 normally restrict
cell proliferation in the limb mesenchyme, and with the loss of Gdf6/Bmp4 enough
mesenchyme is accumulated to generate an additional digit.  However, this does not
explain why the loss of Gdf6 and Bmp4 affects only the preaxial digit or why the
remaining digits appear morphologically normal.
In general, the preaxial digit is most often affected in BMP mutants with
polydactyly.  Like our Bmp4-lacZ/+; Gdf6+/- compound mutants, Bmp7 homozygous
mutants also present with preaxial polydactyly of the hindlimb, although at a lower
144
penetrance (approximately 25%) (Dudley et al., 1995) compared to the 77% in our
compound mutants.  The authors also described the polydactyly as unilateral and
generally a mirror image duplication of the second digit, or a duplication of the first digit
along with the adjoining tarsal element (Dudley et al., 1995), as we described.
Bmp4/Gli3 compound mutants with polydactyly were lacking the preaxial apoptotic
region while the postaxial region is sustained.  Decreased apoptosis in the limb bud could
allow for prolonged survival of the AER and allow for the secretion of more growth
promoting FGFs (Dunn et al., 1997).
Previous reports describe polydactyly being present only in the right hindlimb of
Bmp4+/- single heterozygotes (Dunn et al., 1997), which confirms our own observations
(Table 4.1).  Like our Bmp4/Gdf6 compound mutant mice, Bmp4/Gli3 and Bmp4/Alx4
compound mutants have bilateral polydactyly with increased penetrance and severity
over the Bmp4+/- single heterozygotes (Dunn et al., 1997).  The nature of the interaction
between Bmp4 and Gli3, Alx4, and likely Gdf6, could be that they are components of the
same pathway and regulate each other’s activity.  Another possibility is that they operate
in parallel pathways or pathways which involve slightly different aspects of limb
patterning.  Due to the early embryonic lethality of Bmp4 homozygous mutant mice due
to failed mesoderm formation (Winnier et al., 1995), the role of Bmp4 in limb formation
must be assessed by other means.  By crossing a Bmp4-floxed allele to the Prx1-cre
driver, investigators have generated a conditional knock-out of Bmp4 in the limb bud
mesoderm.  They found that polydactyly in the Bmp4 mutants was associated with
delayed induction and maturation of the AER, resulting in expanded Shh and prolonged
Fgf8 signaling (Selever et al., 2004).  Prolonged Fgf8 expression in the AER is associated
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Table 4.1.  Analysis of the polydactyly phenotype in Bmp4/Gdf6 compound mutants.
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with increases in the number of phalanges in chick limbs (Sanz-Ezquerro and Tickle,
2003).  In this chapter we described variation in the number of phalangeal segments (Fig
4.6, Table 4.1) in the polydactyly limb of our Bmp4/Gdf6 compound mutants.  BMPs do
influence digit number, but this is mediated by secondary affects through the AER and
Shh (Drossopoulou et al., 2000).  Since this appears to be the underlying mechanism
contributing to polydactyly in the Bmp4+/- mouse, it is highly likely a similar effect
would be seen in Bmp4/Gdf6 compound mutants.
The majority (82%) of Bmp7 mutant mice also present with preaxial polydactyly.
However, in these mutants there were no changes in Shh expression in the limb
mesenchyme, but Hoxd-13 expression in the posterior hindlimb was restricted and
weaker compared to wild-type (Luo et al., 1995).  Both Shh and Hoxd13 could be
analyzed in the Bmp4/Gdf6 compound mutants to determine if the patterning of the limb,
rather than changes in the proliferation of the limb bud mesenchyme, is the underlying
mechanism in polydactyly phenotype.
Left/right asymmetry
Interestingly, the preaxial polydactyly of the hindlimb in the Bmp4-lacZ/+;
Gdf6+/- mice preferentially affected both hindlimbs (33%) or just the right hindlimb
(50%) over the left hindlimb alone (17%).  The same observation has been noted in
studies of the Bmp4/Bmp7 compound heterozygotes, which also have unilateral and
bilateral polydactyly with a preference for preaxial polydactyly of the right hindlimb
(Katagiri et al., 1998).  Furthermore, previous studies have failed to detect left hindlimb
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polydactyly in any Bmp4+/- mice (Katagiri et al., 1998), which was consistent with our
findings.
The idea of a role in left/right asymmetry for BMP signaling was initiated with
the finding that BMP family member Nodal is expressed asymmetrically, with one
domain to the left of the notochord and another in the anterior lateral mesoderm on the
left side of the embryo.  The Nodal expression domain in the lateral mesoderm overlaps
with the expression of Shh, and the misexpression of Shh on the right side of the embryo
leads to the ectopic expression of Nodal (Hogan, 1996).  Bmp4 has also been found to be
required for left right patterning: expression of Bmp4 in on the right side induces Fgf8,
which then represses Shh (Levin et al., 1995; Monsoro-Burq and Le Douarin, 2000).  The
loss of embryonic Bmp4 results in the absence of left-side determinants including Nodal
and Lefty2 in the lateral plate mesoderm (Fujiwara et al., 2002), a population of cells that
contributes to the skeletal portion of the limb (Gilbert, 2003).  Furthermore, Bmpr-1a and
the transcriptional modulator Smad1, which are utilized by both Bmp4 and Gdf6, are also
asymmetrically expressed on the right side (Monsoro-Burq and Le Douarin, 2000).  It is
possible that the preference for polydactyly in the right hindlimb in both Bmp4 single
heterozygotes and Bmp4/Gdf6 compound mutants is related to a disruption in the left-
right patterning established in part by BMP signaling.  However, polydactyly was the
only abnormal phenotype in the Bmp4/Gdf6 compound mutants with a noticeable
preference for the left or right side.
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Beyond the skeleton: BMPs and patterning of the dorsal retina
The occurrence of anophthalmia in the Bmp4-lacZ/+; Gdf6-/- embryos
demonstrates an interaction of these two genes in the development of the eye, particularly
the dorsal retina where Bmp4 and Gdf6 are co-expressed.  Bmp4 and Gdf6 have both
independently play a role in the formation of the eye, although this is the first evidence of
an interaction between the different BMPs within the eye.
Ocular defects attributed to mutations in the BMPs, and Gdf6 in particular, have
been well documented.  After screening patients with ocular defects, including
microphthalmia, anophthalmia, and coloboma, a total of seven heterozygous sequence
changes were identified in the GDF6  sequence, two located in the first exon and five
located in the second exon (Asai-Coakwell et al., 2007).  Bmp4 has also been identified
as an underlying genetic factor in human patients with anophthalmia and microphthalmia
(Bakrania et al., 2008).  The affect of Gdf6 on ocular development has also been studied
in zebrafish.  A genome-wide duplication event during evolution produced multiple gene
paralogs in the zebrafish genome, including two for Gdf6, referred to as radar/gdf6a and
dynamo/gdf6b.  Like Gdf6 in the mouse, radar is also expressed in the dorsal retina (Rissi
et al., 1995) and the knock-down of radar in zebrafish resulted in microphthalmia and
coloboma (Asai-Coakwell et al., 2007).
In mice, the haploinsufficiency of Bmpr1a and Bmpr1b in the retina, the receptors
utilized by both Bmp4 and Gdf6, resulted in abnormal retina dorso-ventral patterning
(Murali et al., 2005).  Bmp4 expression in the dorsal retina is thought to affect retinal
patterning by regulating the expression of transcription factor Tbx5 in the optic cup and
downregulating ventral markers Vax and Pax2 (Koshiba-Takeuchi et al., 2000).  The
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disruption of these molecular signals also results in abnormal projections of the retina
ganglion cell axons.  Due to the co-expression of Gdf6, Bmp4, and BMP receptors 1a and
1b in the dorsal retina early in development, it is likely that Gdf6 and Bmp4 are also
interacting in retinal patterning.
Unique role of Gdf6 in the suture       
Much of the literature published on the Gdf family is related to cartilage growth.
Although Gdf5 is one of the earliest markers for joints, bead implanted into the chick
limb actually stimulates cartilage growth (Storm and Kingsley, 1999).  Due to the high
homology between Gdf5 and Gdf6, these two sub-family members likely have similar
functions.  Several defects in the Bmp4/Gdf6 compound mutants are likely related to lack
of growth and proliferation of the cartilage precursors, including failed union of the
ischium and pubic bones and hypoplasia of the thyroid cartilage.  However, Gdf6 must
have an activity separate from cartilage growth since the cranial bones form through
intramembranous ossification, which occurs without a cartilage intermediate.  This makes
the study of Gdf6 in the CS development particularly interesting.
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CHAPTER V
CORONAL CRANIOSYNOSTOSIS IN THE GDF6 MUTANT MOUSE OCCURS
INDEPENDENTLY OF THE BMP ANTAGONIST NOGGIN
Introduction
Craniosynostosis is defined as the premature fusion of one or more of the cranial
sutures, the fibrous joints separating the flat bones of the cranial vault.  These joints are
the main sites for cranial growth during development, and premature fusion of a suture
eliminates growth perpendicular to the site of craniosynostosis.  In an attempt to
compensate and maintain the volume of the skull vault, growth at the unaffected sutures
increases.  This produces a characteristic dysmorphic skull shape that is dependent on
which sutures have undergone fusion (Slater et al., 2008).
In Chapters II and III we demonstrated a role of both Gdf6 and Bmp4, members of
the BMP family, in the earliest stages of CS development.  By E14.5, fusion of the frontal
and parietal ossification centers in Gdf6-/- and Bmp4-lacZ/+; Gdf6+/- embryos can be
visualized through alizarin red staining.  BMP signaling can be inhibited by several
antagonists, including Cerbarus, Dan, Gremlin, Chordin, and Noggin (Xiao, 2007).
Noggin binds to BMP dimers and inhibits their interaction with Type I and Type II
receptors by blocking the binding epitopes for the receptors (Groppe et al., 2002).
Noggin has been definitively shown to bind with high affinity to Bmp2 and Bmp4 and
with less affinity to Bmp7 (Zimmerman et al., 1996).  In Xenopus, the ability of GDF6 to
induce epidermal genes and inhibit neural markers in animal caps was blocked by Noggin
(Chang and Hemmati-Brivanlou, 1999).  The investigators furthermore demonstrated that
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GDF6 and Noggin directly bind with a high affinity, similar to that of BMP2 (Chang and
Hemmati-Brivanlou, 1999).
The role of Noggin in the sutures has been largely restricted to the study of the
interfrontal suture, the suture homologous to the human metopic suture.  The posterior
interfrontal suture in mice is a common model to study the events which contribute to
fusion of a suture, since it is the only suture in mice which undergoes predictable fusion
during postnatal development (Opperman, 2000).  Previous studies demonstrated that
Noggin is expressed postnatally in patent (the sagittal and coronal) sutures but not fusing
sutures (the posterior interfrontal).  Bmp4 is expressed in the suture mesenchyme and
bone fronts of both patent and fusing posterior interfrontal sutures.  Although Noggin is
an antagonist for BMPs, BMPs were able to actually stimulate Noggin expression in
calvarial explants (Rice et al., 2005).  The suppression of Noggin in the presence of Bmp4
stimulation is achieved through FGF2, which is only expressed in the posterior
interfrontal suture.  The over-expression of FGF2 and the gain of function mutations in
FGFR2 that have been associated with Apert’s and Crouzon craniosynostosis syndromes
both inhibited Noggin expression and blocked Bmp4-mediated stimulation of Noggin
(Warren et al., 2003a).
The Noggin homozygous mutant is lethal and the severity of the Noggin
homozygous mutant phenotype was dependent on the genetic background (Tylzanowski
et al., 2006).  The homozygous loss of Noggin is lethal at birth in the DBA/1 and CDA
strains (McMahon et al., 1998; Tylzanowski et al., 2006) or prior to day E14.5 in the
C57Bl/6J (Tylzanowski et al., 2006).  The homozygous mutants that survived to birth
present with failed neural tube closure, broad limbs, loss of vertebrae, and shortened body
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(McMahon et al., 1998).  No abnormal suture phenotype has been reported in the Noggin
homozygous mutants; however, this could have been impossible to examine due to the
presence of exencephaly in a large portion of the Noggin-/- embryos, precluding analysis
of intact calvarial joints.  Furthermore, the expression and activity of Noggin in the suture
during the earliest stages of suture development has been unreported.  We identified
expression of Noggin in the periosteum of the frontal and parietal bones at E14.5 (Fig
5.3), which corresponds to the timepoint when fusion of the ossification centers is first
visible in the Gdf6-/- embryo.
BMPs are secreted signaling proteins, and with both Gdf6 and Bmp4 being
expressed in the frontal bone primordia it is possible that these two family members may
interact with Noggin.  The mechanism leading to suture fusion in the Gdf6-/- embryo and
Bmp4-lacZ/+;Gdf6+/- compound mutants could be directly related to Noggin’s role in
maintaining the patency of the suture mesenchyme.  In the wild-type suture, Gdf6 and
Bmp4 may stimulate Noggin expression through paracrine signaling from the frontal bone
primordia, and in turn, Noggin maintains the suture mesenchyme in undifferentiated state
by inhibiting the osteogenic affects of BMP signaling.
In the present chapter, we investigate the role of Noggin in early suture
development, and the possible interaction with Gdf6, by examining the phenotype of
Gdf6 and Noggin compound mutants.  In performing these crosses we tested three
hypotheses to explain a possible Gdf6/Noggin interaction: 1) Along with Gdf6, Noggin
plays an inhibitory role to maintain the suture mesenchyme in an undifferentiated state;
2) Gdf6 and other BMPs stimulate Noggin expression in the suture and therefore
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indirectly maintain the suture through Noggin; or 3) Noggin does not play a role in early
embryonic suture development.
Despite the hypothesized important role of Noggin in the maintenance of suture
patency discussed in the literature, we found no evidence of an early role of Noggin in the
development of the CS.  Noggin-lacZ/lacZ embryos without exencephaly phenotype form
the cranial sutures, including the CS.  Furthermore, no abnormal suture phenotype was
observed in the Gdf6+/-; Noggin-lacZ/+ mice and no rescue of CS fusion was observed
in Gdf6-/-; Noggin-lacZ/+ embryos other than a possible slight delay (still within the
same embryonic day) in the fusion of the ossification centers.  This upheld our third
hypothesis that Noggin does not play a critical role in embryonic suture development.
Therefore, the role of Gdf6, and likely that also of Bmp4, in the ectopic differentiation of
the suture mesenchyme occurs independently of Noggin’s role in suture patency.
Materials and Methods
Mouse crosses
A mutation in the Noggin locus was generated by replacing the coding sequence
with a lacZ reporter (Brunet et al., 1998).  Noggin-lacZ mice were maintained on a CD1
outbred background.  Embryonic age was determined through detection of the vaginal
plug, with noon of that day observed as E0.5.   To analyze Noggin-lacZ/lacZ
homozygous mutants, Gdf6+/-; Noggin-lacZ/+ compound mutants were crossed.  For
analysis of CS phenotype, Gdf6+/- mice were crossed to Noggin-lacZ/+ mice to generate
wild-type, Gdf6+/- and Noggin-lacZ/+ heterozygotes, and Gdf6+/-; Noggin-lacZ/+
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compound mutants.  For analysis of suture phenotype at embryonic stages and for
analysis of Noggin expression in the suture, Gdf6+/- mice were crossed to Gdf6+/-;
Noggin-lacZ/+ mice to produce wild-type, Gdf6+/- and Noggin-lacZ/+ heterozygotes,
Gdf6+/-; Noggin-lacZ/+ compound mutants, Gdf6-/-, and Gdf6-/-; Noggin-lacZ/+
embryos with 3 missing alleles.  Mouse genotypes and crosses are summarized in Table
5.1.  Genotypes highlighted in the gray boxes were crossed to produce the next
generation. G1 and G2 were analyzed by alizarin red staining for suture phenotypes, and
G1 was additional analyzed for other skeletal phenotypes.  Genotypes highlighted in the
yellow boxes in G2 were analyzed for changes in Noggin-lacZ expression among
Gdf6+/+ (wild-type for Gdf6), Gdf6+/-, and Gdf6-/- embryos (Table 5.1)
Genotyping
Samples were genotyped for Noggin to generate a 211 base-pair wild-type allele
from primers Nog1 and Nog2 and a 160 base-pair mutant allele from primers Nog1 and
Gal1.  Primers: Nog1 5’-GCATGGAGCGCTGCCCCAGC-3’, Nog2 5’-
GAGCAGCGAGCGCAGCAGCG-3’, Gal1 5’-AAGGGCGATCGGTGCGGGCC-3’.
The PCR program included heating the samples to 93oC for 90 seconds then 35 cycles of
alternating between 93oC for 30 seconds (denaturation) and 72oC for 45 seconds
(extension) (protocol from (McMahon et al., 1998)).  Embryos could alternatively be
genotyped for Noggin-lacZ by removing a limb from the embryo and staining for lacZ.
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Table 5.1 Summary of Gdf6/Noggin mouse crosses and genotypes.  Genotypes
highlighted in the gray boxes were crossed to produce the next generation.  G1 and G2
were analyzed by alizarin red staining for suture phenotypes, and G1 was additional
analyzed for other skeletal phenotypes.  Genotypes highlighted in the yellow boxes in G2
were analyzed for changes in Noggin-lacZ expression among Gdf6+/+ (wild-type for
Gdf6), Gdf6+/-, and Gdf6-/- embryos.
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Additional methods
Information of the following methods were discussed in previous chapters: whole-
mount alizarin staining of skeletal preparations (Chapter III), DNA preparations (Chapter
II), histology (Chapter II), lacZ staining (Chapter III), and 3-aminopropylsilane treatment
of slides (Chapter II).
Results
Haploinsufficiency of Gdf6 and Noggin does not produce coronal craniosynostosis
Three alternative results were hypothesized for the interaction of Gdf6 and
Noggin in suture development.  The first was that, like Gdf6, Noggin plays an inhibitory
role to maintain the CS in an undifferentiated state.  To test this hypothesis, we crossed
Gdf6+/- and Noggin-lacZ/+ heterozygotes to produce compound heterozygotes, which
would theoretically remove two inhibitory factors and result in differentiation of the
suture mesenchyme and premature suture fusion.
The established genotyping strategy for the Gdf6 line consists of a duplex PCR,
with one primer pair detecting the wild-type allele and a second detecting the neo cassette
inserted into the mature signaling region of the targeted locus.  However, the Noggin-
lacZ line also contains a neo cassette.  This made it impossible to distinguish Noggin-
lacZ/+ single heterozygotes and Gdf6+/-; Noggin-lacZ/+ compound mutant animals
using the conventional Gdf6 PCR protocol.  Attempts were made to generate allele-
specific primers for the Gdf6 locus, spanning the border between the wild-type sequence
and the neo cassette.  However, the Gdf6 locus is extremely GC rich and the precise
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boundary of the targeted allele was never well defined or previously described, making
attempts for primer design unsuccessful.  Fortunately, by looking at the phenotype and
Mendelian ratios, conclusions could still be drawn from the collected data.
Mice from a Gdf6+/- by Noggin+/- cross were collected at P21 and stained with
alizarin red.  A total of 25 animals were analyzed (Table 5.2).  None of the wild-type
(0/7) (Fig 5.1F) or Gdf6+/- (0/5) (Fig 5.1G) mice presented with coronal
craniosynostosis.  Due to the genotyping issues discussed above, a total of 13 animals
were determined to be either Noggin-lacZ/+ single heterozygotes or Gdf6+/-; Noggin-
lacZ/+ compound mutants, and none of them presented with any suture defects (Fig
5.1H).  On the basis of Mendelian ratios, at least half of the 13 animals were likely to be
compound heterozygotes, and therefore we concluded that compound mutants for Gdf6
and Noggin did not produce suture fusion.  In this group of mice that were either Noggin-
lacZ/+ single heterozygotes or Gdf6+/-; Noggin-lacZ/+ compound mutants, a portion
had fusions in the wrist and ankle (Fig 5.5) that had not been previously reported in Gdf6
or Noggin heterozygotes, and therefore, we were confident that a portion of these mice
were in fact Gdf6/Noggin compound mutants.
Haploinsufficiency of Noggin does not rescue suture fusion in the Gdf6-/- embryo
Our second hypothesis states that Gdf6 and other BMPs stimulate Noggin
expression in the suture and therefore indirectly maintain the suture through Noggin.  To
test this genetically, we produced Gdf6-/-; Noggin-lacZ/+ embryos.  Although a
homozygous mutant allele for Gdf6 would normally result in erroneous differentiation of
the suture mesenchyme, we hypothesized that the haploinsufficiency of Noggin would
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Figure 5.1. Analysis of suture fusion in Gdf6/Noggin compound mutants.  At E18.5, wild-type (A), Gdf6+/- (B), Noggin-lacZ/+,
and Gdf6+/-; Noggin-lacZ/+ (C ) all have normal coronal sutures.  Gdf6-/-; Noggin-lacZ/+ embryos had fusion of specifically the
coronal suture (D), showing the reduction of Noggin dosage was unable to rescue suture fusion in the Gdf6-/- embryo.  Where the
Gdf6-/- embryo has a continuous surface between the frontal and parietal bones (E), the possible remnants of a suture appear in the
Gdf6-/-; Noggin-lacZ/+ embryo (D, yellow arrow).  At P21, no suture phenotype was observed in wild-type (F), Gdf6+/- (G), Noggin-
lacZ/+, and Gdf6+/-; Noggin-lacZ/+ (H) embryos.  I) Location of the coronal suture, frontal, and parietal bones in the P21 mouse.
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Table 5.2.  Analysis of suture fusion in Gdf6/Noggin compound mutants.
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reduce the inhibition of BMP signaling.  This would allow for an increase in signaling by
other members of the BMP family to compensate for the loss of Gdf6, thereby
maintaining the undifferentiated suture mesenchyme and rescuing suture fusion in the
Gdf6-/- embryo.
To test this second hypothesis, Gdf6+/- and Gdf6+/-; Noggin-lacZ/+ mice were
crossed.  This cross generated wild-type, Gdf6+- and Noggin-lacZ/+ heterozygotes,
Gdf6+/-; Noggin-lacZ/+ compound mutants, Gdf6-/-, and Gdf6-/-; Noggin-lacZ/+
embryos within the same litter.  Due to the fact that Gdf6-/- mice die at the perinatal
stage, embryos were collected at E18.5 and stained with alizarin red and alcian blue.
Despite our genotyping challenges we did have the advantage in this cross of being able
to distinguish Gdf6-/-; Noggin-lacZ/+ embryos from Noggin-lacZ/+ and Gdf6+/-;
Noggin-lacZ/+ embryos, since they completely lack the Gdf6 wild-type allele targeted by
the PCR genotyping primers.  In this cross, the wild-type, Noggin-lacZ/+, and Gdf6+/-;
Noggin-lacZ/+ embryos all had normal CSs (Fig 5.1A-C, arrows).  However, the Gdf6-/-;
Noggin-lacZ/+ embryos did have fusion of specifically the CS (Fig 5.1D), showing the
reduction of Noggin dosage was unable to rescue suture fusion in the Gdf6-/- embryo.
Yet where the Gdf6-/- embryo has a continuous surface between the frontal and parietal
bones (Fig 5.1E), the possible remnants of a suture appear in the Gdf6-/-; Noggin-lacZ/+
embryo (Fig 5.1D, yellow arrow), as described in the Bmp4-lacZ/+; Gdf6+/- embryos.
This suggests that although the suture still fuses in the Gdf6-/-; Noggin-lacZ/+ embryo,
the loss of Noggin may also delay the fusion event.  If this were the case, the suture
would initially form, unlike the Gdf6-/- embryo, but fuse sometimes prior to E18.5.
161
Slight delay in coronal suture fusion in the Gdf6-/-; Noggin-lacZ/+ embryos
In order to determine if the suture remnants in the Gdf6-/-; Noggin-lacZ/+
embryos were indicative of delayed suture fusion, Gdf6+/- and Gdf6+/-; Noggin-lacZ/+
mice were crossed and embryos were collected at various timepoints in development.  As
discussed in Chapters II and III, the frontal and parietal bones in the Gdf6-/-embryo are
fused at E14.5, at the first appearance of the ossification centers for the frontal and
parietal bones (Fig 2.2 E-H), where complete fusion in the Bmp4-lacZ/+; Gdf6+/-
compound mutant can be delayed for several days but ultimately results in a completely
fused suture (Fig 3.2, 3.3).
At the E14.5 timepoint, wild-type, Gdf6+/- and Noggin-lacZ/+ single
heterozygotes, and Gdf6+/-; Noggin-lacZ/+ compound mutants have normal CSs (Fig
5.2A-C).  Although the Gdf6-/-; Noggin-lacZ/+ embryo showed signs of fusion even at
this earliest timepoint (Fig 5.2D), the fusion did not appear as complete as in the Gdf6-/-
embryo (Fig 5.2E).  Where the Gdf6-/- frontal and parietal bones appeared as a single
continuous bone, the Gdf6-/-; Noggin-lacZ/+ embryo, bones could still be distinguished,
with a small bridge of ossified bone between the two (Fig 5.2D, yellow arrow).  This
suggests that fusion in the Gdf6-/-; Noggin-lacZ/+ embryos may be delayed, albeit very
slightly (still within the E14 day), compared to the Gdf6-/- embryo.  Although fusion was
complete by E15.5, a ridge (Fig 5.2I, yellow arrow) was observed between the fused
frontal and parietal bones that is not present in the smooth single fused bone in the Gdf6-
/- embryo (Fig 5.2J) as a sign of a previously existing suture.  No unilateral fusion, like
that found in the Bmp4-lacZ/+; Gdf6+- embryos, was observed in the Gdf6-/-; Noggin-
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Figure 5.2.  Timing of coronal suture fusion in Gdf6/Noggin compound mutants.  At E14.5, wild-type (A), Gdf6+/- (B) and
Noggin-lacZ/+ and Gdf6+/-; Noggin-lacZ/+ embryos (C) have normal coronal sutures.  The Gdf6-/-; Noggin-lacZ/+ embryo showed
signs of fusion even at this earliest time-point (D, yellow arrow), but the fusion did not appear as complete as in the Gdf6-/- (E),
suggesting that fusion in the Gdf6-/-; Noggin-lacZ/+ embryos may be delayed, albeit very slightly (still within the E14 day), compared
to the Gdf6-/-.  Fusion was complete by E15.5 (I), a ridge was observed between the fused frontal and parietal bones (I, yellow arrow)
as a sign of a previously existing suture.
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lacZ/+ embryos after E14.5, despite having the same mixed background (C57BL/6J and
CD1) as the Bmp4-lacZ/+ by Gdf6+/- crosses.
Noggin expression is maintained in the E14.5 suture
Although Noggin does not appear to play an important role in prenatal suture
development, it is possible that there were more subtle changes in Noggin expression at
the suture level that could contribute to the Gdf6 craniosynostosis phenotype.  Changes
such as alterations in the levels or localization of Noggin expression may not be red
staining, by utilizing the Noggin-lacZ line.  In Gdf6 wild-type embryos, Noggin-lacZ was
expressed in the periosteal layer surrounding the frontal and parietal bones (Fig 5.3A), in
addition to a cartilage element that underlies the suture (Fig 5.3A, B, asterix).  Noggin
appeared to be expressed at low levels within the suture mesenchyme, if at all (Fig 5.3A,
arrow).  Noggin is similarly expressed in the periosteum of the Gdf6+/- embryonic suture
(Fig 5.3B).  In the Gdf6-/- suture, the frontal and parietal bones are fused into a single
bone, and likewise, Noggin is expressed continually in the periosteum across the fused
portion where the suture should reside (Fig 5.3C, arrow).  Other than the morphological
changes cause by failed suture formation, there seems to be no difference in Noggin
expression that correlates with the loss of Gdf6.
Noggin does not play a critical role in early suture formation
Although previous studies have reported the embryonic lethality of Noggin
homozygous mutants occurs by E14.5, our Gdf6 and Noggin crosses produced a mixed
genetic background (C57BL/6J and CD1) allowing the Noggin homozygous mutants to
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Figure 5.3.  Noggin expression in the E14.5 Gdf6 suture.  In Gdf6+/+ embryos, Noggin-lacZ was expressed in the periosteal layer
surrounding the frontal and parietal bones (A), in addition to a cartilage element that underlies the suture (A, B asterix).  Noggin
appeared to be expressed at low levels within the suture mesenchyme, if at all (A, arrow).  Noggin is similarly expressed in the
periosteum of the Gdf6+/- embryonic suture (B).  In the Gdf6-/- suture, the frontal and parietal bones are fused into a single bone, and
likewise, Noggin is expressed continually in the periosteum across the fused portion where the suture should reside (C, arrow).  Fb,
frontal bone; pb, parietal bone.
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survive at least to E18.5.  Although the CD1 strain is outbred, previously published
works have described the Noggin homozygous mutant phenotype as highly stable on this
background (Tylzanowski et al., 2006).
We observed similar phenotypes in our Noggin homozygous mutant embryos at
E18.5 as has been previously reported (Brunet et al., 1998).  The Noggin homozygous
mutants had gross axial skeletal deformities, particularly in the vertebrae, ribs, sternae,
and limbs, which were short and broad with multiple joint fusions (Fig 5.4B) compared to
wild-type (Fig 5.4A).  Although still deformed, the cranial vault appeared less
significantly affected than the axial skeleton, although a large portion of the Noggin-
lacZ/lacZ embryos presented with exencephaly and therefore no cranial bones or suture
could be observed (Fig 5.4E).  However, several Noggin-lacZ/lacZ embryos did have
intact cranial bones.  Although the bones appeared to have delayed ossification (Fig
5.4D) compared to wild-type littermates (Fig 5.4C), the cranial sutures, including the CS
(Fig 5.4D, arrow) were present and readily visible.  Therefore, although Noggin may play
a critical role in the maintenance of a patent suture during adulthood, it does not appear to
be required for the prenatal suture formation or maintenance.
Fusions in the carpal and tarsal bones of Gdf6/Noggin compound mutants
The cranial sutures are not the only anatomical location where a genetic
interaction of Gdf6 and Noggin could occur.  To test to see if there were interactions
between Gdf6 and Noggin in non-cranial skeletal elements, P21 mice from the Gdf6+/-
and Noggin-lacZ/+ cross were examined for abnormal skeletal phenotypes.  Again, the
genotyping problems caused by a neo cassette in both the Gdf6 mutant and Noggin-lacZ
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Figure 5.4.  Skeletal phenotype of the Noggin homozygous mutant embryo.  The
Noggin homozygous mutant embryos had gross axial skeletal deformities, particularly in
the vertebrae, ribs, sternae, and limbs, which were short and broad with multiple joint
fusions (B) compared to wild-type (A).  A large portion of the Noggin-lacZ/lacZ embryos
presented with exencephaly and therefore no cranial bones or suture could be observed
(E).  Several Noggin-lacZ/lacZ embryos did have intact cranial bones with cranial
sutures, including the coronal suture (D, arrow).
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alleles prevented Noggin-lacZ/+ and Gdf6+-; Noggin-lacZ/+ mice from being
distinguished.  But through analysis of Mendelian ratios and previous published
information on the Noggin phenotype, conclusions could still be drawn from the collected
data.
When crossing Gdf6+/- and Noggin+/- mice to produce compound heterozygotes,
limb abnormalities became evident or were exacerbated, including fusions in the carpal
and tarsal bones of the wrist and ankle, a site where Gdf6 has been previously shown to
be expressed in developing joints (Settle et al., 2003).  The wild-type wrist is composed
of multiple articulating bones, including the metacarpals I-V, the 1, 2, 3, and 4/5 distal
carpals, the central carpal bone (Fig 5.5A), the radiale and ulnare bones, and the radius
and ulna.  Out of a total of 31 animals analyzed from a Gdf6+/- and Noggin+/- cross,
none of the wild-type animals presented with any wrist phenotype (9/9) (Fig 5.5A, Table
5.3).  In the Gdf6+/- animals, 5/6 had fusion of the second and central carpals in at least
one of the forelimbs (Fig 5.5B, Table 5.3) while 1/6 had an additional fusion of the
second, third, and central carpals (Fig 5.5C, Table 5.3).  In the animals that were
genotyped to be either Noggin-lacZ/+ heterozygotes or Gdf6+/-; Noggin-lacZ/+
compound mutants, we observed unilateral or bilateral fusion of the second and central
carpals in 9/16 animals (Fig 5.5B, Table 5.3) or unilateral or bilateral fusion of the
second, third, and central carpals in 7/16 animals (Fig 5.5C, Table 5.3).
In the wild-type hindlimb, the bones of the ankle are composed of the metatarsals
I-V, the distal tarsal bones 1-3 and 4/5, the central tarsal (Fig 5.5D), talus, and the
calcaneous bones.  When Gdf6+/- and Noggin+/- mice were crossed, a total of 33
animals were analyzed and ankle fusions were categorized by genotype and phenotypes
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Figure 5.5. Carpal and tarsal fusions present in Gdf6 and Noggin single and compound heterozygotes. A) Normal arrangement
of carpals bones seen in wild-type mice, including the second. third, and central carpals.  B) Fusion of the second and central carpals.
C) Fusion of the second, third, and central carpals.  D-E) Normal arrangement of the tarsal bones seen in wild-type (D) and Gdf6+/-
(E) mice. F) Fusion of the second, third, and central tarsals.  G) Fusion of the second, third, fourth/fifth, and central tarsals, with the
persistence of a small joint between the third and fourth/fifth tarsal segments (arrow).  c, central carpal; C, central tarsal.
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Table 5.3.  Analysis of carpal fusions in Gdf6 and Noggin single and compound
heterozygotes.
Table 5.4.  Analysis of tarsal fusions in Gdf6 and Noggin single and compound
heterozygotes.
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(Table 5.4).  No ankle fusions (Fig 5.5D) were observed in the wild-type animals (11/11,
Table 5.4).  Most Gdf6+/- mice formed normal joints (Fig 5.5E), although fusion of the
second, third, and central tarsals (Fig 5.5F) was rarely observed (1/6, Table 5.4).  In the
animals determined to be either Noggin+/- or Gdf6+/-; Noggin-lacZ/+ mice, fusions of
the second, third, and central tarsals were observed (Fig 5.5F) (6/16, Table 5.4) along
with fusions of the second, third, fourth/fifth, and central tarsals (2345c) (Fig 5.5G) (8/16,
Table 5.4) and combinations of the two fusions in the limbs of the same animal (1/16,
Table 5.4).  For animals in which the 2345c tarsal segments were fused, the entire central
region of the ankle was a single block of bone, with only a small remnant of a joint
remaining between the 3 and the 4/5 tarsal segments (Fig 5.5G, arrow).
Discussion
In this chapter, we report that Noggin does not play a critical role in the formation
of the CS, due to the fact that Noggin homozygous mutant embryos do form cranial
sutures, including the CS (Fig 5.4).  In addressing our first and second hypotheses, the
haploinsufficiency of Noggin, in addition to Gdf6, failed to alter suture phenotypes
substantially in Gdf6/Noggin compound mutants and also failed to rescue coronal
craniosynostosis in the Gdf6-/- embryo.  This suggests that the mechanism leading to
suture fusion in the Gdf6 homozygous mutant occurs independently of Noggin activity in
the suture.
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Noggin is not required for embryonic suture development
There are several reasons that could explain this seemingly insignificant role of
Noggin in early suture development.  One could be the lack of expression of Noggin in
the suture region during early suture development.  Although Noggin expression was
found in postnatal coronal and sagittal sutures (Warren et al., 2003a), no Noggin
expression is detectable in the suture region of Noggin-lacZ embryos at the time when
Gdf6 and Bmp4 are initially expressed in the frontal bone primordia at E10.5 (McMahon
et al., 1998; Patel et al., 2006), but instead appears to be mostly restricted to the neural
tube and caudal notochord (McMahon et al., 1998).  According to lacZ expression in the
Noggin-lacZ knock-in line at E14.5, when fusion of the ossification centers is visible in
the Gdf6-/- embryo and beginning in the Bmp4-lacZ/+; Gdf6+/- embryo, Noggin appears
to have little to no expression in the suture mesenchyme, but instead is expressed in the
periosteum of the frontal and parietal bones (Fig 5.3).  In the periosteum, Noggin could
be regulating the growth of the frontal and parietal bones while not having a large role in
maintaining suture patency at early developmental timepoints.  In fact, multiple BMPs
(Gdf6, Bmp4) and BMP effectors (Msx2, Alx4, FoxC1) are expressed in the frontal bone
and/or are known to be associated with growth of the frontal bone (Maxson and Ishii,
2008), and therefore regulation of these BMPs by Noggin would not be unexpected.  The
postnatal expression of Gdf6 in the suture region is not known, but Bmp4 expression in
the frontal bones is primarily embryonic and is downregulated after birth (Kim et al.,
1998a).
Another possibility is that BMPs stimulate frontal bone growth but inhibit
osteogenic differentiation in the suture.  In Chapter II, we showed that reduced Gdf6
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resulted in increased differentiation (Fig 2.5), and the same in Chapter III, with the
reduction of both Gdf6 and Bmp4 leading to suture mesenchyme differentiation (Fig 3.4).
However, the additive reduction of Gdf6 and Bmp4 in the Bmp4-lacZ/+; Gdf6-/- embryo
does result in delayed ossification of the frontal bones (Fig 3.3).  The effect of BMP
signaling on the development of the cranial sutures might depend on the identity of the
suture and the developmental stage.  During embryonic development, reduced BMP
signaling may promote synostosis while in postnatal stages reduced BMP signaling
promotes an open and patent suture (Maxson and Ishii, 2008), and therefore postnatal
loss or haploinsufficiency of Noggin during embryonic development may not have a
phenotypic effect on the suture at that stage.  Indeed, in most of the studies in which
application of Noggin protein prevented suture fusion, the protein was applied ectopically
and at postnatal stages (Shen et al., 2009b; Warren et al., 2003a).   Interestingly,
application of Noggin protein was able to prevent post-operative refusion of the CS in a
rabbit craniosynostosis model (Cooper et al., 2007), but was unable to prevent the initial
craniosynostosis event (Cray et al., 2011).  This data together suggests that Noggin may
not play a large role in the craniosynostosis phenotype, but a large role in bone wound
healing, and the events that occur in the posterior interfrontal suture may not be
indicative of all synostosis events.
Interaction of Gdf6 and Noggin in carpal and tarsal joint formation
Since Noggin is an antagonist of BMP signaling, the loss of Noggin should result
in a global increase in BMP signaling.  Indeed there are widespread skeletal defects in the
Noggin homozygous mutant with the severity increasing caudally (Fig 5.4).  The limbs
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are short but broadened with fusions of the elbows and digit joints.  The loss of joints in
the Noggin-/- embryo correlates with failed upregulation of Gdf5 in early joint
development, suggesting a failure of joint specification, not a secondary fusion event
(Brunet et al., 1998).  The Gdf6 homozygous mutant mouse also has multiple joint
associated defects, including fusions in the carpal and tarsal joints (Settle et al., 2001).
These joints generally form large precursors that subdivide into individual skeletal
elements, but in the Gdf6-/- mouse the precursors fail to divide at sites of fusion.  Gdf5
specifies only a subset of the joints affected in the Noggin homozygous mutants, and
therefore other genes are likely involved, such as fellow family member Gdf6.  We were
confident that a number of defects would  be apparent in Gdf6/Noggin compound
mutants, particularly in the limb.
Despite the severe skeletal defects present in the Noggin homozygous mutant
embryo, the Noggin heterozygous mutant presents with more subtle phenotypes.
Previous reports have described carpal and tarsal fusions in 100% of the animals
examined, on three different background strains (CD1, Dba/1, and C57BL/6J)
(Tylzanowski et al., 2006).  These included fusions of the second, third, and central
carpals (23c) or fusions of the third and central carpals (3c) (Tylzanowski et al., 2006).
Previous work demonstrated that the Gdf6 homozygous mutant mouse also presents with
23c carpal fusions (Settle et al., 2003), with no fusions present in the Gdf6+/- mice.  We
found slightly different results in our cross, with 5/6 Gdf6+/- mice having fusions of the
second and central carpals (2c).  These differences are likely attributed to differences in
background.  In the initial description of the Gdf6 mutant phenotype, the mice were on a
mixed 129/SvJ and C57BL/6J background (Settle et al., 2003), where the mice we
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analyzed had been backcrossed onto a C57BL/6J line for more than 10 generations and
then crossed to the Noggin-lacZ line, which is on the outbred CD1 background.  It is
possible that some protective alleles found in the 129/SvJ background were eliminated in
our crosses.
Although we could not tell the difference between Noggin-lacZ/+ and Gdf6+/-;
Noggin-lacZ/+ mice, Mendelian ratios would suggest that the 2c fusions were the
Noggin-lacZ/+ single heterozygotes (9/31), and the more severe 23c fusions were the
Gdf6+/-; Noggin-lacZ/+ compound mutants (7/31).  While the haploinsufficiency of
Noggin produced the similar 23c carpal fusion as the Gdf6-/- mouse (Settle et al., 2003),
the ankle fusions were distinct.  The Gdf6-/- mouse presents with fusion of the second
and third tarsals (23) and fusion of the central tarsal and the talus (Settle et al., 2003).
Previously reported work has described 23c tarsal fusion in the Noggin heterozygote
(Tylzanowski et al., 2006).  Although our study cannot distinguish between the Noggin-
lacZ/+ single heterozygotes and the Gdf6+/-; Noggin-lacZ/+ compound mutants, the
incidence of 23c tarsal fusion phenotype in our sample (6/16) is close to Mendelian ratios
and likely present in only the Noggin heterozygotes (Table 5.4).  The most extensive
fusion of the second, third, fourth/fifth and central tarsals (2345c) is likely present in the
Gdf6+/-; Noggin-lacZ/+ compound mutants.  The 2345c fusion in the compound mutants
differs from the Gdf6-/- phenotype in that it includes the 4/5 tarsal segment, but excludes
fusion with the talus.  As mentioned above, the loss of the carpals and tarsal joints in the
Noggin heterozygote has been attributed to the loss of Gdf5 in the presumptive joints
(Brunet et al., 1998; Tylzanowski et al., 2006).  In fact, the Gdf6+/-; Noggin-lacZ
phenotype more closely resembles the phenotype seen in the Gdf5-/- mouse, with failed
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joint formation in the distal tarsals, producing a single large block of bone in the ankle
(Settle et al., 2001).
In mice with 2/3/C/4/5 ankle fusion, predicted Gdf6/Noggin compound mutants,
we observed a “T-shaped” joint remaining at the border between the third and fourth/fifth
tarsal bones (Fig 5.5G, arrow).  Interestingly, previous work also described a similar joint
remaining in the fusion of the second, third, and central carpals at a site of known Gdf5
expression (Tylzanowski et al., 2006).  The authors attribute this to the persistence of a
Gdf5 expression.  However, this joint is also a site of Gdf6 expression, and therefore, it is
equally likely that additive expression of Gdf5 with Gdf6 is able to compensate for one
another.  We also observed a similar “T-shaped” joint in the Gdf6+/-; Noggin-lacZ/+
compound mutants between the third and fourth/fifth tarsals, where Gdf6 and Gdf5 are
expressed at low levels, if at all (Settle et al., 2003).  It is likely that with the complex
expression of BMPs in the developing limb, there is some redundancy and compensation
that allows specific joints or parts of joints to form.
Gdf6 and Noggin likely interact in the formation of the middle ear bones
Due to the profound role of BMPs in bone and joint formation, it is surprising that
so few skeletal phenotypes were found in the Noggin-lacZ/+ single heterozygote and our
Gdf6+/-; Noggin-lacZ/+ compound mutants.  In our Bmp4-lacZ/+ and Gdf6+/- crosses in
Chapter IV, no fusions were observed in bones of the limbs (not shown).  The Gdf6-/-
mouse additionally has defects in the bones of the middle ear, the malleus, incus, and
stapes, with changes in the shape of the articular surfaces and increased distances
between the bones.  This was thought to be caused by reduced cartilage growth and
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proliferation at the articular surfaces (Settle et al., 2001).  Klippel-Feil syndrome, a
genetic disorder mapped to a paracentric inversion downstream of GDF6, is often
characterized by conductive hearing loss (Tassabehji et al., 2008).  Although Noggin does
not appear to play a large role in prenatal suture development, Noggin haploinsufficiency
has been reported to produce multiple abnormalities in humans, including
symphalangism, multiple synostosis syndrome, and tarsal and carpal coalition syndrome
(Tylzanowski et al., 2006).  Several of these conditions are associated with missense
mutations in Noggin, and like the Noggin heterozygous mice, are characterized by carpal
and tarsal bone fusions, in addition to conductive hearing loss (Gong et al., 1999).  On
some genetic backgrounds, the Noggin heterozygote mouse had conductive hearing loss,
caused by excess bone formation in the stapes (Hwang and Wu, 2008).  This was
attributed to chondrocyte hyperplasia from unregulated BMP signaling.  We saw no
evidence of a stapes malformation in our Noggin-lacZ/+ single heterozygotes or Gdf6+/-;
Noggin-lacZ/+ mice (not shown), however our crosses were performed on a mixed
C57BL/6J and CD1 background.  Noggin+/- mice with conductive hearing loss were
reported on a congenic C57BL/6J background but this phenotype was not reported when
on a mixed C57BL/6J;FVB background (Hwang and Wu, 2008).  In addition to Gdf6,
Bmp4, Bmp2, and Bmp7 are also expressed in the mesenchyme surrounding each bone of
the middle ear (Hwang and Wu, 2008; Settle et al., 2001), and therefore the likely
contribution of Gdf6 and other BMPs in the development of the middle ear bones cannot
be overlooked.
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Activity of Gdf5 in the joints of the limb resembles the activity of Gdf6 in the coronal
suture
In many ways the activity of Bmp4 and Gdf6 in the development of the CS seem
contradictory.  BMPs are known for their ability to induce bone formation, but the loss of
these two genes leads to bone formation across the suture mesenchyme.  Although
Noggin was a good candidate for an intermediate factor in connecting BMP signaling to
inhibited differentiation of the suture mesenchyme, in this chapter we demonstrated that
Noggin does not play a role in embryonic suture development.  Therefore, there are likely
other unidentified secondary factors involved in the Gdf6- and Bmp4-mediated
craniosynostosis phenotype.
The paradoxical role of Gdf6 in suture development in many ways mirrors the
role of the Gdf subfamily members in the limb.  Gdf5 is one of the earliest markers for
joint development and thus was an early candidate as a repressor of the normal cartilage
growth process (Storm et al., 1994).  However, beads soaked in Gdf5 protein embedded
into chick limbs in culture were found to stimulate the growth and differentiation of
existing cartilage and localized fusion of joints (Storm and Kingsley, 1999), despite the
fact that Gdf5-/- mice present with joint fusions (Storm and Kingsley, 1996).  Therefore,
Gdf5 cannot directly induce joint formation, but instead has chondrogenic roles and
likely an indirect role in joint formation in vivo.  Likewise in our studies, beads soaked in
Gdf6 protein actually stimulated osteogenic differentiation when implanted into the
frontal bone, even though the loss of Gdf6 increases differentiation in the suture
mesenchyme (Fig 2.11).  In both the sutures and the limb, the seemingly contradictory
functions could be attributed to different ligand concentrations, the localized expression
of receptors or BMP antagonists, or the formation of heterodimers with other members of
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the BMP family.  The CS is a relatively simple system of study, with a defined set of
tissues involved in the formation and maintenance of the suture structure and also a
limited group of known genes to be involved in the signaling events.  Thus, the suture
may serve as a useful model in studying the complex activity and interaction of BMPs
outside of simple osteogenic induction.
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CHAPTER VI
CONCLUSION
Future Directions
In this body of work we have demonstrated a role of Gdf6 (and Bmp4) in
inhibiting premature differentiation of the CS mesenchyme.  Although we addressed
questions regarding the developmental timing of suture fusion and the underlying
mechanism, many questions still remain:  Are mutations in Gdf6 found in human
craniosynostosis patients? How does Gdf6 inhibit suture differentiation? What additional
factors are involved in the Gdf6 signaling pathway?  How does Gdf6 interact with other
pathways in the suture?  Is Gdf6 autoregulated?  And are there regulatory elements
driving Gdf6 expression in the suture?
Are mutations in Gdf6 found in human craniosynostosis patients?
Despite the severity of the craniosynostosis phenotype in the Gdf6 mutant mouse,
Gdf6 has not yet been implicated as a craniosynostosis-associated gene in humans.
Preliminary work in sequencing Gdf6 failed to identify mutations in humans with coronal
craniosynostosis (David Kingsley, Max Muenke, and Simeon Boyd, personal
correspondence).  This could be attributed to the fact that CS fusion was only observed in
Gdf6-/- mice, not in heterozygotes, making it a recessive and undoubtedly rare genotype
in humans.  However, a common theme in the BMP field is that mutations in BMPs that
are often recessive in mice are dominant in humans (Ducy and Karsenty, 2000).
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Therefore, mutations in the coding region of the Gdf6 gene could explain some human
craniosynostosis cases in which the etiology is still unknown.  Furthermore, mutations in
Gdf6 could be one of several genes that contribute to a polygenic phenotype.
In the heterogeneous descriptions of Klippel-Feil Syndrome, which was mapped to a
paracentric inversion downstream of Gdf6, some patients were reported to have
microcephaly (Tassabehji et al., 2008).  However, the presence or absence of
craniosynostosis was not reported.  Currently, the only connection between Gdf6 and
human craniosynostosis is a condition called Nablus mask-like facial syndrome,
characterized by tight glistening facial skin, flat and broad nose, and a frontal upsweep of
hair (Salpietro et al., 2003).  Some patients also report digit defects, including short toes,
clinodactyly, and a wide interdigit gap (Salpietro et al., 2003).  In all the reported Nablus
patients, the condition was mapped to a microdeletion in 8q21-22, where several genes
are located, including Gdf6 (Raas-Rothschild et al., 2009).  However, only two of the
patients had a deletion that included the Gdf6 locus (Fig 6.1).  Interestingly, one of these
two patients had coronal craniosynostosis (Salpietro et al., 2003), a feature not found in
Nablus patients where the deletion did not include Gdf6.  Although the deletion is
heterozygous, it is possible that the haploinsufficiency of Gdf6 is particularly penetrant in
human craniosynostosis.
A future goal of this project could be to search for Gdf6 mutations in patients with
craniosynostosis.  Vanderbilt currently has a running DNA Databank called “BioVU”, a
repository of DNA samples extracted from patient blood samples that are available for
Vanderbilt researchers.  The samples are connected to the patient’s medical record, but
with de-identified information.  Patients with non-syndromic craniosynostosis could be
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Figure 6.1.  Genomic microdeletions of Nablus mask-like facial syndrome.  Mapping
of microdeletion in patients with Nablus mask-like facial syndrome.  Patients 1&2
reported by Shieh et al. 2006 mapped the deletion to include the coding region for Gdf6.
One of these two patients presented with coronal craniosynostosis.  The red box denotes
the region unique to these two patients.
Adapted from Raas-Rothschild et al 2009.
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selected for targeted sequencing of Gdf6 (and Bmp4).  Although known human Gdf6
mutations are rare, it is possible that as an understudied member of the BMP family, the
contribution of Gdf6 to human disease has simply been overlooked.
Craniosynostosis is generally not diagnosed until infancy, with the appearance of
a dysmorphic cranial shape.  Furthermore, the majority of human cases are spontaneous,
with no known family history.  Therefore, in utero screening for craniosynostosis is not
practical.  However, identifying craniosynostosis-associated mutations in Gdf6 can be
useful as a diagnostic tool and provide insight and understanding to patients and their
families.
With approximately 70% of craniosynostosis cases having no known etiology,
this leaves much room for the identification of more craniosynostosis-associated genes.
In addition to Gdf6 and Bmp4, mutations in other members of the BMP family (e.g.
Bmp2), BMP receptors, Smad proteins, and downstream effectors of BMP signaling may
all contribute to premature fusion of a suture.  In Chapters III and V we described some
variation in the craniosynostosis phenotype in embryos from a mixed genetic
background, suggesting the presence of modifier genes.  These modifiers could affect the
severity and penetrance of suture fusion.  Using an unbiased approached to identify
craniosynostosis genes, such as whole-exome sequencing of coronal craniosynostosis
patients, could highlight some of these identified genetic interactions.
How does Gdf6 inhibit suture differentiation?
What tissues receive Gdf6 signal?  In Chapter II we showed expression of Gdf6
mRNA in the frontal bone primordia at E10.5-E12.5.  However, Gdf6 is a secreted
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signaling protein, and although it is expressed in the frontal bone primordia, several
different tissues could be receiving a Gdf6 paracrine signal.  These may include not only
the suture mesenchyme, but also the parietal bone rudiment or periosteum.  Perhaps
partly due to the high homology between BMP family members (members of Gdf
subfamily have almost 100% homology in the mature region), we were unable to find a
commercially available Gdf6 antibody that functioned reliably in immunohistochemical
approaches.
If the question of which cells receive Gdf6 signal cannot be address through Gdf6
protein localization, the answer could be addressed indirectly.  One way to approach this
question is through the examination of phospho-Smad 1/5/8.  Binding of BMPs ligands to
Type I and Type II receptors activate Smads 1/5/8, which translocate to the nucleus to
activate a set of target genes (Ducy and Karsenty, 2000).  By comparing the localization
and levels of phospho-Smad in the suture region between wild-type and Gdf6 mutant
embryos, one could infer whether the suture mesenchyme is directly receiving a Gdf6
signal, or if the suture fusion is a secondary results of a frontal bone defect.  This would
also address the question of whether the increased differentiation of the suture
mesenchyme in Gdf6-/- and Bmp4/Gdf6 compound mutants is due to increased BMP
osteogenic signals in the suture mesenchyme.
BMPs do signal through a non-canonical Smad-independent pathway (p38
mitogen-activated protein kinase (MAPK)).  BMP receptors activate a downstream
pathway that includes the adaptor protein XIAP, TAB1 (TAK1 binding protein), TAK1
(TGF-β activated kinase 1), and the p38/Jnk pathway (Botchkarev, 2003).  Studies show
that BMP-2 bonded to pre-formed receptors complexes activated the Smad pathway.
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However, when BMP-2 induced the recruitment of receptors the p38 MAPK pathway
was activated (Nohe et al., 2002).  Bmp4 also activated the MAPK pathway in
lymphocytes (Fiori et al., 2006).  To address the possibility of non-canonical BMP
signaling, the localization of phospho-p38 could also be examined.
We mentioned the possibility that premature suture fusion is a secondary affect of
a frontal bone defect.  Although Gdf6 is only expressed in the frontal bone primordia,
Bmp4 is also expressed in the dura and suture mesenchyme.  Due to the different origins
of the frontal bone (neural crest) and the suture mesenchyme and parietal bones
(mesoderm), Cre-drivers could be utilized to eliminate Gdf6 and/or Bmp4 in specific sub-
structures of the suture.  Although a Cre-loxP allele for Gdf6 would have to be generated,
Cre-drivers for the neural crest (Wnt1-Cre) (Danielian et al., 1998) and mesoderm
(Mesp1) (Yoshida et al., 2008) and a conditional allele for Bmp4 (Bmp4-loxP) (Jiao et al.,
2003) are already available.  Similar studies are reported with Bmp4.  The conditional
deletion of Bmp4 in the neural crest through Wnt1-Cre produced a frontal bone defect
(Maxson and Ishii, 2008), but no effect on the suture was reported.  This could be due to
the fact that the CS mesenchyme is mesoderm-derived, and therefore some Bmp4
expression would be maintained in the suture region.  The lack of a suture abnormality
with the conditional deletion of Bmp4 might also be attributed to compensation by Gdf6.
Conditionally deleting combinations of Gdf6 and Bmp4 could further clarify their
interaction.
Although we have demonstrated a genetic interaction between Gdf6 and Bmp4 in
suture development, what is the nature of this interaction?  Bmp4 and Gdf6 do share type
I (Bmpr1a and Bmpr1b) and type II (BmprII and AcvrIIa) receptors (Mazerbourg et al.,
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2005), although which receptors are expressed in the suture region, where, when, and in
what combination has not been explored.  We have already initiated some preliminary
work on this question by designing in situ hybridization RNA probes specific for each of
the shared type I and type II receptors (the design information for Bmpr1b and BmprII is
described in Appendix B and demonstrated in the dorsal retina in Figure 4.7).
Information on the localization of the BMP receptors in the suture region would also
provide mechanistic insight, such as which tissues are competent to receive BMP signals
at the timepoints when Gdf6 and Bmp4 are co-expressed (E10.5-E12.5).
Although no suture defects are reported in homozygous mutants for Bmpr1b and
AcvrIIa, mutants for Bmpr1a and BmprII are embryonic lethal.  Using Cre-drivers
specific for neural crest or mesoderm-derived tissue (e.g. Wnt1 and Mesp1) could be used
to conditionally delete the BMP receptors or combination of the receptors from the suture
region in order to identify those critical to suture development.
The signaling properties of Gdf6 might also be dependent upon the assembly of
receptor complexes.  Studies demonstrate that different signals can be transduced
depending on whether the receptor complexes are pre-formed or assembled upon binding
of the ligand, and furthermore, which receptor (type I or type II) does the ligand bind to
first (Nickel et al., 2009).  Gdf6 can bind multiple type I (Bmpr1a and Bmpr1b) and type
II (BmprII and AcvrIIa), providing yet more complexity to the signaling pathway
(Mazerbourg et al., 2005).  This complexity might explain some the anti-osteogenic
activity of Gdf6 in the suture mesenchyme versus the pro-osteogenic activity in the
frontal bone.  More information on the receptor usage in the suture region might shed
some light on how Gdf6 functions in the suture region.
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Do Gdf6 and Bmp4 form heterodimers?  In Chapter III, we reported an interaction
between Gdf6 and Bmp4 in the development of the CS.  Bead implantation experiments
involving Gdf6 (Chapter II) and Bmp4 (Kim et al., 1998b) showed an increase in
differentiation and proliferation of the frontal bone, which is difficult to explain in the
light of the increased differentiation of the suture mesenchyme we observed in our Gdf6-
/- and Bmp4-lacZ/+; Gdf6+/- sutures.  Another possible explanation for these different
functions is that Gdf6 and Bmp4 form heterodimers.  BMP homodimers and
heterodimers can have different potencies and functions (Butler and Dodd, 2003).  In the
case of Twist1, the ratio of Twist1 homodimers to Twist1/E-protein heterodimers affects
the patency of the suture mesenchyme (Connerney et al., 2006).  It is known that Gdf6
forms heterodimers with Bmp2 in Xenopus (Chang and Hemmati-Brivanlou, 1999), and
given the high homology between Bmp2 and Bmp4, it would not be surprising if Gdf6
was able to form heterodimers with Bmp4.
First, do Gdf6 and Bmp4 form heterodimers?  A strategy that could be used to
answer this question would be to express cDNAs encoding epitope-tagged versions of
Gdf6 and Bmp4 in cells.  Supernatants from transfected cells would then be analyzed for
the presence of heterodimers through immunoprecipitation.  If heterodimers were present,
antibodies specific for Bmp4 would pull out both Bmp4 and Gdf6, which could be
confirmed through western blot analysis.  This was the strategy used to demonstrate that
Gdf7 and Bmp7 form heterodimers (Butler and Dodd, 2003) and that Gdf6 and Bmp2
form heterodimers (Chang and Hemmati-Brivanlou, 1999).  A similar strategy could be
employed in vivo by injecting tagged Gdf6 RNA into a zebrafish embryo and test for a
Gdf6-Bmp4 protein interaction by co-immunoprecipitation.  Additional in vivo
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techniques that could be utilized include FRET (Fluorescence Resonance Energy
Transfer) and yeast two-hybrid.
Second, do Bmp4/Gdf6 heterodimers have a different activity than the
homodimers?  To test this, we would require purified Bmp4/Gdf6 heterodimers.  One
strategy to obtain purified heterodimers is to take supernatant from cells expressing
recombinant Gdf6 and Bmp4 protein, each with a different epitope tag, and run it through
sequential affinity columns specific for each tag.  This would enable isolation of the
heterodimers while eliminating the homodimers.
In our bead implantation studies, Gdf6 protein was able to stimulate ALP activity
in the frontal bone primordia, however, Gdf6 alone is a poor inducer of osteogenesis
(Bobacz et al., 2006).  This opens the possibility that Bmp4/Gdf6 heterodimers could be
more osteogenic than Gdf6 homodimers.  Homodimer and heterodimer functions could
be tested in osteoblast cell lines or primary calvaria cells, comparing their ability to
induce matrix formation.  Additionally, a bead implantation experiment, as described in
Chapter II, could be carried out to examine the ability of Gdf6 and Bmp4 homodimers to
promote frontal bone differentiation, through the analysis of bone differentiation markers
ALP, Runx2, or Bsp, compared to differentiation in beads treated with Gdf6/Bmp4
heterodimers.  To test our hypothesis that Gdf6 had context-dependent activity, additional
implantations could be carried out with beads implanted into the suture mesenchyme and
parietal bone primordia.
If Bmp4/Gdf6 heterodimers do have a different function from the homodimers,
why does this occur?  Are signaling cascades affected by which member of the dimer
binds first?  Do the heterodimers have different association, disassociation, degradation,
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or diffusion rates from the monomers?  These are all issues that might impact the activity
of Gdf6/Bmp4 homodimers versus heterodimers and could be addressed in future studies.
What additional factors are involved in the Gdf6 pathway?
What are the downstream targets of Gdf6 signaling?  Despite the large amount of
research on members of the BMP family, the set of target genes activated by their
signaling is still largely unknown.  Changes in the expression of candidate genes in the
Gdf6-/- embryo could be assessed through in situ hybridization or quantitative real-time
PCR, although this would be restricting the study to known craniosynostosis genes
(FGFRs, Twist1, Msx2, etc) or bone-related genes (osterix, osteocalcin, bone sialo-
protein).  Expanding the study to a large-scale analysis would allow for the detection of
novel interactions or understudied genes, and thereby provide a clearer picture of the
mechanism of Gdf6 signaling.
One approach that could be used is laser capture microdissection.  In this
methodology, Gdf6 mice could be crossed to a reporter mouse line with fluorescently
labeled tissues.  In our case, we could again utilize the Wnt1-Cre (Danielian et al., 1998)
and R26R-YFP lines (Srinivas et al., 2001) to fluorescently label derivatives of the neural
crest, including the frontal bone primordia.  We have previously performed crosses
utilizing the GNZ (Stoller et al., 2008) line, a modified R26R allele with nuclear-localized
GFP expression.  However, this line failed to generate the fluorescent intensity necessary
for histological analysis.  Therefore, the more robust R26R-YFP line (Srinivas et al.,
2001) would be better suited for this study.  The R26R-YFP and Wnt1-Cre lines would be
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crossed to the Gdf6 mutant line in order to compare the differences in gene expression
between wild-type, Gdf6+/-, and Gdf6-/- embryos.
At E12.5 in mice, the frontal bone primordia is still present but the suture
mesenchyme is also its own distinct population of cells.  In embryo sections, the frontal
bone would be highlighted by fluorescence.  Laser capture microdissection would be
used to isolate cells from frontal bone or the adjacent suture mesenchyme from the
sectioned material.  Total RNA would be isolated from the microdissected tissue and
converted to cDNA.  To identify differentially expressed genes between the Gdf6
genotypes, we could use high-throughput whole-transcriptome sequencing, also referred
to a RNA-Seq (Mortazavi et al., 2008).  This procedure would allow us to identify not
only genes up or downregulated in the Gdf6-/- embryo compared to wild-type, but also
differences in the frontal bone compared to the parietal.
We could also investigate the downstream activators of Gdf6 signaling through
the Smad proteins, which transduce the signal to the nucleus.  ChIP-sequencing could be
used to compare sites of pSmad binding between untreated calvarial cells to those treated
with Gdf6 protein, or even calvaria cells isolated from wild-type and Gdf6-/- embryos.
This would highlight specific pathways and provide strong clues to the mechanisms of
coronal craniosynostosis in the Gdf6-/- mouse.
Does Gdf6 interact with other BMP antagonists?  In Chapter V we explored the
possible interaction between Gdf6 and the BMP antagonist Noggin.  Noggin was a likely
candidate for an interaction due to an important role in postnatal suture maintenance and
the periosteal expression in embryonic cranial bones.  However, Noggin is just one of the
many antagonists of BMP signaling, which also include Cerbarus, Dan, Gremlin, and
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Chordin (Yanagita, 2005).  Mutant mice for Gremlin (Khokha et al., 2003), Dan (Dionne
et al., 2001), and Cerbarus (Simpson et al., 1999) were generated but have no described
cranial defects.  Although Dan is an inefficient antagonist of BMP-2/4 signaling, an
interaction between Dan and GDF-5 was demonstrated in frogs (Dionne et al., 2001).
There is also a mouse mutant for Chordin, and although the mice do not have coronal
craniosynostosis, they do have microcephaly (Bachiller et al., 2003).  The expression of
these BMP antagonists in the suture region or potential function in suture development is
not reported.  Although we saw no interaction between Gdf6 and Noggin, it is possible
that other BMP antagonists that are important in embryonic suture development.
How does Gdf6 interact with other pathways in the suture?
The complex signaling at the suture involves multiple pathways, including BMP,
FGF, and WNT, and there is much evidences for indirect interactions between the
pathways.  Therefore, the suture defect in the Gdf6-/- mouse could be produced or
exacerbated by affecting signaling in other pathways.  Here are some examples of
interactions between BMP and other pathways.  Msx2 and Alx4 are downstream effectors
of BMP signaling, and like Gdf6, they affect the proliferation and differentiation of the
frontal bone (Antonopoulou et al., 2004; Ishii et al., 2003).  Msx2 and Alx4 feed into the
FGF pathways by affecting the expression of the FGFRs. We performed some
preliminary work looking at the expression of FGFR3 in Gdf6 mutants and saw some
evidence of increased FGFR3 in the Gdf6-/- suture (not shown).  Gain of function
mutations in FGFR3 are associated with premature suture fusion through increases in
differentiation and proliferation at the bone fronts.  BMPs also enhance FGF response in
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the bone fronts through Twist1.  Furthermore, the formation of Twist1 homodimers and
heterodimers is affected by BMP signaling, and alterations in the ration of homodimers to
heterodimers can generate a fused suture (Connerney et al., 2006).  Axin-2, an inhibitor of
the WNT pathway, promotes osteogenic differentiation in a positive feedback loop with
BMPs (Liu et al., 2007).  Examination of the affects of Gdf6 on the expression of other
members of these pathways would not only further the understanding of signaling in the
suture but also the general interaction of multiple pathways.
Is Gdf6 expression autoregulated?
From in situ hybridization data presented in Chapter II, we suggested that Gdf6
expression is autoregulated.  In the frontal bone and brachial arches expression there
appears to be a negative feedback mechanism with a positive feedback mechanism in the
dorsal retina.  What is causing these tissue-specific differences?  Since Gdf6 is a secreted
signaling factor, secondary factors must be modulating this autoregulation at the
transcriptional level.
Gdf6 expression is driven by long-distance regulatory elements (Mortlock et al.,
2003).  Are some regulatory elements silenced in specific tissues?  Or is tissue specificity
affected by what transcription factors are present in that tissue?  Such questions could be
explored using ChIP (to determine what transcription factors bind to tissue-specific
regulatory elements) or ChIP-ChIP (to determine if the chromatin in the region of the
regulatory element is in an open and active conformation).
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Does long-distance regulation affect Gdf6 suture expression?
Is there an enhancer driving Gdf6 expression in the frontal bone rudiment? Like
many members of the BMP family, Gdf6 is flanked by a large gene desert that contains
multiple distant non-coding cis-regulatory elements (Mortlock et al., 2003).  Using
overlapping Bacterial Artificial Chromosomes (BACs) in conjunction with a lacZ
reporter, approximately 280 kilobases of the Gdf6 locus was divided into five regulatory
regions and tested for their ability to drive expression of the reporter in regions where
Gdf6 is expressed.  These BAC lines were able to drive expression of lacZ in eleven
anatomical sites, including the digit tips, whisker buds, dorsal retina, elbow joints, and
larynx in mice (Fig 6.2A) (Mortlock et al., 2003).
One of these five BACs tested, referred to as D-βgeo or 125L11, drove expression
of the lacZ reporter in ectoderm overlying the parietal bone at E9.5 (not shown) and
E10.5 (Fig 6.2B, arrow).  This is the same timepoint as Gdf6 expression in the frontal
bone primordia.  Because the BACs are overlapping, this narrows down the area in which
the regulatory element resides to an approximately 60 kb region 3’ of the Gdf6 coding
region (Fig 6.2A, red box).  Although expression of Gdf6 in the parietal ectoderm was not
detected through in situ hybridization studies, the lacZ reporter in the BAC construct may
have the ability to highlight sites of low-level gene expression that cannot be detected
through in situ analysis.  Reduced Gdf6 signaling from the ectoderm to the underlying
parietal bone rudiment and could contribute to the delay in parietal bone differentiation
we observed in the Gdf6-/- embryos in Chapter II.
Regions of the Gdf6 gene desert analyzed through BAC transgenic mice failed to
drive expression of lacZ in the frontal bone or the suture mesenchyme.  However, not all
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Figure 6.2.  Cis-regulatory elements in the Gdf6 gene desert.  A) Using BACs with a lacZ reporter, approximately 280 kilobases of
the Gdf6 locus was divided into five regulatory regions and tested for their ability to drive expression of the reporter in region where
Gdf6 is expressed.  These BAC lines were able to drive expression of lacZ in eleven anatomical sites adapted from Mortlock et al.
2003.  B) The D-βgeo BAC drove expression of the lacZ reporter in ectoderm overlying the parietal bone at E10.5 (arrow). C) Gdf6 is
flanked by a 1 Mb gene desert where additional cis-regulatory elements may reside, including an element driving expression of Gdf6
in the frontal bone primordia.
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the lines produced were examined for expression at E10.5-E12.5 when Gdf6 is expressed
in the frontal bone primordia.  Furthermore, this study did not identify cis-regulatory
elements that corresponded to all sites of Gdf6 expression, suggesting that additional
regulatory elements reside even more distant from the Gdf6 coding region and outside the
region spanned by the BACs.  Therefore, a future extension of this project could be to
locate the likely cis-regulatory element that drives expression of Gdf6 in the frontal bone
primordia by examining the remaining BACs spanning the gene desert.
Could a mutation in a regulatory element contribute to craniosynostosis?  In addition
to the Gdf6 coding region, mutations in the regulatory elements could explain some of the
cases of human craniosynostosis in which the etiology is unknown.  Locating a Gdf6
regulatory element specific for the suture region would allow for more targeted sequence
analysis.  In humans, mutations in cis-regulatory sequences for SHH and SOST are
associated with abnormal limb development or Van Buchem disease respectively (Loots
et al., 2005; Sagai et al., 2005), demonstrating the contribution of cis-regulatory elements
to human disease.
This is likely also the case for Gdf6.  Tcm is an autosomal dominant mouse
mutant characterized by microphthalmia.  Genetic mapping reduced the critical region to
a 1.3 Mb region containing five known genes, including Gdf6 (Wang et al., 2005).
Because of the expression of Gdf6 in the dorsal retina and the microphthalmia and
anophthalmia phenotypes observed in our own crosses, Gdf6 is a likely candidate for the
Tcm mutation.  None of the candidate genes had mutations in the coding region, therefore
the mutation most likely resides in a regulatory element for Gdf6.  In collaboration with
Dr. Dwight Stombolian, our lab found that Gdf6 is upregulated in the eyes of Tcm mice
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relative to wild-type (Y. Hou, D. Clendenning, and D. Mortlock, unpublished results).  In
addition, a familial case of Klippel-Feil syndrome has been attributed to a paracentric
inversion that interrupts the GDF6 gene desert, although the coding region is unaffected
(Clarke et al., 1995; Tassabehji et al., 2008).  Therefore, the phenotype is likely due to
several Gdf6 cis-regulatory elements that are affected by the change in genomic
positioning; resulting in altered chromatin structure, changes in the position of repressing
elements, or separation of Gdf6 from regulatory elements located past the inversion site.
Since all these changes could produce variation in gene expression without affecting the
coding region, it would be important to know the location of the non-coding sequence or
sequences that drive expression of Gdf6 in the suture region.  Such elements would also
be candidates for screening potential sites of mutations in human craniosynostosis
patients.  However, due to the large number of polymorphisms that likely reside within
the one megabase gene desert for Gdf6, the regulatory elements would have to first be
identified.  The identification of tissue-specific regulatory elements could also be useful
for the development of tools for further study of cranial suture development, such as
transgenic lines made to drive expression in the frontal bone rudiment.
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Thesis Summary and Conclusions
The goal this work was to gain a developmental understanding of Gdf6 in the
formation of the CS through the study of the initiation of the suture phenotype, the timing
and location of Gdf6 cranial expression, and the interaction of Gdf6 with other BMP
family members.  Although the phenotype of the Gdf6 mutant mouse was published
almost a decade ago (Settle et al., 2003), the study of craniosynostosis has remained
restricted to a small set of genes, including FGFR1-3, Twist1, Msx2, the Ephrins, Nell-1,
and Axin2.  BMPs are widely known for their role in skeletal patterning and osteogenesis,
but their role in the dynamics at the suture has been less clear.  Even less was known
about the Gdf sub-family and how the members function.
This study shows the importance of Gdf6 in the development of the CS in that it is
one of the earliest, most penetrant, and most severe of the mouse craniosynostosis
models.  A suture defect is evident in Gdf6-/- mice even prior to the onset of ossification
with the loss of the undifferentiated suture mesenchyme by E12.5, resulting in complete
fusion of the CS by E14.5.  We characterized the expression of Gdf6 in the frontal bone
primordia from E10.5-E12.5, and showed evidence for auto-regulation of Gdf6 in this
structure.  We also demonstrated an interaction of Gdf6 and Bmp4 in the development of
the CS, a relationship that is carried over to multiple skeletal (sternum, thyroid cartilage,
pelvis) and non-skeletal (dorsal retina) structures.  Although Noggin has been noted as an
important factor in suture patency (Warren et al., 2003a), we demonstrated that it does
not play in important role in early prenatal suture formation and the removal of Noggin
has no effect on the Gdf6 suture phenotype.
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Clinical applications of Gdf6 in the suture
Although our work described only an embryonic role of Gdf6 in the development
of the CS, we did not examined the possible role of Gdf6 in postnatal suture patency.
When fused sutures are excised from infants with craniosynostosis, the defect that led to
premature suture fusion is still present and it is common for the new suture space to re-
fuse.  Therefore, finding treatments to prevent this re-fusion event would eliminate the
need for additional cranial surgeries.  In rats, when beads soaked in recombinant Noggin
were implanted into the space generated after removal of a fused suture, the bead
inhibited suture re-fusion (Cooper et al., 2009; Shen et al., 2009b).  From our data
suggesting an inhibitory effect of Gdf6 on suture mesenchyme differentiation, a similar
strategy could be utilized with Gdf6 protein.
BMPs are especially attractive to be used in therapeutic manipulation because
they are secreted factors.  Several BMPs, particularly rhBMP2 and rhBMP7, are already
being used to treat patients with breaks and fractures, spinal fusion, and mandibular
defects.  Even rhGDF5 is being developed as a potential clinical tool in spinal fusions and
injections into mice show stimulation of cranial bone growth (Moore et al., 2010).  Gdf-5,
-6, and –7 mutants all have defects in the tendons and new studies show that it could also
have clinical applications to humans (Mikic, 2004).  BMP treatments are beneficial in
that they eliminate the need to harvest bone grafts from the patient and are able to
stimulate healing at sites of non-union between two bones.
Due to the highly osteogenic nature of BMP-2, a continued problem associated
with clinical applications is finding a way to deliver physiologically relevant levels of
protein.  Large concentrations of protein can result in excess bone formation at undesired
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sites, while the clearance of low levels of protein might occur too fast to produce an
effect in vivo (Groeneveld and Burger, 2000).  Almost a decade after BMP-2 began to be
use in patients, research showed that the patients had a five times higher risk for
developing malignant cancer after treatment (Carragee et al., 2011).  Previous studies
demonstrated that compared to Bmp2 and Bmp7, Gdf6 is weakly osteogenic (Bobacz et
al., 2006).  Since the function of the Gdfs is mostly related to cartilage growth, and the
cranial bones are formed without a cartilage intermediate, this suggests that Gdf6 could
be more specific as a clinical tool than other members of the BMP family in the treatment
of craniosynostosis by providing a signal to inhibit suture mesenchyme differentiation
without the strong ectoptic induction of bone formation.
Mutations in Gdf6 have been associated with several human phenotypes,
including Nablus mask-like facial syndrome (Raas-Rothschild et al., 2009; Salpietro et
al., 2003; Shieh et al., 2006), Klippel-Feil Syndrome (Tassabehji et al., 2008), and ocular
defects (Asai-Coakwell et al., 2007; Gosse and Baier, 2009).  As we gain a more
thorough understanding of the function of BMPs in the etiology of craniosynostosis,
clinical applications to other conditions could also be attainable.
Advancing the understanding of BMP signaling
The suture offers a useful model for the study of BMP signaling.  The suture
region has the advantages of involving few tissues (bone, bone fronts, suture
mesenchyme, and dura), with known BMP expression, and are known to signal to each
other.  Although BMPs are widely studied in endochondral bone, the suture provides a
system to also study BMPs involvement in intramembranous ossification.   There is
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already evidence for indirect interactions between BMPs and other pathways in the suture
(FGF and WNT).  The suture can be used to address large questions in the BMP field,
including how do BMPs interact?  How do so many ligands transmit signals utilizing
only a few receptors?  What are the downstream effectors of BMP signaling?  It is clear
that not only will the study of the suture expand the understanding of BMPs, but also
highlight the critical yet diverse role of this family of proteins.
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APPENDIX A
GENOTYPING PCR PRIMERS FOR VARIOUS MOUSE LINES
Mouse Line Allele Genotyping Primers Product Size
Wild-type 5’-AGCTCTTGGTCATGGATGTTTCTC-3’
5’-CTGATGTAGCCCTTCCACCTTTC-3’
176 bpGdf6
Targeted
allele
5’-TGGAGAGGCTATTCGGCTATGAC-3’
5’-TACTTTCTCGGCAGGAGCAAGG-3’
310 bp
Bmp4-lacZ LacZ 5’-TTTCCATGTTGCCACTCGC-3’
5’-AACGGCTTGCCGTTCAGCA-3’
375 bp
Wnt1-Cre Transgene 5’-ATTCTCCCACCGTCAGTACG-3’
5’-CGTTTTCTGAGCATACCTGGA-3’
475 bp
R26R Wild-type &
Mutant
5’-AAAGTCGCTCTGAGTTGTTAT-3’
5’-GCGAAGAGTTTGTCCTCAAGG-3’
5’-GGAGCGGGAGAAATGGATATG-3’
500 bp (WT)
250 bp (Mut)
Noggin-lacZ Wild-type &
Mutant
5’-GCATGGAGCGCTGCCCCAGC-3’
5’-GAGCAGCGAGCGCAGCAGCG-3’
5’-AAGGGCGATCGGTGCGGGCC-3’
211 bp (WT)
160 bp (Mut)
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APPENDIX B
IN SITU HYBRIDIZATION PROBES, PRIMERS, AND CONDITIONS
RNA
Probe
Target
Primers Probe Linearization
enzyme
RNA
Polymerase
Product
Size
Hybridization
Temperature
Antisense NotI Sp6Gdf6 5’- AAGCATGGAAGGAGGATGAAAGGG- 3’
5’- CGACCTCCAGTAACTTTAGTGTTGTCA –3’ Sense SpeI T7
937 65oC
ColIIa Metsaranta et al., 1991 Antisense EcoRI T7 405 65oC
Runx2 5’- AAAGCTTCAGAACTCTTAGAATGA-3’
5’-ATCATATTAAAAAGCCAAGCACAAG-3’
Antisense SpeI T7 672 63oC
BMPR1b 5’- AACCCTTGCCAAAATGTCAG – 3’
5’- GGTGTGTCGGGCAGTAAGTT –3’
Antisense SacII Sp6 506 65oC
BMPR2 5’- GTGACAGGGCAGTCCATTCT –3’
5’- CAGCAATCCATTGTTTTTGC –3’
Antisense SacII Sp6 424 65oC
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APPENDIX C
SUMMARY OF DEFECTS AND ABNORMALITIES IN ANALYZED MOUSE MUTANTS
Gdf6+/- Gdf6-/- Bmp4-lacZ/+ Bmp4-lacZ/+;
Gdf6+/-
Bmp4-lacZ/+;
Gdf6-/-
Gdf6+/-;
Noggin-lacZ/+
Long bones Femur,
Elbow
Digits Polydactyly Polydactyly
Cranial
Middle ear
bones,
CS fusion
CS fusion CS fusion
Manbrio-
sternal joint
Unfused
(21%)
Unfused
(60%)
Carpals 2c fusion 23c fusion 2c, 23c fusions
Tarsals 2/3 and CT
fusions
23c, 2345
fusions
23c, 2345
fusions
Vertebrae Unfused Unfused
Eye Microph-
thalmia
Microph-
thalmia
Anopthalmia
Thyroid
cartilage
Hypoplasia Hypoplasia Hypoplasia
Pelvic bones
Small
ischium/
pubis gap
Small
ischium/
pubis gap
Larger
ischium/
pubis gap
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